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Abstract 
Selective protein degradation is a crucial control mechanism which impacts nearly every 
aspect of eukaryotic cell biology.  It is achieved via the ubiquitin-proteasome pathway 
whereby multimers of ubiquitin are conjugated to substrate proteins and subsequently 
recognised and degraded by the proteasome.  The specificity of substrate recognition is 
provided by E3 ubiquitin ligase enzymes.  Seven in Absentia homologue-1 (SIAH1) is a 
highly conserved E3 ubiquitin ligase which recognises and binds to an array of substrate 
proteins facilitating their ubiquitination and degradation.  The identification of various 
SIAH protein substrates has revealed that SIAH1 and its family members play a role in a 
number of cellular processes including cell-cycle regulation, cell differentiation, and 
apoptosis.  Previous studies also revealed that SIAH1 has a novel role in the testes as 
removal of the equivalent gene in mice (Siah1a) results in male sterility.  Despite the 
numerous studies which have led to the identification of various SIAH substrates, how 
these proteins and their stability relates to the observed Siah1a mutant phenotype of male 
sterility remains unclear.  Therefore, to better understand SIAH1 function in the testes, a 
number of SIAH1 interacting proteins identified in a yeast 2-hybrid screen of a human 
testes cDNA library were investigated.  Primarily, experiments focused on finding out 
whether or not any of these proteins were targets for SIAH1-mediated degradation.  Two 
prime candidates were further investigated including NELF-A, a transcriptional regulator 
of developmental control genes, and ASPP1, a p53 interacting protein which promotes 
apoptosis.  Further investigation into the SIAH1:NELF-A interaction confirmed that a 
genuine molecular interaction occurred in vitro.  Transient transfection assays and 
analysis of NELF-A protein in Siah1a-/-Siah2-/- fibroblasts revealed that SIAH proteins 
predominantly target ectopically expressed NELF-A protein for degradation and analysis 
of NELF-A regulation by the murine family of Siah proteins revealed that the closely 
related Siah1a protein, Siah1b, has diverged in function.  Consistent with SIAH1’s role in 
apoptotic regulation, SIAH1 was found to regulate the stability of ASPP1 and its 
homolog ASPP2.  To better understand the downstream consequences of SIAH1-
mediated degradation of ASPP1 and to shed light on ASPP1 function, protein interaction 
screens were carried out to identify major ASPP1-binding protein partners.  A diverse set 
of interacting partners were identified implying ASPP1 is a multifunctional protein 
involved in a number of cellular pathways.  
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1.1 The importance of regulated protein degradation 
In eukaryotes, intracellular protein degradation is a highly selective process, whereby 
proteins are broken down into their constituent amino acids at widely differing rates. 
Protein half lives can vary from several minutes for some regulatory enzymes, to several 
days or weeks.  This selective process impacts a range of cellular functions and serves 
several important homeostatic purposes.  For example, regulated turnover of cell cycle 
regulators and signal transducers is essential to control cell cycle progression, cell 
division and signal transduction .  Similarly, gene expression patterns and developmental 
programs can be altered via coordinated destruction of transcriptional regulatory proteins, 
such as general initiation and elongation factors (Conaway et al., 2002).  Additionally, 
turnover of proteins that are mutated, damaged, or mis-folded prevents the accumulation 
of aberrant proteins, which may pose a threat to cellular integrity.   This is essential in 
protecting cells against environmental stress.   
Not surprisingly, aberrations in the tightly controlled process of protein degradation have 
been implicated in the pathogenesis of many diseases including cancer, 
neurodegenerative disorders, immunological disorders and several others (Ciechanover et 
al., 2004).  Understanding the mechanisms involved in this process are therefore of the 
upmost importance for understanding and treating human disease.  Over the last 30 years, 
studies primarily carried out by Avram Hershko, Aaron Ciechanover, and Irwin Rose 
revealed that selective protein degradation is achieved largely via the ubiquitin-
proteasome pathway.  It soon became apparent that this pathway impacts nearly every 
aspect of eukaryotic cell biology and as a result, Hershko, Ciechanover, and Rose were 
awarded the Nobel prize in chemistry in 2004.  Their experimental studies and findings 
are reviewed by Hershko (2005), Varshavsky (2005) and  Kresge et al., (2006). 
1.2 The ubiquitin-proteasome pathway 
Eukaryotic proteins which are destined for degradation in the ubiquitin-proteasome 
pathway are firstly ‘tagged’ with multimers of an extremely well conserved protein 
known as ubiquitin (76 amino acids, 8.6kDa).  This marcomolecular tag serves to mark 
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proteins for recognition and subsequent destruction by the 26S proteasome, a large multi-
subunit protease (Figure 1).  
 
Figure 1. The ubiquitin-proteasome pathway. Proteins are marked for degradation by the covalent 
attachment of several ubiquitin molecules forming a polyubiquitin chain.  This chain is recognised by the 
26S proteasome, which cleaves the protein into numerous small peptide fragments.  The ubiquitin tag is 
recycled and the small peptide fragments are then degraded to amino acids by peptidases in the cytoplasm 
or used for antigen presentation. 
Tagging proteins with ubiquitin chains, known as ubiquitination or ubiquitylation, is an 
ATP-dependent process which requires three enzymatic components, an E1 (ubiquitin-
activating enzyme), an E2 (ubiquitin-conjugating enzyme) and an E3 (ubiquitin ligase 
enzyme).  Firstly, the process begins with a single E1 ubiquitin-activating enzyme which 
activates the C-terminus of ubiquitin via a two-step intra-molecular ATP-dependent 
reaction.  Activated ubiquitin is then transferred to the active site cysteine of an E2 
enzyme (Hershko et al., 1998).  To date, 35 active E2 enzymes have been identified in 
humans (van Wijk et al., 2010).  E2 enzymes then interact with a specific E3 partner to 
catalyze the attachment of ubiquitin to target proteins.  This process culminates in the 
formation of a stable isopeptide linkage between the carboxyl-terminal glycine of 
ubiquitin and the ε-amino group of an acceptor lysine residue in the target protein (Figure 
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2).  In some cases, an additional component referred to as an E4 aids the E3 in 
polyubiquitination of the target protein (Koegl et al., 1999; Hoppe 2005).   
 
Figure 2. Ubiquitin conjugation. E1 adenylates ubiquitin and links the terminal carboxylate group of 
ubiquitin to a sulfhydryl group of E1 by a thioester bond.  Activated ubiquitin is then shuttled to a cysteine 
residue in the active site of an E2 ubiquitin-conjugating enzyme.  Finally, an E3 ligase catalyzes the 
transfer of ubiquitin from E2 to a ε-amino group on the target protein.  Figure from Berg et al., (2002). 
Since the initial description of the ubiquitin proteasome pathway as a protein tagging and 
breakdown system, knowledge in this area has rapidly advanced, with thousands of 
proteins being shown to be degraded by this mechanism. 
Protein modification by ubiquitin also has non-conventional (non-degradative) functions.  
These non-traditional functions are dictated by the number of ubiquitin units attached to 
proteins (mono- versus polyubiquitination) and also by the type of ubiquitin linkage chain 
that is present.  Monoubiquitination for example (i.e. the attachment of a single ubiquitin 
molecule to a single site on a protein) is implicated in many cellular functions including 
protein trafficking between various cellular compartments, DNA repair and 
transcriptional regulation.  Protein regulation by monoubiquitination is reviewed by 
Hicke (2001).  Ubiquitination can also be reversed by specific deubiquitinating enzymes 
(DUBs) which cleave covalent isopeptide linkages.   
1.2.1 Types of ubiquitin chains 
A single ubiquitin molecule contains seven lysine residues (K6, K11, K27, K29, K33, 
K48 or K63), and multi-ubiquitin chains are built by formation of an isopeptide bond 
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between Gly76 of one ubiquitin to the ε-amino group of one of the seven potential lysine 
residues.  Each residue is capable of chain initiation and all seven chain types have been 
identified in vivo (Meierhofer et al., 2008).  As well as homotypic ubiquitin chains 
whereby the same lysine residue is sequentially used for conjugation, matters are greatly 
complicated by reports of mixed lineage chains, utilising several distinct lysines to 
connect consecutive ubiquitins and heterologous chains, connecting ubiquitin with other 
ubiquitin-like proteins (Ikeda et al., 2008).  It is the E2 enzymes and specific E2/E3 
combinations which are the main determinants for lysine selection from which to 
construct ubiquitin chains (van Wijk et al., 2010).   
The most common site of chain initiation and linkage is K48.  It is the K48 chains that 
are the predominant signal for degradation by the proteasome and these are the most 
abundant ubiquitin chains in the cell.  Chain linkage through K63 however is also quite 
common.  K63 chains do not seem to play a role in protein turnover but have been 
implicated in a number of other processes such as signal transduction, endocytosis, and 
DNA damage repair (Sun et al., 2004; Mukhopadhyay et al., 2007).  K63-ubiquitination 
has also been associated with protein inclusion bodies in neurodegenerative disease (Lim 
et al., 2010).  Although various other types of chains exist, available information is not 
yet sufficient to fully understand their function. 
1.2.2 Ubiquitin-like proteins  
In addition to ubiquitin itself, many ubiquitin-like proteins (UBLs) have been identified 
(Hochstrasser 2009).  These ubiquitin-like molecules are structurally similar to ubiquitin 
and are processed, activated, and conjugated to target proteins by enzymatic steps that are 
similar to the corresponding mechanisms for ubiquitin (Kerscher et al., 2006).  These 
conjugates can also be removed by specific UBL-isopeptidases which function similarly 
to deubiquitinating enzymes.   
To date, at least ten UBLs have been identified in mammalian cells.  These include 
APG8, APG12, SUMO (small ubiquitin-related modifier), NEDD8, ISG15 (interferon 
stimulated gene), FAT10, UBL5, UFM1, URM1 and HUB1.  Covalent attachment of 
these UBLs to target proteins does not generally signal for protein degradation.  Instead, 
attachment of UBLs can adjust substrate conformation, affect affinity for ligands or other 
interacting molecules and alter substrate localisation.  They influence a variety of 
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biological processes including DNA synthesis, DNA repair, cell-cycle control, 
transcription, translation, signal transduction, protein quality control and more 
(Welchman et al., 2005).   
Cross regulation between the various conjugation pathways often occurs as some proteins 
can be modified by more than one UBL.  For instance, SUMO modification often acts 
antagonistically to that of ubiquitination resulting in stabilisation of protein substrates 
(Denuc et al., 2010).  Thus, the attachment of ubiquitin and UBLs to proteins is now a 
widely recognised form of protein modification, involved in all cellular regulatory 
activities. 
1.2.3 E3 Ubiquitin Ligases 
E3 ubiquitin ligases play a particularly important role in regulating protein breakdown as 
it is these which select specific protein substrates for ubiquitination (Hershko et al., 
1986).  They constitute a large and complex superfamily and many hundreds of genes 
encoding E3 ubiquitin ligases have been identified in the human genome (Li et al., 2008).   
Each E3 ligase can target a number of proteins for ubiquitin modification, however the 
detailed molecular mechanisms of protein selection are poorly understood and the exact 
protein substrates for each E3 are mostly unknown.  E3 enzymes which are specific for 
targeting proteins for modification with UBLs such as SUMO and NEDD8 have also 
been identified, however herein ubiquitin-specific E3’s are discussed.  
The importance of E3 ubiquitin ligases is highlighted by the number of cellular processes 
they regulate and the number of human diseases associated with absence or inefficiency 
of E3 ligase function.  For example, germline mutations in the gene encoding the BRCA1 
E3 ubiquitin ligase result in defective E3 activity and are associated with an inherited 
predisposition for breast and ovarian cancer (Futreal et al., 1994; Miki et al., 1994).  
Also, mutations in the E3-ubiquitin ligase parkin cause a recessively transmitted early 
onset form of Parkinson’s disease (Kitada et al., 1998), a degenerative disorder of the 
central nervous system.  These mutations result in defective ligase activity so protein 
substrates accumulate in neurons and contribute to disease development (Dawson 2006).  
Abnormal protein ubiquitylation due to loss of an E3 ligase or inappropriate targeting is 
also associated with other neurodegenerative disorders such as Alzheimer's and 
Huntington's disease.  For reviews on the role of ubiquitin-protein ligases in 
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neurodegenerative disease see Mayer (2003) and Ardley and Robinson (2004).  For 
further examples of how dysregulated ubiquitin ligase activity contributes to the 
development and progression of various cancers see Newton and Vucic (2007), Sun 
(2006) and Confalonieri et al (2009).  Not surprisingly, E3 ubiquitin ligases are attractive 
therapeutic targets for treatment of human disease.  
Generally, E3 ubiquitin ligases can be classified into three main types based on their 
structure and mechanism of action.  These include the HECT (homologous to E6-AP 
carboxy-terminus) domain family, the U-box family and the RING (really interesting new 
gene) finger family (Jackson et al., 2000).  Each of these three classes of E3 ligases have 
distinct domains responsible for binding to E2 enzymes (RING-finger, HECT or U-box 
domain), and other domains which function to recruit substrates. 
The HECT domain proteins are large monomeric E3’s which contain a cysteine residue 
that forms a covalent bond with the activated ubiquitin before transferring it to the 
substrate (Scheffner et al., 1995).  For reviews on HECT E3 ligase regulation, function 
and their roles in human disease see Kee and Huibregtse (2007); Scheffner and Staub 
(2007); Rotin and Kumar (2009).   RING and U-box E3 ligases however do not possess 
an active-site cysteine residue and these E3’s simply serve as a scaffold, bringing the E2-
ubiquitin complex and substrate in close proximity to mediate the transfer of ubiquitin 
from the E2 enzyme directly to the substrate. 
The vast majority of E3 ubiquitin ligases are members of the RING finger family and 
over 600 human genes encoding RING finger E3s have been identified (Freemont 2000; 
Deshaies et al., 2009),  The RING finger constitutes a small zinc-binding domain that 
binds to specific E2 enzymes (Lorick et al., 1999; Joazeiro et al., 2000).  The U-box E3s 
have a similar tertiary structure to that of the RING finger except that the U-box scaffold 
is stabilised by salt-bridges and hydrogen bonds rather than zinc ions (Aravind et al., 
2000; Hatakeyama et al., 2003). 
The RING-type and U-box ligases can be further subdivided into monomeric ligases, or 
multi-subunit E3’s.  Examples of monomeric RING-type ligases include the oncoprotein, 
Mdm2, which regulates the stability of the tumour suppressor, p53 (Fang et al., 2000); 
Parkin, which modulates the stability of the transcription factor SIM2 (Okui et al., 2005); 
and Cbl, which catalyzes the ubiquitination of tyrosine-kinase cell surface receptors 
Chapter 1                                                                                                                                        Introduction                                                              
 
8 
 
(Levkowitz et al., 1999).  The best understood multisubunit E3’s are the SCF (Skp1-
Cul1-F-box) complexes.  For a review on these ligases see Willems et al., (2004).  A 
number of diverse substrates of SCF complexes have been identified, including key 
regulators of the cell cycle and key molecules that control inflammation, such as NF-κB 
(Karin et al., 2000) and β-catenin (Latres et al., 1999). 
In addition to substrate ubiquitination, many E3 ligases can also self- or auto-ubiquitinate 
in the presence of an E2 enzyme, a property that may be used as an autoregulatory 
mechanism to control its own intracellular levels. 
1.3 The Siah family 
Drosophila SINA (Seven in Absentia) and its mammalian orthologs are evolutionarily 
conserved E3 ubiquitin ligases containing an N-terminal RING-finger domain required 
for interaction with E2 ubiquitin conjugating enzymes, and a C-terminal substrate binding 
domain which interacts with target proteins (Hu et al., 1997a).  Drosophila SINA was first 
isolated in a screen for mutations which affect the morphology of the Drosophila eye and 
it was the first of the family to be defined (Carthew et al., 1990).  SINA targets the 
transcriptional repressor, tramtrack for degradation and is essential for the correct 
development of R7 photoreceptor cells in the compound eye (Carthew et al., 1994; Tang 
et al., 1997).  More recently, Cooper et al., (2008) identified a novel Drosophila protein 
which is homologous to Sina which they named Sina-Homologue, SinaH (46% identical 
to SINA).  SinaH can also direct the degradation of the transcriptional repressor 
Tramtrack (Cooper et al., 2008). 
Characterisation of murine Sina homologues by Della et al., (1993) revealed that the 
mouse genome contains a family of five Siah (Seven in Absentia Homologue) genes 
found at unlinked chromosomal positions (Holloway et al., 1997).  Two of these genes, 
Siah1-ps1 and Siah1-ps2, are pseudogenes as they contain a number of frame shifts and 
in-frame stop codons within the expected coding region.  However, the remaining three 
genes, Siah1a, Siah1b and Siah2 have open reading frames and are expressed.  
Comparison of Siah1a and Siah1b cDNA revealed that they were 97% identical at the 
nucleotide level, differing by only 25 nucleotides (Holloway et al., 1997).  Comparison of 
their protein sequence revealed they were 97.8% identical at the amino acid level 
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differing by only six amino acids (Holloway et al., 1997). The Siah2 cDNA sequence 
however, is more divergent showing 73% nucleotide and 78% amino acid homology with 
Siah1a/1b (Della et al., 1993; Holloway et al., 1997). 
In contrast, only two SINA homologues have been identified in the human genome, 
SIAH1 and SIAH2 (Adams et al., 1992; Nemani et al., 1996; Holloway et al., 1997), both 
of which encode functional proteins.  The SIAH1 and SIAH2 proteins are 76% and 68% 
identical to the Drosophila SINA protein and 44% and 40% identical to SinaH (Hu et al., 
1997a; Cooper et al., 2008).  The human SIAH1 and murine Siah1a proteins differ by 
only one amino acid and the ancestral Siah1 gene of humans and mice is Siah1a (Hu et 
al., 1997a).  Despite efforts by various groups, no human variant cDNAs corresponding 
to murine Siah1b have been identified (Hu et al., 1997a; Holloway et al., 1997).  
Therefore this suggests that Siah1b arose after the human and mouse lineages separated.  
Also, Wheeler et al., (2002) were unable to detect rat cDNAs corresponding to murine 
Siah1b suggesting that Siah1b is a mouse specific gene which does not exist in other 
species.   
1.3.1 SIAH expression  
The Drosophila Sina gene was reported to be widely expressed in embryonic, larval, 
pupal and adult tissues (Carthew and Rubin, 1990) and the murine Siah1a, Siah1b and 
Siah2 genes were reported to be widely expressed at a low levels in the embryo and adult 
(Della et al., 1993).  Similarly, Hu et al (1997a) reported that human SIAH1 and SIAH2 
are expressed at low, but uniform levels in most adult tissues and it was later established 
that levels of Siah family proteins are maintained at low levels through ubiquitination-
dependent protein turnover (Hu et al., 1999).  Human SIAH1 and SIAH2 were found to 
auto-regulate their own stability through interactions of their RING-domains with E2 
enzymes (Hu and Fearon, 1999).  
More recently, splicing variants of human SIAH1 have also been identified.  These are 
designated SIAH-1L, encoding a 298 amino acid protein, and SIAH-1S, encoding a 195 
amino acid protein, and these appear to have differing expression patterns and functional 
activity compared to the 282 amino acid SIAH1 protein (Iwai et al., 2004; Mei et al., 
2007; Wen et al., 2010a).   
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1.3.2 SIAH substrates  
The SINA and SIAH proteins have been found to localise in both the nucleus and the 
cytoplasm whereby they facilitate the ubiquitination and degradation of several, 
seemingly unrelated proteins listed in Table 1 (Carthew et al., 1990; Roperch et al., 
1999).  They can achieve this either by binding directly to the substrate (Susini et al., 
2001) or by functioning as a multi-subunit complex, binding to ‘co-factor’ proteins, 
which instead of becoming ubiquitinated, act as molecular links to other substrates.   For 
example, SIAH1, APC (adenomatous polyposis coli), SIP (Siah interacting protein), Skp1 
and Ebi form a multi-subunit complex and target β-catenin for degradation (Matsuzawa 
et al., 2001).   Both SIP and APC have been shown to interact with the C-terminus of 
SIAH1, although no direct interaction with the substrate, β-catenin has been reported (Liu 
et al., 2001).   
In a second example, formation of a complex including Drosophila SINA, Phyllopod 
(Phyl) and the F-box protein Ebi, results in the ubiquitination and degradation of the 
transcriptional repressor, tramtrack.  In this complex it is the nuclear protein, Phyl, which 
functions as the adaptor to physically link tramtrack with SINA (Tang et al., 1997; Li et 
al., 2002; Cooper et al., 2008).  Thus, not all SIAH-binding proteins are targets for SIAH 
mediated degradation.  All of the SIAH interacting proteins identified to date which are 
not targets for SIAH-mediated degradation are listed in Table 2. 
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Substrate  Protein function References 
Transcriptional regulators 
BOB1/ 
OBF-1 
Transcriptional co-activator which regulates 
transcriptional activity in B lymphocytes. 
(Boehm et al., 2001; Tiedt et 
al., 2001) 
c-myb Oncogenic transcription factor involved in cellular 
proliferation and apoptosis. 
(Tanikawa et al., 2001) 
CtIP  Transcriptional co-repressor involved in cellular 
proliferation, DNA repair and cell cycle control. 
(Germani et al., 2003) 
HDAC3 Histone deacetylase which represses transcription. (Zhao et al., 2010) 
N-CoR  Transcriptional co-repressor which promotes chromatin 
condensation.  
(Zhang et al., 1998; Frasor et 
al., 2005) 
PML  Transcriptional co-regulator and key component of PML 
bodies.  The PML gene is often involved in oncogenic 
chromosomal translocation with the retinoic acid receptor 
(RAR)α gene associated with acute myelocytic leukemia 
(AML). 
(Fanelli et al., 2004) 
TIEG1  Transcription factor which regulates cell proliferation, 
differentiation and apoptosis. 
(Johnsen et al., 2002) 
Enzymes 
FIH  A hydroxylase which regulates the hypoxia inducible 
factor (HIF1α) a central regulator of the hypoxic response. 
(Fukuba et al., 2008)  
PHD1 and 
PHD3  
Catalyze the hydroxylation of HIF1α resulting in HIF1α 
ubiquitination and degradation. 
(Nakayama et al., 2004a; 
Nakayama et al., 2004b) 
OGHDC  Rate-limiting enzyme in the mitochondrial Krebs cycle. (Habelhah et al., 2004) 
Neuronal 
AF4 Transcription cofactor which is important in the normal 
function of the central nervous system.  The Af4 gene is 
also frequently disrupted in childhood leukaemia. 
(Bursen et al., 2004; Oliver 
et al., 2004) 
Synphilin-1 Synaptic vesicle protein of unknown function.  Interacts 
with α-synuclein in neuronal tissue and is a major 
component of Lewy bodies, which characterise 
pathological conditions such as Parkinson's disease.   
(Nagano et al., 2003; Liani 
et al., 2004; Avraham et al., 
2005) 
Synapto-
physin 
Synaptic vesicle membrane protein of unknown function. (Wheeler et al., 2002) 
Group 1 
mGluRs  
G protein-coupled receptors which perform a variety of 
functions in the central and peripheral nervous systems.  
Only the long splice forms of mGluR1 are down regulated 
by SIAH proteins. 
(Moriyoshi et al., 2004) 
Others 
AML1-ETO 
and PML-
RARα 
Chimeric fusion proteins which contribute to the 
pathogenesis of leukaemias. 
(Kramer et al., 2008)  
β-catenin Functions as both a transcriptional activator and a cellular 
adhesion molecule.  Mutated in multiple cancers. 
(Liu et al., 2001; Matsuzawa 
et al., 2001) 
BAG-1*  Inhibitor of apoptosis. A study by Matsuzawa et al., 
(1998) implied that BAG-1 negatively regulates Siah1a.  
In contrast, studies by Sourisseau et al., (2001) imply that 
Siah2 targets BAG-1 ubiquitination and degradation.   
(Matsuzawa et al., 1998; 
Sourisseau et al., 2001) 
DCC  Transmembrane receptor for netrin-1 required for axon 
guidance.  
(Hu et al., 1997b) 
EB3 Microtubule plus-end-binding protein involved in (Ban et al., 2009) 
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microtubule polymerisation.  Facilitates cell cycle 
progression and may play a role in cell migration. 
HIPK2  Protein kinase which interacts with several transcription 
factors. Key regulator of apoptosis and the hypoxic 
response. 
(Winter et al., 2008; Calzado 
et al., 2009; Kim et al., 
2009) 
Kid  A chromosome and microtubule binding-protein 
implicated in the normal progression of mitosis and 
meiosis. 
(Germani et al., 2000) 
KSHV 
ORF45  
Protein encoded by the Kaposi’s sarcoma-associated 
herpes virus (KSHV) genome which is essential for 
KSHV infection. 
(Abada et al., 2008) 
MYPT1 A subunit of the myosin phosphatase holoenzyme.  
Control of myosin phosphorylation plays an important 
role in many cellular functions including smooth muscle 
contraction. 
(Twomey et al., 2010) 
Numb Membrane-associated protein which plays a role in the 
determination of cell fate during development. 
(Susini et al., 2001) 
PEG10* Suppresses apoptosis in hepatocellular carcinoma 
although functional mechanism is unknown.  Studies by 
Yoshibayashi et al., (2007) suggest that PEG10 is another 
target of SIAH1-mediated degradation however this was 
not confirmed. 
(Yoshibayashi et al., 2007) 
PLCЄ  Hydrolyses phospholipids and plays an important role in 
various signal transduction processes.  
(Yun et al., 2008) 
Polycystin-1 Transmembrane protein involved in cell adhesion.  May 
regulate intracellular calcium homoeostasis and other 
signal transduction pathways. 
(Kim et al., 2004b) 
repp86 Integral component of the mitotic spindle which plays an 
essential role in cell cycle progression. 
(Szczepanowski et al., 2007) 
Spry2  Regulates receptor tyrosine kinase signalling, cell growth 
and differentiation. 
(Nadeau et al., 2007) 
TRAF2 Associates with, and mediates signal transduction from 
members of the TNF receptor superfamily. 
(Habelhah et al., 2002) 
Tramtrack Transcriptional repressor involved in eye development in 
Drosophila. 
(Li et al., 1997; Tang et al., 
1997; Cooper et al., 2008) 
TRB3  Negative regulator of various signal transducers including 
AF4.  Also involved in insulin signalling. 
(Zhou et al., 2008) 
T-STAR Alternative splicing factor.   (Venables et al., 2004) 
RINGO A cyclin dependent kinase (CDK) activator involved in 
cell cycle regulation 
(Gutierrez et al., 2006) 
Table 1. SIAH substrate proteins identified to date that are targeted for proteasomal degradation. 
Abbreviations: AML, acute myeloid leukemia; BOB-1, B-cell Oct-binding protein; CtIP, C-terminal 
interacting protein; DCC, deleted in colorectal cancer; EB3, end-binding protein 3; FIH, factor inhibiting 
HIF1α; HIPK2, homeodomain interacting protein kinase 2;  Kid, Kinesin like DNA binding protein; KSHV 
ORF45, Kaposi’s sarcoma-associated herpes virus open reading frame 45; mGluRs, metabotropic 
glutamate receptors; MYPT1, myosin phosphatase target subunit 1; N-CoR, nuclear receptor co-repressor; 
OBF-1, Oct binding factor 1; OGHDC, 2-oxoglutarate dehydrogenase complex; PEG10, paternally 
expressed gene 10; PHD1 and PHD3, prolyl-hydroxylases 1 and 3; PLCЄ, phospholipase CЄ; PML, 
promyelocytic leukemia protein; repp86, restrictedly expressed proliferation-associated protein; Spry2, 
sprouty 2; TIEG1, transforming growth factor β inducible early gene-1; TRAF2, TNF receptor-associated 
factor 2; TRB3, tribbles 3 homolog. *Although evidence suggests these proteins are substrates for SIAH 
mediated degradation, published studies are not conclusive. 
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Interacting 
protein 
Protein function References 
E2 enzymes   
UbcH5 A canonical E2 enzyme which is active in a broad number 
of ubiquitin transfer reactions.  
(Matsuzawa et al., 2001) 
UbcH8 E2 enzyme enriched in the brain.  Facilitates the 
ubiquitination of α-synuclein, AML1-ETO and PML-
RARα in combination with Siah. 
(Wheeler et al., 2002; 
Kramer et al., 2008; Lee et 
al., 2008b) 
UbcH9 SINA interacts with Drosophila Ubc9, and both human 
SIAH1 and SIAH2 were found to interact with the human 
homolog, UbcH9 in a yeast 2-hybrid assay.  UbcH9 
however conjugates SUMO, not ubiquitin (Desterro et al., 
1997).  
(Hu et al., 1997b) 
Neuronal   
α-synuclein Protein of unknown function, primarily found in neural 
tissue.  Monoubiquitination of α-synuclein by Siah 
proteins promotes its aggregation into insoluble fibrils 
found in Lewy bodies.   
(Liani et al., 2004; 
Engelender 2008; Lee et al., 
2008b; Rott et al., 2008) 
Dab-1 Signal transducer which regulates neuronal positioning in 
the developing brain.  Interaction with Siah results in 
inhibition of Siah activity. 
(Park et al., 2003) 
Synphilin-
1A 
Protein of unknown function.  Ubiquitination by SIAH 
does not promote its degradation but instead increases the 
formation of synphilin-1A inclusions found in Lewy 
bodies.  Synphilin-1A also appears to regulate SIAH 
activities. 
(Szargel et al., 2009) 
Others   
α-tubulin Cytoskeletal protein. (Germani et al., 2000) 
APC Plays a critical role in several cellular processes such as 
cell division, cell growth and cell migration.  It is a 
member of the protein complex which targets β-catenin for 
degradation. 
(Liu et al., 2001; Matsuzawa 
et al., 2001) 
GAPDH Glycolytic enzyme which plays a major role in apoptosis.  
Interaction with SIAH results in translocation to the 
nucleus, SIAH stabilisation and apoptosis. 
(Hara et al., 2005; Hara et 
al., 2006) 
PEG3 Induces apoptosis in cooperation with Siah1a. (Relaix et al., 2000) 
Phyllopod Drosophila adaptor protein required for tramtrack 
degradation by SINA.  A fragment of the phyllopod 
protein has been shown to inhibit mammalian Siah protein 
activity. 
(Li et al., 2002; Cooper et 
al., 2008; Moller et al., 
2009) 
POSH A scaffold component of the apoptotic JNK pathway (Xu et al., 2006) 
Ski A transcriptional co-repressor. Interaction with Siah2 
inhibits Siah2 activity. 
(Zhao et al., 2010) 
SIP Adaptor protein required for SIAH-mediated degradation 
of β-catenin.  Recently identified as a potential regulator of 
apoptosis.  
(Matsuzawa et al., 2001; 
Santelli et al., 2005; Luo et 
al., 2010) 
Vav GDP/GTP exchanger protein which regulates cytoskeletal 
reorganisation and signalling pathways.  SIAH2 inhibits its 
activity.   
(Germani et al., 1999) 
Table 2. SIAH-interacting proteins identified to date which are not targeted for proteasomal 
degradation.  Abbreviations: APC, adenomatous polyposis coli; Dab-1, disabled-1; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; PEG3, paternally-expressed gene 3; POSH, plenty of SH3s; 
SIP, Siah interacting protein; Ubc, ubiquitin conjugating enzyme.  
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Some of the SIAH substrates listed in Table 1 are targeted for proteolytic degradation by 
both human SIAH1 and SIAH2 proteins.  For example, DCC is regulated by both SIAH1 
in SIAH2 (Hu et al., 1997b).  In some cases, substrates are targeted for degradation by 
solely one SIAH member, for example TRAF2 is targeted for proteasomal degradation by 
SIAH2 but not SIAH1 (Habelhah et al., 2002).  In most publications however, only one 
SIAH family member is analysed and often it is not clear which SIAH family member is 
under scrutiny.  Thus, further investigation is needed to determine whether or not the 
proteins in tables 1 and 2 are regulated by or are regulators of each of the murine and 
human Siah/SIAH proteins.  
It is clear however that SIAH proteins operate in diverse signalling pathways as they 
interact with such a varied array of proteins.  As a result SIAH proteins play a critical role 
in a range of biological processes including cell cycle control, apoptosis, tumour 
suppression (discussed further in sections 1.3.4 and 1.3.5), axon guidance (Hu et al., 
1997b), and the hypoxic response (see section 1.3.7).   
1.3.3 Siah1b and SIAH1 are direct transcriptional targets of p53 
A number of studies have reported that overexpression of p53 induces expression of 
Siah1 family genes.  p53 is a homotetrameric transcription factor that can activate/repress 
the transcription of a number of genes controlling cell cycle progression, apoptosis, and 
DNA repair.  It plays an extremely important role in regulating cell proliferation and is 
one of the most frequently mutated genes in human tumours (Bergamaschi et al., 2004).  
p53 is normally present at low levels in the cell but in response to various types of 
cellular stress, protein levels increase considerably and it accumulates in the nucleus 
where it binds to specific DNA sequences (El-Deiry et al., 1992).  Activation of p53 
results in either cell cycle arrest or the induction of apoptosis.   
The murine Siah1b gene was found to be activated during p53-mediated apoptosis by 
Amson and colleagues in (1996).    Later, analysis of the Siah1b promoter revealed that it 
contains a functional p53 responsive element which is bound by p53 in vitro and in vivo 
and activation of p53 leads to a significant increase in Siah1b transcription (Fiucci et al., 
2004).  Thus Siah1b is a direct transcriptional target of p53.  
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A number of reports have also shown that the human SIAH1 gene is activated by p53.  
For instance, Matsuzawa et al., (1998) found that genotoxic stress or overexpression of 
p53 in 293 cells resulted in an increase in SIAH1 mRNA levels.   Liu et al., (2001) further 
confirmed this in 293T cells showing that SIAH1 mRNA levels increased when p53 was 
overexpressed.  They also showed that levels of the SIAH1 substrate, β-catenin were 
dramatically reduced when p53 was transiently overexpressed.  Gene expression analysis 
by Yoon et al., (2002) also revealed that human SIAH1 transcription significantly 
correlated with the dosage of p53.   
Maeda et al., (2002) also found that SIAH1 mRNA was increased by p53 overexpression 
in three different cell lines (Saos2, 293, K562).   Surprisingly however, reporter plasmids 
containing the promoter region of SIAH1 did not respond to p53 (Maeda et al., 2002).  
They therefore hypothesised that p53 may activate the SIAH1 gene through another 
region of SIAH1 or induction by p53 may not be due to transcription, but by mRNA 
stabilisation.   
Later, a novel SIAH1 transcript, SIAH-1L was characterised (Iwai et al., 2004).  This 
transcript contains an extra 48bp and is transcribed from an alternative in-frame ATG 
start codon.  A p53 responsive element was identified upstream of this alternative in-
frame ATG start codon and it was revealed that SIAH-1L mRNA was strongly induced 
after p53 activation whereas the 849bp SIAH1 mRNA remained unchanged (Iwai et al., 
2004).  Thus, this study implied that is was SIAH-1L which was the p53 inducible 
transcript. 
It is important to note that, in the majority of publications, the effect of p53 on Siah gene 
expression is largely investigated through overexpression studies.  In order to investigate 
whether Siah genes are activated by p53 physiologically, David Bowtell and colleagues 
analysed levels of Siah1a, Siah1b, and Siah2 mRNA in tissues harvested from wild-type 
mice in which p53 activation was induced by whole body gamma-irradiation (Frew et al., 
2002).  In this study they found that established p53 target genes (including p21 and 
cyclin G) were strongly activated, but Siah gene expression was not (Frew et al., 2002).  
It is possible that regulation of Siah gene expression differs between human and murine 
cells or alternatively, p53 may not play a major role in regulating Siah expression in vivo.  
However, in stark contrast to other publications they also report that transfection of p53 
in 293 or 293T cells had no affect on SIAH1 expression (Frew et al., 2002).  
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Discrepancies between studies may be due to differing experimental conditions.  
However, in support of SIAH1 being a direct p53 transcriptional target, several studies 
have shown that overexpression of SIAH1 mimics the effects of p53 activation, 
promoting either apoptosis or cell cycle arrest.   
1.3.4 SIAH1, apoptosis and cell cycle control  
A number of publications have revealed that SIAH1 plays an important role regulating 
cell proliferation and cell apoptosis. Overexpression of SIAH1 was reported to induce 
apoptosis in U937 cells, a human leukemic monocyte lymphoma cell line (Roperch et al., 
1999), and SIAH1 overexpression in MCF-7 cells, a breast cancer cell line, was found to 
both inhibit cell growth and increase apoptosis (Bruzzoni-Giovanelli et al., 1999).  
Consistent with a role in apoptosis, elevated expression of SIAH1 has been observed in 
dying cells.  For example, Nemani et al., (1996) demonstrated that expression of SIAH1 
is elevated in some leukemic cells and normal intestinal epithelial cells that have reached 
the terminal stage and are dying by apoptosis.  It has also been shown that SIAH1 protein 
is stabilised upon activation of the apoptotic JNK pathway and contributes to JNK-
mediated cell death (Xu et al., 2006; Wen et al., 2010b). 
Matsuzawa et al., (1998) found that transient transfection of SIAH1 in 293 cells and 
GM107 fibroblast cells resulted in growth arrest without induction of apoptosis.  
Similarly, Reliax et al., (2000) reported that expression of Siah1a alone in murine 
fibroblasts induced growth arrest however, when they co-expressed PEG3 another p53-
inducible gene, cells underwent apoptotic cell death.  Thus, they demonstrated that PEG3 
co-operates with Siah1a to promote apoptosis.  PEG3 was found to be specifically 
activated during p53 mediated apoptosis but not during p53-dependent cell cycle-arrest 
and so it was proposed that PEG3 performed a pivotal role in determining the choice 
between cell death and survival.   
It is possible that SIAH1 induces apoptosis or inhibits cell growth through ubiquitination 
and proteasomal degradation of some of its targets proteins.  A number of functional 
studies have revealed that SIAH proteins can target various transcription factors 
(including c-myb, CtIP and TIEG1, see Table 1) for degradation which are important in 
controlling cell cycle progression and apoptosis.  SIAH proteins also regulate β-catenin, a 
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multifunctional protein which activates expression of target genes to promote cell cycle 
progression and inhibit apoptosis, thus providing a link between SIAH proteins and cell 
cycle control.  As well as transcription factors and β-catenin, SIAH proteins also target 
the protein kinase HIPK2 for degradation (Winter et al., 2008; Calzado et al., 2009).  
HIPK2 is a key a mediator of DNA damage-induced apoptosis thus implicating SIAH in 
the DNA damage response.  The exact way in which SIAH1 contributes to the decision 
between promotion of apoptosis or cell-cycle arrest, however is not clearly defined. 
1.3.5 SIAH1 and tumour suppression 
Given that SIAH1 can promote apoptosis and inhibit cell growth, SIAH1 is often referred 
to as a tumour suppressor.   In support of SIAH1 functioning as a tumour suppressor, 
studies by Robert Amson and Adam Telerman whose research focuses on tumour 
reversion, the process by which some cancer cells lose their malignant phenotype, have 
revealed that up-regulation of SIAH1 expression is crucial to tumour reversion (Nemani 
et al., 1996; Roperch et al., 1999; Tuynder et al., 2002).  The molecular programme of 
tumour reversion is reviewed by Telerman and Amson (2009).  It is perhaps therefore not 
surprising that there is accumulating evidence in the literature suggesting that SIAH 
genes, particularly SIAH1 are down regulated or inactivated in human cancer and so 
SIAH1 may be an effective therapeutic molecule in treating the disease. 
1.3.6 SIAH1 and disease  
Mutational analysis of the SIAH1 gene in gastric tumours identified two somatic missense 
mutations in two out of the nine gastric cancers examined (Kim et al., 2004a).  Functional 
analysis revealed that these mutants were unable to down-regulate β-catenin in HEK293T 
cells and they were unable to induce apoptosis (Kim et al., 2004a).  Thus, mutation of the 
SIAH1 gene appears to contribute to the development and/or progression of a subset of 
gastric cancers via β-catenin stabilisation and inhibition of apoptosis.  Also, down 
regulation of SIAH1 expression has been observed in advanced stages of hepatocellular 
carcinoma (HCC) suggesting that inactivation of SIAH1 plays an important role in HCC 
progression (Matsuo et al., 2003; Yoshibayashi et al., 2007).  Introduction of SIAH1 into 
hepatoma cells has been shown to efficiently induce apoptosis and inhibit cell growth 
thus demonstrating that SIAH1 may be an effective therapeutic molecule for HCC 
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(Yoshibayashi et al., 2007).  Downregulation of both SIAH1 and SIAH2 in breast 
tumours has also been reported (Confalonieri et al., 2009) and analysis of SIAH1 and 
SIAH-1L mRNA expression  in breast cancer cell lines revealed that SIAH1 and SIAH-1L 
mRNAs were absent in four of five breast cells lines (He et al., 2010).  Thus, SIAH 
genes, and SIAH1 in particular, are believed to be a key genes in halting cancer 
progression.  
As well as playing a role in tumorigenesis, SIAH activity plays an important role in 
Parkinson’s disease (PD), the second most common neurodegenerative disorder in 
humans.  PD is characterised by progressive loss of dopaminergic neurons due to 
accumulation of ubiquitinated protein aggregates called Lewy bodies.  These deposits 
have been found to contain both SIAH1 and SIAH2, and the SIAH substrates α-synuclein 
and synphilin-1.  SIAH proteins have been shown to interact with and mono-ubiquitinate 
α-synuclein which is the primary protein component of Lewy bodies (Liani et al., 2004; 
Lee et al., 2008b; Rott et al., 2008).   Monoubiquitination of α-synuclein does not result 
in protein degradation but instead appears to promote protein aggregation both in vitro 
and in vivo which is toxic to cells (Lee et al., 2008b; Rott et al., 2008; Engelender 2008).  
SIAH proteins have been also shown to promote polyubiquitination and proteasomal 
degradation of synphilin-1 (Nagano et al., 2003; Liani et al., 2004).  However, inability of 
the proteasome to degrade polyubiquitinated synphilin-1 again leads to the formation of 
ubiquitinated inclusions. Thus, SIAH proteins play a key role in promoting inclusion 
formation.   
Mutation screening of the SIAH1 gene in 209 PD patients failed to identify any disease 
causing mutation suggesting that genetic alterations of SIAH1 do not contribute to the 
pathogenesis of PD (Franck et al., 2006).  It is possible however that too few patients 
were used in this study or, alternatively, PD pathogenesis may result from defects in other 
components of the ubiquitin proteasome pathway. 
1.3.7 SIAH2, the hypoxic response and tumorigenesis 
In contrast to SIAH1, SIAH2 plays an important role in regulating the cellular response 
to hypoxia which is triggered when cells are deprived of adequate oxygen.  Cells exposed 
to decreased oxygen alter various cellular activities in order to maintain homeostasis.   
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Essentially SIAH2 controls the stability of prolyl hydroxylases, PHD3 and PHD1 (see 
Table 1), which in turn regulate the stability of hypoxia inducible factor (HIF), a 
transcription factor which is considered to be a key regulator of the hypoxic response.  
HIF regulates the expression of many genes involved in the cell cycle, cell death, cellular 
metabolism, cell migration and angiogenesis (formation of blood vessels).   For a more in 
depth summary on the role of SIAH2 in the hypoxic pathway see the review by 
Nakayama (2009).    
Hypoxia often occurs in tumorigenic environments.  As tumours grow, they rapidly 
outgrow their blood supply leaving regions with insufficient oxygen.  In these hypoxic 
regions HIF triggers a response necessary to recruit new blood vessels thus playing an 
important role in promoting tumour cell survival.  This pathway is reviewed by Semenza 
(2007).  As SIAH2 indirectly controls HIF abundance, the potential role of SIAH2 in 
tumour development has been studied in various mouse models (Qi et al., 2008).  Results 
showed that SIAH2 seems to promote vasculogenesis, cell growth and metastasis (Qi et 
al., 2008).  Consistent with this, a number of studies have shown that inhibition of SIAH2 
activity blocks formation of tumours (Schmidt et al., 2007; Ahmed et al., 2008; Qi et al., 
2008; Moller et al., 2009). 
1.3.8 Siah mutants  
As noted earlier (section 1.3) the Drosophila sina mutant lacks R7 photoreceptor cells in 
the compound eye.  However, the mutant phenotype is not restricted to the eye.  Flies 
which are homozygous null for the sina allele have sensory bristle abnormalities, a 
reduced adult life-span, lethargic adult behaviour and they are sterile (Carthew et al., 
1990). While SINA’s role in R7 cell fate determination has been elucidated, it remains 
unknown as to why the sina mutant flies are subviable and infertile. 
In order to gain a greater physiological understanding of the role of mammalian Siah 
proteins, Siah1a and Siah2 mutant mice were generated by David Bowtell and colleagues 
(Dickins et al., 2002; Frew et al., 2003).  Siah1a mutant mice were postnatally growth 
retarded (Figure 3) and few survived beyond 3 months (Dickins et al., 2002).  Females 
were sub-fertile and males were sterile due to cell cycle arrest during the first meiotic 
division of spermatogenesis (Dickins et al., 2002).  It was hypothesised that the 
previously identified Siah substrate Kid (see Table 1), which is a chromosome and 
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microtubule binding-protein, may be required for successful chromosome segregation 
and completion of meiosis.  However researchers were unable to detect any difference in 
Kid abundance in Siah1a mutants and controls (Germani et al., 2000; Dickins et al., 
2002).  The abundance of other known Siah target proteins including β-catenin and Bag-1 
were also measured in a various tissues, but again no differences were detected in the 
steady state levels of these proteins when comparing Siah1a mutants and controls.  
Further analysis revealed that Siah1a mutant mice also had a low bone volume phenotype 
and exhibited skeletal abnormalities, thus showing Siah1a is also essential for normal 
bone metabolism (Frew et al., 2004). 
Due to Siah1 genes being linked to negative regulation of the cell cycle, Dickins et al., 
(2002) compared the growth of murine embryonic fibroblasts (MEFs) derived from wild-
type and Siah1a-/- embryos.  They found that Siah1a-/- MEFs did not display cell cycle or 
proliferative defects (Dickins et al., 2002).  Since Siah1a and Siah1b are almost identical, 
it was hypothesised that Siah1b expression may mask the full consequences of Siah1a 
absence.  Interestingly, Siah1b resides on the X chromosome, which is transcriptionally 
silenced during meiosis in male germ cells.  Therefore it is likely that it is only when this 
gene is silenced by X chromosome inactivation during spermatogenesis that a true Siah 
gene loss of function phenotype is observed.  For that reason, this may explain why 
removal of Siah1a has dire consequences solely in the meiotic cells of the testes.  
 
Figure 3. Siah1a deficiency causes growth retardation. A two week old Siah1a-/- mutant mouse (right) 
and a wild-type littermate of the same sex (left). Figure from Dickins et al, (2002). 
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In contrast to Siah1a-/- mice, Siah2 mutant mice were largely phenotypically normal.  
Cellular responses that were regulated by previously identified Siah2 substrates (TRAF, 
OBF-1 and DCC) also appeared to be unaffected (Frew et al., 2003).  Combined mutation 
of Siah1a and Siah2, however, resulted in neonatal lethality, proving that Siah1a and 
Siah2 do have overlapping functions which is perhaps not surprising considering their 
high degree of similarity (Frew et al., 2003).  
Given the proposed tumour suppressor function of human SIAH1 and its murine homolog 
Siah1a, it is of interest to note that there was no apparent increase in tumour incidence in 
Siah1a or Siah2 knockout mice.  Therefore, this implies that Siah proteins do not play a 
significant role in tumour development.  However, it is likely that multiple gene 
disruptions affecting various cellular pathways are required for tumour formation.  
David Bowtell and colleagues also attempted to generate a Siah1b mutant mouse, 
however Siah1b-/- embryos exhibited either severe developmental abnormalities or were 
reabsorbed during pregnancy (Frew et al., 2002).   Therefore, Siah1b appears to be 
essential for viability during embryonic development.   
Despite the numerous biochemical studies which have led to the identification of various 
Siah substrates, how these proteins and their stability relates to the observed Siah mutant 
phenotypes, particularly male sterility, remains unclear.  Therefore, ongoing experiments 
aiming to identify the full repertoire of Siah substrates and interacting proteins should 
further our understanding of the physiological functions of the Siah gene family.   
1.4 SIAH1 yeast 2-hybrid screen 
Prior to this study, a yeast 2-hybrid screen was performed to identify interacting partners 
of the human T-STAR protein, an alternative splicing factor which is predominantly 
expressed in the developing brain and testes (Venables et al., 1999; Stoss et al., 2001).  
Alternative splicing of precursor-mRNA (pre-RNA) is an important regulatory 
mechanism that increases the diversity of proteins transcribed from a single gene.  The 
highest levels of alternative splicing events are observed in testes tissue and this is 
believed to be important during spermatogenesis which involves many cellular changes 
and regulatory steps (Venables 2002; Yeo et al., 2004; Grosso et al., 2008).  The principal 
interactors identified in the T-STAR yeast 2-hybrid screen were SIAH1 and SIAH2.  
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Because the murine SIAH1 homlog, Siah1a, was known to be essential for male germ 
cell development (Dickins et al., 2002), it was hypothesised that the SIAH1:T-STAR 
interaction may be essential to successful germ cell production.  Further investigation 
into this interaction however, found that although human T-STAR was targeted for 
degradation by SIAH1, mouse T-STAR was not (Venables et al., 2004).  Therefore, 
modulation of T-STAR by SIAH1 could not help explain the Siah1a mutant phenotype.   
In order to further characterise the role of SIAH1, a yeast 2-hybrid screen of a human 
testis cDNA library was carried out using SIAH1 as bait (Dr Julian Venables, 
unpublished data).  A human testis cDNA library was used because high levels of Siah 
expression in mouse testes were previously reported which correlates with the defective 
spermatogenic phenotype in Siah1a mutant mice (Della et al., 1995).   
Ten proteins were identified in this screen, two of which were previously identified SIAH 
binding proteins, T-STAR (Venables et al., 2004) and SIAH1BP1 (identified as an 
interacting partner of SIAH in the 2-hybrid system by Gang Hu, Andrew Holloway, and 
David Bowtell, unpublished data).  The eight remaining proteins represented novel 
SIAH1 interactors some of which are involved in apoptosis, transcriptional regulation and 
splicing.  A brief summary of the principal interactors is presented in Table 3. 
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Gene  
symbol 
Protein name Function 
ATF3 
 
Activating 
transcription factor 3 
(ATF3) 
Binds CRE elements and represses/activates transcription. ATF3 
expression is induced by many physiological stresses and 
numerous studies have shown it plays an important role in host 
defence against invading pathogens and cancer (Thompson et al., 
2009).  An investigation into the interaction between SIAH1 and 
ATF3 was previously reported (MacLennan 2007). 
PPP1R13B 
 
Apoptosis-
stimulating protein of 
p53 (ASPP1) 
Binds to and regulates various proteins which play key roles in 
controlling apoptosis.  Interacting proteins include the tumour 
suppressor protein p53 and its family members (Samuels-Lev et 
al., 2001; Bergamaschi et al., 2004). The biological function of the 
ASPP family proteins and their potential role in tumorigenesis is 
discussed by Sullivan and Lu (2007). 
CCDC92 
 
Coiled-coil domain 
containing protein 92 
(CCDC92) 
The CCDC92 gene was recently identified as one of 43 genetic loci 
involved in lipid metabolism (Chasman et al., 2009) however the 
function of the encoded protein is unknown.   
PHC2 Polyhomeotic-like 
protein 2 (PHC2) 
Component of the chromatin-associated polycomb repressive 
complex involved in homeotic gene regulation (Isono et al., 2005).  
It is also a component of an E3 ubiquitin ligase complex which 
ubiquitinates histone H2A (Wang et al., 2004).  Thus, PHC2 plays 
an important role in regulating chromatin dynamics and 
transcription. 
PUF60 SIAH binding protein 
1  (SIAH1BP1) 
A splicing factor homologous to U2AF65, a subunit of the U2 
small nuclear ribonucleoprotein auxiliary factor (U2AF) which is 
an essential component of the splicing machinery  (Page-McCaw et 
al., 1999; Hastings et al., 2007).  This protein also regulates 
expression of the proto-oncogene, c-myc via interactions with 
transcription factor IIH and the far upstream element (FUSE) 
binding protein (Liu et al., 2006; Cukier et al., 2010).  
KHDRBS3 RNA-binding protein 
T-STAR 
Member of the SAM68 family of RNA-binding proteins involved 
in signal transduction and mRNA splicing.  Previously shown to be 
specifically degraded by SIAH1 (Venables et al., 2004). 
WHSC2 Negative elongation 
factor A (NELF-A) 
Component of the negative elongation factor (NELF) complex 
which binds to elongating RNA polymerase II and stalls 
transcription (Yamaguchi et al., 2001). 
VAPA Vesicle-associated 
membrane protein A 
(VAPA) 
Type IV integral membrane protein which associates with 
intracellular vesicles and the endoplasmic reticulum (Skehel et al., 
2000).  It is involved in the regulation of membrane trafficking, 
lipid transport and metabolism, and the unfolded protein response 
(Nishimura et al., 1999; Peretti et al., 2008) 
ZC3H14 Zinc finger CCCH-
type containing 
protein 14 (ZC3H14) 
Binds to polyadenosine RNA  (Kelly et al., 2007).   Multiple 
ZC3H14 transcripts have been identified and alternate isoforms 
locate to different areas of the cell.   Nuclear isoforms are 
implicated in mRNA processing and a cytoplasmic isoform may 
modulate gene expression in the cytoplasm  (Leung et al., 2009).   
ZC3H11A Zinc finger CCCH-
type domain 
containing protein 
11A (ZC3H11A) 
Reported to interact with U2AF65 (Prigge et al., 2009) and the 
TREX mRNA export complex (Dufu et al., 2010) however the 
functional outcome of these associations are undefined.  
Table 3. SIAH1 interacting proteins identified in a yeast 2-hybrid screen of a human testis cDNA 
library. Positive clones were sequenced and a BLAST search was carried out to confirm which proteins 
were encoded by the positive hits.  
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1.5 Research objectives 
Siah proteins are involved in an array of cellular functions due to their ability to target 
many different proteins for proteasomal degradation.  Previous studies revealed that the 
Siah1a gene in mice is essential for germ cell production in the testes as Siah1a male 
mutant mice are sterile.  Despite the wealth of knowledge on Siah proteins however, very 
little is known as to how SIAH proteins regulate germ cell development in the testes.  
Therefore the aim of this study was to further investigate SIAH1 interacting proteins 
identified in a human testes yeast 2-hybrid screen performed by Dr Julian Venables.  The 
overall objective was to establish whether or not any of these proteins were targets for 
SIAH1-mediated ubiquitination and subsequent proteasomal degradation.  Initially, we 
set out to determine whether or not these proteins contained a SIAH-binding motif, map 
the interacting domains, in both SIAH1 and its target proteins, and investigate the 
stability of the SIAH1 interactors in the presence and absence of SIAH1 in cell culture.  
Once likely SIAH1 targets were identified we sought to analyse endogenous protein 
regulation in Siah deficient cells in an attempt to further understand the consequences of 
the interaction in vivo.   
One of the likely SIAH1 target proteins identified in the SIAH1 yeast 2-hybrid screen 
was a protein called ASPP1 (Apoptosis Stimulating Protein of p53) which has been 
shown to promote p53 mediated apoptosis, much like SIAH1.  The mechanisms by which 
SIAH1 and ASPP1 proteins stimulate apoptosis however are not clearly defined, 
therefore in order to better understand ASPP1 protein function and the downstream effect 
of SIAH1 mediated degradation of this protein, we carried out protein interaction screens 
in order to identify its major protein binding partners.  A more detailed introduction into 
ASPP1 and our interest in this protein is discussed in context in the introductions to 
chapters 5 and 6.    
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2.1 Standard molecular biology techniques 
2.1.1 PCR 
The reagents used in a typical 50µl reaction mixture are listed in Table 4. 
Reagent Quantity for a 50µl reaction 
dH2O 39.3µl 
10X PCR Buffer (contains 500mM KCl, 100mM Tris-HCl and 
15mM MgCl2) 
5µl 
2mM dNTPs 2.5µl 
10µM Forward primer 1µl 
10µM Reverse primer 1µl 
Template DNA (~100ng) 1µl 
Taq polymerase  0.2µl 
Table 4. PCR recipe. 
10X PCR buffer and Taq DNA polymerase were purchased from New England Biolabs. 
Deoxyribonucleotide triphosphates (dNTPs) were purchased from Promega.  Primers 
used in this project are listed in appendix A. 
Typical PCR conditions consisted of an initial denaturation step at 92ºC for 1 minute 
followed by 32 cycles of denaturation at 92ºC for 30 seconds, annealing at 60ºC for 30 
seconds, extension at 72ºC for 1 minute with a final extension at 72ºC for 4 minutes.  
PCR amplification was carried out using a DNA Engine DYAD thermal cycler (MJ 
Research).   
2.1.2 Restriction digests 
Approximately 500ng of plasmid DNA or PCR product were digested using 5-10 units of 
the appropriate restriction enzyme with the suitable buffer (New England Biolabs or 
Promega) in a total volume of 50µl.  Samples were incubated at 37ºC for 1-3 hours. 
2.1.3 Purification of DNA after PCR or restriction digest 
To remove residual enzymes, buffers and dNTPs, samples were purified using a 
QIAquick PCR purification kit (Qiagen) according to the manufacturer’s instructions. 
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2.1.4 Ligations and re-cleavage 
The appropriate vector and DNA insert were ligated in a 20µl reaction volume.  
Reactions consisted of 200 units of T4 DNA ligase and T4 DNA ligase buffer (New 
England Biolabs).  Ligations were incubated at 16ºC overnight in a DNA Engine DYAD 
thermal cycler (MJ Research).  Re-cleavage of the vector was carried out after ligation in 
a 50µl reaction volume, using an enzyme which would cut the re-ligated vector.  This 
was to select against any vector which had re-circularised/re-ligated without the desired 
insert.   
2.1.5 Dialysis 
Dialysis of 50µl ligation/re-cleavage mixes was carried out on dialysis discs (Millipore) 
to remove residual salt from the ligation/digest buffers.  Samples were dialyzed against 
dH2O for 1 hour at room temperature.   
2.1.6 Transformation of electrocompetent bacterial cells  
Plasmids were transformed into E. coli DH5α by electroporation using a method derived 
from Dower et al., (1988).  In brief, plasmid DNA was mixed with electro-competent 
cells on ice and then transferred to a pre-cooled 1mm electroporation cuvette (Molecular 
BioProducts).  Electro-competent DH5α frozen stocks were prepared by Caroline 
Dalgliesh (IHG, Newcastle University, UK).  Cells were electroporated at 1.5kV, 25µF 
capacitance, and 200Ω resistance using a Gene Pulser (Bio-Rad).  Electroporated cells 
were immediately incubated in 1ml of LB broth (10g/l Sodium Chloride, 10g/l Tryptone, 
5g/l Yeast extract) for 1 hour at 37ºC, allowing them to recover.  Cells were plated out on 
LB agar plates containing the appropriate selective antibiotic (LB Broth + 15g/l Agar + 
50µg/ml Ampicillin or 50µg/ml Kanamycin).  Plates were incubated overnight at 37ºC.   
2.1.7 Transformation of heat-shock competent bacterial cells  
Plasmid DNA was mixed with a 30µl aliquot of JM109 E. coli cells and incubated on ice 
for 1 minute.  Cells were heat-shocked at 42°C for 1 minute and immediately transferred 
to ice.  After 1 minute on ice, 1ml of pre-warmed LB medium was added and 
transformants were allowed to recover for 1 hour at 37°C.  Cells were pelleted by 
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centrifugation and excess medium was discarded.  Cell pellets were re-suspended in the 
remaining LB and then plated out on LB-agar containing the selective antibiotic.   Plates 
were incubated overnight at 37ºC.   
2.1.8 Purification of plasmid DNA 
Single colonies of transformed bacteria were used to inoculate 5ml of LB broth 
containing the selective antibiotic (50µg/ml) and were incubated in a 37ºC shaker 
overnight.    Cultures were centrifuged at 2,500rpm at 15ºC for 10 minutes and plasmid 
DNA was prepared from the pelleted bacteria using a QIAprep Miniprep Kit (Qiagen) 
following the manufacturer’s instructions.  All plasmids used in this project are listed in 
appendix B. 
2.1.9 Agarose gel electrophoresis 
1-2% agarose gels were prepared containing 1X Tris-acetate-EDTA buffer (TAE) (0.04M 
Tris base, 0.04M Acetate and 0.001M EDTA) pH 8, and ethidium bromide (final 
concentration of 0.5µg/ml).  DNA samples were prepared by adding an appropriate 
amount of 10X Orange G loading dye (20% ficoll, 1mM EDTA and 2µg/µl Orange G).  
Samples were run at 60-100 volts in 1X TAE until sufficient separation was achieved.  
DNA was visualised under UV light using a Gene Genius Bioimaging System (Syngene) 
and sizes were estimated using either 10Kb SmartLadder (Eurogentec) or 1Kb plus ladder 
(New England Biolabs).   
2.1.10 DNA sequencing 
Sequencing reactions were carried out by Geneservice (Cambridge, UK).  Purified 
plasmid DNA at a minimum concentration of 100ng/µl was sent along with 32pmol of 
the appropriate primer. 
2.1.11 Microscopy 
GFP fluorescence in HEK293 cells was viewed using a Zeiss Axiovert200 Fluor Arc 
microscope.  Immunofluorescence images were captured using a fluorescence Axioplan2 
microscope. 
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2.1.12 Site-directed mutagenesis  
Mutagenic oligonucleotide primers were designed to contain the desired point mutation 
in the middle of the primer with 10-15 bases of correct Siah1b sequence either side.  
They were designed to have a minimum GC content of 40%, a C/G base on either end 
and to have a minimum melting temperature of 74°C.  For each mutation, two 
oligonucleotides were designed which anneal to the same sequence on opposite strands of 
the Siah1b-FLAG plasmid.   Primers used for mutagenesis are listed in Table 5. 
Primer name Target Sequence (5′-3′) Mutation 
Siah1b-a (pos13/5)F   Siah1b  GAGCCGTCAGACTGCTACAGCATTATCC A5T 
Siah1b-a (pos13/5)R  GGATAATGCTGTAGCAGTCTGACGGCTC A5T 
Siah1b-a (pos28/10)F Siah1b  GCTACAGCATTACCCACTGGCACCTC S10P 
Siah1b-a (pos28/10)R  GAGGTGCCAGTGGGTAATGCTGTAGC S10P 
Siah1b-a (Pos80/27)F Siah1b  CCTGCCTTGACTGGCACAACTGCATCC D27G 
Siah1b-a (Pos80/27)R  GGATGCAGTTGTGCCAGTCAAGGCAGG D27G 
Siah1b-a (Pos301/101)F Siah1b  CCCCTGTAAATATGCCGCTTCTGGATGTG S101A 
Siah1b-a (Pos301/101)R  CACATCCAGAAGCGGCATATTTACAGGGG S101A 
Siah1b-a (Pos303/102)F Siah1b  CTTCCCCTGTAAATATTCCTCTTCTGGATGTG A102S 
Siah1b-a (Pos303/102)R  CACATCCAGAAGAGGAATATTTACAGGGGAAG A102S 
Siah1b-a (Pos336/113)F Siah1b  GCCACACACCGAAAAGGCAGAGCACG K113E 
Siah1b-a (Pos336/113)R  CGTGCTCTGCCTTTTCGGTGTGTGGC K113E 
 Table 5. Primers used for site-directed mutagenesis. Primers were purchased from IDT. 
Siah1b point mutants were generated following the Stratagene QuickChange mutagenesis 
protocol.  Reactions were set up as indicated in Table 6. 
Reagent Quantity for a 50µl reaction 
dH2O 35µl 
10x Pfu Buffer (Stratagene)  5µl 
dNTPs (100mM total) 1µl 
Primer mix (100ng/µl each)  3µl 
Template (10ng/µl) 5µl 
PfuTurbo DNA polymerase (Stratagene) 100U  1µl 
Table 6. Site-directed mutagenesis PCR recipe (adapted from the Stratagene QuickChange mutagenesis 
protocol). 
Mutants were generated by temperature cycling using a DNA Engine DYAD thermal 
cycler (MJ Research).  The template plasmid was denatured by an initial denaturation 
step at 95ºC for 2 minutes followed by 18 cycles of denaturation at 95ºC for 30 seconds, 
annealing of oligonucleotide primers containing desired mutation at 65ºC for 1 minute, 
PfuTurbo DNA polymerase extension at 72ºC for 10 minutes followed by a final 
extension at 72ºC for 10 minutes.   
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1µl of the DpnI restriction enzyme (10 U/µl) was added directly to each sample and 
reactions were incubated at 37°C for 3 hours to permit digestion of  the parental (i.e., the 
non-mutated) DNA.  The plasmid DNA was then cleaned up using the Qiagen PCR 
purification kit following manufacturer’s instructions and transformed into heat-shock 
competent JM109 E. coli cells.  Plasmid DNA was purified from JM109 colonies and 
mutations were verified by DNA sequencing.    
2.2 RNA-based methods 
2.2.1 RNA extraction 
Total cellular RNA was extracted from cultured cells or tissue using Trizol Reagent 
(Invitrogen) following manufacturer’s instructions.  Briefly, samples were resuspended in 
100µl of Trizol reagent and incubated at room temperature for 5 minutes.  20µl of 
chloroform was added and samples shaken to mix.  After a further incubation for 10 
minutes, the samples were centrifuged at maximum speed for 15 minutes at 4ºC.  The top 
aqueous layer was transferred to a new tube and an equal volume of isopropanol was 
added.  The samples were incubated at room temperature for 10 minutes and then 
centrifuged again at maximum speed for 10 minutes at 4ºC.  The supernatant was 
removed and the RNA pellet was washed in 70% ethanol.  The RNA pellet was then 
resuspended in nuclease free dH2O and quantified using a NanoDrop Spectrophotometer 
(NanoDrop Technologies). 
2.2.2 Reverse transcriptase PCR (RT-PCR) 
cDNA was transcribed from total RNA and then amplified using the OneStep RT-PCR 
kit (Qiagen) following manufacturer’s instructions.  Briefly, 5µl reactions were set up as 
indicated in Table 7. 
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Reagent Quantity for a 5µl reaction 
5x OneStep RT PCR Buffer 1µl 
dNTPs (10mM each) 0.2µl 
10µM Forward primer 0.3µl 
10µM Reverse primer 0.3µl 
Q-Solution 1 µl 
RNA (50ng/µl) 2µl 
OneStep RT PCR Enzyme mix 0.2µl 
Table 7. OneStep RT-PCR recipe (adapted from the Qiagen protocol). 
Reactions were incubated at 50oC for 30 minutes, then 95oC for 15 minutes, followed by 
34 cycles of denaturation at 94oC for 30 seconds, annealing at 56oC for 30 seconds, 
extension at 72oC for 1 minute with a final extension at 72oC for 10 minutes.  Reactions 
were carried out using a DNA Engine DYAD thermal cycler (MJ Research).  Primers 
used for RT-PCR are listed in Table 8. 
Primer name Sequence (5′-3′) Purchased from 
HPRT-F CTGGTGAAAAGGACCTCTCG Sigma 
HPRT-R TGGCAACATCAACAGGACTC Sigma 
Siah1a-F ATTACCCACTGGCACCTCAA IDT 
Siah1a-R TGGCCACTCTGACACTGAAG IDT 
Siah2-F GGGCTGTTCCCTGACTCTAC IDT 
Siah2-R CCCTGGCAGGTTAATGTCTG IDT 
Siah1b-F TGACCAAGAATGTGGAACCTT Sigma 
Siah1b-B TGGCAACACATAGTCAAAGCA Sigma 
Table 8. Primers used for RT-PCR. 
2.3 Protein based methods 
2.3.1 SDS-PAGE 
Samples were sonicated in 2X SDS sample loading buffer (100mM Tris-HCl pH6.8, 
200mM DTT, 4% SDS, 20% Glycerol, 0.2% Bromophenol Blue) to disrupt any intact 
DNA.  Samples were incubated for 5 minutes at 95ºC and centrifuged at 10,000rpm for 2 
minutes before loading onto a discontinuous gel.  Gels were made with a 4% stacking gel 
(0.125mM Tris pH6.8, 0.1% SDS, 0.1% ammonium persulphate, 0.2% TEMED and 4% 
acrylamide) and a 10% acrylamide resolving gel (375mM Tris pH8.8, 0.1% SDS, 0.1% 
ammonium persulphate, 0.2% TEMED and 10% acrylamide). Samples were 
electrophoresed in 1X SDS-PAGE running buffer (30mM Tris, 188mM Glycine, 0.1% 
SDS) at 150V for 45 minutes.   
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Gels were used either for Western blotting (see below), or stained using either 
SimplyBlue Safe stain (Invitrogen) or PlusOne Coomassie Blue PhastGel (GE 
Healthcare).  One tablet of PlusOne coomassie was dissolved in 400ml of staining 
solution (25% Methanol and 10% acetic acid).  De-staining of coomassie stained gels was 
carried out in 7% acetic acid and 50% Methanol and SimplyBlue stained gels were de-
stained with dH2O.  For both Western blotting and staining, protein sizes were estimated 
using Broad Range Pre-stained Protein Marker (New England Biolabs).   
2.3.2 Western blot 
PAGE gels were transferred in Western transfer buffer (39mM Glycine, 58mM Tris, 
0.04% SDS, 20% Methanol) to Hybond-C Extra nitrocellulose membrane (Amersham 
Biosciences) using a Semi-Dry Trans-Blot apparatus (Bio-Rad) for 45 minutes at 15V.  
Filters were soaked with Ponceau stain (Sigma) to determine blotting efficiency then 
washed in TBS-T (8.75g/l NaCl, 6.5g/l Tris-HCl, 2ml/l Tween).  Filters were incubated 
with block solution (10% non-fat dried milk in TBS-T) for 1 hour at room temperature on 
a rotating wheel to block non-specific binding sites.  Block was then removed and the 
primary antibody added at the appropriate dilution in block (for dilutions see Table 9).  
This was incubated at room temperature for 1 hour on a rotating wheel.  Filters were then 
washed three times in TBS-T to remove residual primary antibody (5 minutes per wash).  
Horseradish peroxidase (HRP) conjugated secondary antibody was added at the 
appropriate dilution in block and incubated at room temperature for 1 hour on a rotating 
wheel.  Filters were then washed twice in TBS-T to remove residual secondary antibody.  
The resulting signals were visualised by enhanced chemiluminescence (ECL).  For this, 
equal volumes of ECLI (1% Luminol, 0.44% Coumaric acid, and 100mM Tris pH 8.5) 
and ECLII (0.02% hydrogen peroxide in 100mM Tris pH 8.5) were added to the 
membrane and left for 1 minute.  Excess ECL was then removed and filters were exposed 
on photographic film (Kodak).  Films were developed in a Compact X4 developer 
(Xograph Imaging Systems). 
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Antibody name Source Mono/ 
Polyclonal 
Species Dilution  
for WB 
Dilution  
for IF/TS 
α-ASPP1 Thornton, 2005 Polyclonal Sheep 1:500 1:100 
α-β Actin                 Sigma    Polyclonal Rabbit 1:1000 - 
α-Clusterin  Santa Cruz  Polyclonal Goat 1:250 - 
α-FLAG Sigma Monoclonal Mouse 1:1000 - 
α-GFP Clontech  Monoclonal Mouse 1:1000 - 
α-HA CRUK Monoclonal Mouse 1:500 - 
α-Hsp70 Stressgen  Monoclonal Mouse 1:500 - 
α-NELF-A Santa Cruz Polyclonal Rabbit 1:300 1:50 
α-p53  CRUK Polyclonal Mouse 1:250 - 
α-RNAPII Upstate Monoclonal Mouse 1:500 - 
α-Sec16A Watson et al., 2006 Polyclonal Sheep 1:1000 - 
α-tubulin Sigma Monoclonal Mouse 1:3000 - 
α-Ubiquitin Sigma Polyclonal Rabbit 1:100 - 
α-V5 Invitrogen Monoclonal Mouse 1:5000 1:200 
α-YBX1 Cohen et al., 2010 Polyclonal Rabbit 1:1000 - 
α-mouse IgG(HRP) Amersham  Polyclonal Sheep 1:1000 - 
α-goat IgG(HRP) DAKO Polyclonal Rabbit 1:1000 - 
α-rabbit IgG(HRP) Jackson Lab Polyclonal Goat 1:1000 - 
α-sheep IgG(HRP) DAKO Polyclonal Rabbit 1:1000 - 
α-rabbit IgG(488) Molecular Probes Polyclonal Donkey - 1:400 
α-sheep IgG(594) Molecular Probes Polyclonal Donkey -  1:400 
α-mouse IgG(594) Molecular Probes Polyclonal Donkey -  1:400 
α-rabbit IgG(Biotin) DAKO Polyclonal Goat - 1:300 
Table 9. Antibodies used for Western blotting (WB), immunofluorescence (IF) and tissue staining 
(TS). 
2.3.3 Stripping Western blots 
When investigating more than one protein on the same Western blot, in some cases blots 
were stripped to remove primary and secondary antibodies from the membrane.  To do 
this, stripping buffer (62.5mM Tris-HCl pH 6.8, 2% SDS) was warmed by microwaving 
at 900W for 20 seconds and then 2-beta mercaptoethanol was added to a final 
concentration of 0.1M.  Blots were incubated in this solution with agitation for 40 
minutes at room temperature.  Stripping solution was disposed of and blots were washed 
with TBS-T (three 5 minute washes).  Efficiency of stripping was checked by the 
enhanced chemiluminescence (ECL) reaction described previously (see 2.3.2).   
2.3.4 In vitro transcription and translation 
Plasmids encoding the appropriate proteins downstream of a T7 promoter 
(SIAH1pCDNA and Luciferase T7 TNT control plasmid) were transcribed and translated 
using the TNT-quick T7 coupled Transcription/Translation system (Promega).  35S-
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methionine was incorporated into the protein products, which were subsequently 
analysed by SDS-PAGE and autoradiography. 
2.3.5 In vitro pull down 
Pull-downs were performed as described previously (Venables et al., 2004).  Briefly, in 
vitro-translated and 35S-methionine-labelled proteins were added to GST-fusion proteins 
attached to glutathione agarose.  They were then incubated for 1 hour with rotation at 
room temperature.  The samples were washed four times in PBS, containing 1mM DTT 
to remove any unbound protein before analysis by SDS-PAGE and autoradiography. 
2.3.6 Immunocytochemistry  
Cells were grown on coverslips (in 12-well plates) in the appropriate growth medium 
until 60-75% confluent.  Cells were washed in 1X PBS and fixed in 100% methanol for 1 
minute at -20°C.  The methanol was removed and cells were washed three times with 1X 
PBS. 
Cells were permeabilised by incubating in 1% Triton X-100 for 10 minutes at room 
temperature.  Permeabilised cells were then washed three times with PBS to remove 
Triton X-100.  Cells were incubated in blocking solution (10% horse serum in 1X PBS) 
for 1 hour at room temperature and then incubated in the appropriate primary antibody 
diluted in blocking solution for 2 hours at room temperature (for antibodies and dilutions 
see Table 9).  After three washes in 1X PBS, the cells were then incubated with the 
appropriate fluorescent conjugated secondary antibody diluted in blocking solution for 1 
hour at room temperature and washed as before. The coverslips were then mounted in 
VectaShield Mounting Medium with 4’,6-diamidino-2-phenylindole (DAPI) (Vector 
Laboratories) and images were captured using a fluorescence Axioplan2 microscope.  
2.3.7 Immunohistochemistry  
Slices of paraffin wax-embedded tissue sections (7-8µm) from wild-type mouse testes 
were prepared and mounted on slides by Dr Ingrid Ehrmann (IHG, Newcastle 
University).   Sections were de-waxed by washing twice in HistoClear (National 
Diagnostics) for 12 minutes.  Sections were then hydrated by washing in ethanol (2x 5 
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minute washes in 100% ethanol, followed by a 5 minute wash in 70% ethanol and finally 
a 5 minute wash in 50% ethanol).  To block endogenous peroxidase activity sections 
were incubated in a methanol peroxide solution (3% H2O2 in Methanol) for 30 minutes 
and then rinsed in water.  Antigens were revealed by microwaving the sections at 900W 
for 20 minutes in 0.01M sodium citrate buffer pH 6.0.  Once cooled, the sections were 
incubated in blocking solution (10% horse serum in TBS) to block non-specific antibody 
binding sites for 20 minutes at room temperature.  The sections were then incubated with 
the primary antibody diluted in TBS overnight at 4°C in a humidified chamber (for 
dilutions see Table 9).  Sections were then washed 4X with TBS before addition of the 
appropriate biotinylated secondary antibody which was diluted in blocking solution (for 
dilutions see Table 9).   Sections were incubated with the secondary antibody at room 
temperature for 30 minutes followed by another 3 washes in TBS.  Biotinylated 
secondary antibody was visualised using the avidin-biotin-horseradish peroxidase system 
(ABC-HRP) and diaminobenzidine (Sigma) following manufacturer’s instructions.   
Sections were counter-stained with haematoxylin to stain nuclei, dehydrated through 
graded alcohols (2x 5 minute washes in 70% ethanol, followed by 2x 5 minute washes in 
100% ethanol) and HistoClear (5 minute wash), before being mounted in Histomount 
(National Diagnostics).  Images were captured/analysed using a Zeiss Axioplan 2 light 
microscope. 
2.3.8 Bacterial expression and purification of fusion proteins 
2.3.8.1 BL21 calcium chloride transformation 
For expression of GST and histidine-tagged fusion proteins, E. coli BL21 cells were 
transformed with the appropriate plasmid (pGEX or pET32a) encoding the fusion protein. 
1µl of standard mini-prepped plasmid DNA was added to 100µl of competent E. coli 
BL21 cells and incubated on ice for 20 minutes. The cells were then heat shocked at 42°C 
for 1 minute and immediately returned to ice for a further minute. The cells were allowed 
to recover in 1ml LB broth for 1 hour at 37°C. The cells were then plated out onto LB 
agar plates containing the selective antibiotic, ampicillin, and were incubated overnight at 
37°C. 
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2.3.8.2 Large-scale protein expression  
Large scale protein expression was carried out using Overnight Expression Instant TB 
Medium (Novagen) according to the manufacturer’s instructions.  Briefly, a single colony 
was taken from the transformed BL21 cell plate and used to inoculate 3mls of Overnight 
Express Instant TB Medium (Novagen) containing ampicillin to generate a ‘starter 
culture’.  This culture was incubated in a 37°C shaker until an optical density of 0.5 at 
A600nm was reached.  100mls of pre-warmed Overnight Express Instant TB Medium 
(Novagen) (containing ampicillin) was then inoculated with the whole starter culture. At 
this point 0.5ml samples of the cultures were taken.  The 100ml culture was then 
incubated at 37°C for a further 16 hours.  After 16 hours, further 0.5ml samples were 
taken and the remaining cultures were centrifuged at 3,000rpm for 10 minutes and the 
supernatants removed.   
2.3.8.3 Purification of GST-fusion proteins 
Bacterial cell pellets containing GST fusion proteins were resuspended in 10ml 1X PBS.  
2mg of Lysozyme (Sigma) were added to lyse the cells, and incubated for 20 minutes at 
room temperature.  Lysates were then sonicated on ice to break up DNA.   DTT was 
added to a final concentration of 1mM, 1X PMSF was added, triton X-100 was added to a 
final concentration of 2% along with 200 units of DNase I (Roche).  Samples were 
incubated with shaking for 30 minutes, at room temperature.  KCl was added to a final 
concentration of 500mM.  The sample volume was then made up to 20ml with 1X PBS.  
The samples were re-sonicated and freeze-thawed between -80°C and room temperature 
to ensure there was no intact DNA.   To test solubilisation, 10µl of cell lysate was saved.  
The remaining cell lysate was centrifuged at 14,000rpm for 10 minutes at 4°C.  The 
supernatant containing the soluble material was retained, and the pelleted insoluble 
material was discarded.  Total cell lysate and soluble supernatant were analysed via SDS-
PAGE to ensure the GST-fusion protein was soluble.   
To purify the GST-tagged peptide, 40mg of glutathione agarose (Sigma) was resuspended 
in 1ml dH2O and rotated for 2 hours at room temperature.  The agarose was then washed 
4 times in 1X PBS.  After the last wash a 50% slurry was created by resuspending the 
agarose in equal amount of 1X PBS.  500µl of the 50% slurry was added to 10ml of the 
soluble cell lysate (containing the GST-tagged protein).  This was incubated with rotation 
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for 1 hour at room temperature.  Following the 1 hour incubation, the agarose was 
pelleted by centrifugation at 3,000rpm for 1 minute.  The supernatant was removed and 
saved for analysis of purification efficiency.  The glutathione agarose with the attached 
GST-fusion protein was then washed 5 times in 10ml PBS, containing 0.5mM DTT and 
0.25M KCl.  Agarose was pelleted between washes by centrifugation at 3,000rpm for 1 
minute.  Finally, the GST-fusion-bound beads were re-suspended in an equal volume of 
the PBS wash buffer.  To check purification, 10µl of the GST-fusion-bound beads were 
analysed by SDS-PAGE.  
2.3.8.4 Purification of Histidine-fusion proteins 
Bacterial cell pellets containing histidine fusion proteins were resuspended in 50ml 
equilibration buffer (50mM sodium phosphate pH 8.0, 0.3M sodium chloride and 10mM 
imidazole).  The samples were then freeze-thawed between -80°C and room temperature 
and then sonicated on ice.  The lysed cultures were centrifuged at 10,000rpm for 30 
minutes at 4°C and the soluble supernatant material was retained. 
For ASPP1(357-532)His, purification was carried out under native conditions using 
ProCatch His resin (Macs Molecular).  The required amount of ProCatch His resin was 
transferred to a sterile tube and pelleted by centrifugation at 3,000rpm for 2 minutes.  The 
supernatant was discarded and the resin was pre-equilibrated by adding 10 volumes of 
equilibration buffer.  The resin was pelleted again and the pre-equilibration wash was 
repeated.  The soluble cell lysate containing the histidine-fusion protein was then added 
to the resin and mixed on a rotating wheel for 1 hour at room temperature. The samples 
were centrifuged at 3,000rpm at 4°C for 5 minutes to pellet the resin and the supernatants 
discarded. The His-bound resin was then washed five times in wash buffer (50mM 
sodium phosphate pH 8.0, 0.3M sodium chloride and 20mM imidazole).     
Bound protein was eluted by adding 1ml of elution buffer (50mM sodium phosphate pH 
8.0, 0.3M sodium chloride and 250mM imidazole) and mixing on a rotating wheel for 10 
minutes at room temperature. The samples were then centrifuged at 7,000rpm for 30 
seconds and the supernatants retained.  The elution process was repeated twice and eluted 
samples were assayed by SDS-PAGE. 
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2.3.9 Purification of α-ASPP1 polyclonal antibody 
2.3.9.1 IgG isolation 
Total IgG was separated from the sera by caprylic acid purification, a method derived 
from Mckinney and Parkinson (1987).   Sera was diluted in four volumes of 60mM 
sodium acetate pH 4.0.  To precipitate non-IgG proteins caprylic acid (25µl per ml of 
serum/acetic acid) was added in drop wise manner whilst stirring.  The mixture was 
incubated at room temperature for 30 minutes, and centrifuged at 10,000rpm for 30 
minutes at 4ºC.  The supernatant was then filtered through Whatman paper to remove any 
protein precipitate.  The resulting IgG was neutralised with one tenth volume of 10X PBS 
and cooled to 4°C.  Ammonium sulphate (0.277 g per ml) was slowly added whilst 
stirring to precipitate the IgG.  This was incubated for a further 30 minutes whilst stirring 
at 4°C.   IgG was collected by centrifugation at 10,000rpm for 15 minutes at 4°C.  The 
supernatant was discarded and the precipitated IgG was resuspended in 25ml of 1X PBS 
and dialysed overnight at 4°C in 1X PBS.  
2.3.9.2 Affinity purification
The purified His-tagged ASPP1 epitope (see section 2.3.8.4) was coupled to a SulfoLink 
column (Pierce) following the manufacturer’s instructions.  The column was then washed 
sequentially with 10 gel-bed volumes of 10mM Tris pH 7.5, 100mM glycine pH 2.5, 
10mM Tris pH 8.8, 100mM triethylamine pH 11.5 and 10mM Tris pH 7.5, respectively.  
Total IgG (see above, section 2.3.9.1) was run through the column three times to attach 
the antibody to the epitope.  The columns were then washed with 20 gel-bed volumes of 
10mM Tris pH 7.5 and then with 10mM Tris pH 7.5 containing 0.5M sodium chloride.   
To elute the antibody, first 10 gel-bed volumes of 100mM glycine pH 2.5 was added to 
the column and elutions were collected in 850µl fractions.  Each collected fraction was 
neutralised by addition of 150µl 1M Tris pH 8.0.  The pH of the column was then 
adjusted by washing with 10 gel-bed volumes of 10mM Tris pH 8.8.   The basic elution 
was performed following the same procedure but this time 10 gel-bed volumes of 
100mM triethylamine pH 11.5 was added.  Each collected fraction was tested for protein 
content by Bradford assay (Bio-Rad, following manufacturer’s instructions) and the 
positive fractions were dialysed overnight at 4°C against 1X PBS. 
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2.3.9.3 Pre-absorption assay 
To test the specificity of the generated antisera, the His-tagged ASPP1 epitope attached to 
ProCatch His resin (see section 2.3.8.4) was first incubated with agitation in blocking 
solution (10% non-fat dried milk in TBS-T) for 30 minutes at room temperature.  The 
antisera was then added at the optimum concentration (for dilutions see Table 9) and 
incubated for a further 30 minutes. The peptide and antiserum mixtures in blocking 
solution were then used as the primary antibody and the standard method for Western 
blotting was followed.   
2.3.10 Immunoprecipitation with Protein A Dynabeads 
To analyse proteins co-immunoprecipitating with ASPP1 in mouse testes the outer 
membrane of the mouse testes were removed, and testes were broken down in 1X PBS 
using a pipette.  Tissue was transferred to an eppendorf and spun down at maximum 
speed for 5 minutes in a cooled centrifuge.  The supernatant was discarded and tissue was 
lysed in IP lysis buffer (50mM Tris pH 7.4, 100mM KCl, 5mM MgCl2, 0.1% NP-40, 
5mM NaF, 175µg/ml PMSF and 1X Roche Complete Protease Inhibitor Cocktail) on ice 
for 20 minutes.  To detect ASPP1 interacting proteins in Saos2 cells, cells were harvested 
as described in section 2.5.6 and the cell pellet was lysed in IP lysis buffer as above.  In 
both experiments soluble material was separated by centrifugation at maximum speed for 
15 minutes at 4ºC.  Soluble cell lysate was then added to approximately 80µg of ASPP1 
antibody or, as a control, 80µg of sheep IgG.  Soluble cell lysate plus antibody was 
incubated overnight with rotation at 4ºC.   
When immunoprecipitating GFP-tagged proteins, HEK293 cells were transfected and 
harvested as described in sections 2.5.1 and 2.5.6.  Harvested cells were resuspended in 
IP lysis buffer and soluble cell lysate prepared as described above.  Soluble cell lysate 
was then added to 10µg of GFP antibody and incubated overnight with rotation at 4ºC 
The next day, protein A Dynabeads (Invitrogen) were washed 3 times with 0.1M sodium 
phosphate pH 8.1 (100µl of Dynabeads per IP).Soluble cell lysate was then added to 
washed beads and incubated on a rotating wheel at room temperature for 1 hour.  
Samples were then washed three times with 1X PBS and subsequently resuspended in 
SDS sample loading buffer followed by analysis by Western blotting. 
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2.3.11 Immunoprecipitation using α-FLAG affinity resin 
When immunoprecipitating FLAG-tagged proteins, transfected HEK293 cells or Flp-In 
HEK293 cells were harvested as described in section 2.5.6.  The cell pellets were 
resuspended in 1ml IP lysis buffer (50mM Tris pH 7.4, 100mM KCl , 5mM MgCl2, 0.1% 
NP-40, 5mM NaF and 1X Roche Complete Protease Inhibitor Cocktail) and incubated for 
20 minutes on ice.  Meanwhile FLAG resin (Sigma) was prepared by washing 3X in TBS 
pH 7.4 (20µl of 50% slurry per sample).  Cell lysates were then centrifuged at maximum 
speed for 10 minutes at 4ºC to separate any insoluble material.  Soluble supernatants were 
added to the prepared FLAG resin and incubated overnight at 4°C with rotation.   
The next day the samples were centrifuged for 30 seconds at 9,000rpm and supernatants 
were saved to check IP efficiency.  The resin was then washed three times (5 minutes 
with rotation per wash) in 1ml IP wash buffer (50mM Tris pH 7.4, 100mM KCl, 0.1% 
NP-40).  To determine whether or not immunoprecipitations were successful, 5µl of 
FLAG slurry was removed and added to 5µl of SDS sample loading buffer.  Samples 
were resolved by SDS-PAGE and analysed by Western blotting. 
2.3.12 Mass spectrometry 
Protein samples were separated on pre-cast SDS-PAGE gels (NuPAGE 4-12% Bis-Tris 
Gel, Invitrogen) and stained with SimplyBlue SafeStain (Invitrogen) following the 
manufacturer’s instructions.  Protein bands of interest from the ASPP1-FLAG 
immunoprecipitation (IP) were excised using a clean scalpel and digested using a Trypsin 
Profile In-gel digest (IGD) kit (Sigma).  In brief, excised protein bands were placed in 
1.5ml eppendorfs which were pre-washed with 100µl of peptide extraction solution.  Gel 
pieces were then de-stained by incubating at 37°C for 30 minutes with 200µl de-staining 
solution.  This de-staining process was repeated and the gel pieces were dried using a 
Speed Vac for approximately 30 minutes.  Proteins in the dried gel were digested 
overnight at 37°C with trypsin.  Following the overnight incubation, liquid (containing 
the extracted tryptic peptides) was removed from the re-hydrated gel piece and 
transferred to a new tube.  ASPP1 IP and Sheep IgG IP protein samples were prepared by 
Karen Lowdon and sample peptides were analysed via mass spectrometry by the North 
East Proteome Analysis Facility (NEPAF) at Newcastle University. 
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2.4 Yeast 2-hybrid  
2.4.1 Yeast culture 
Yeast strain Y190 was streaked out from a frozen stock on YP agar plates (18g/l Agar, 
20g/l Peptone, 10g/l Yeast extract, 2% Glucose and 20µg/ml Adenine).  Freezer stocks 
were prepared by Dr Ingrid Ehrmann (IHG, Newcastle University).  Plates were 
incubated at 30ºC for 72 hours.  A single colony of Y190 was picked from a YP agar 
plate and used to inoculate 100ml of YP broth (20g/l Peptone, 10g/l Yeast extract, 2% 
Glucose and 20µg/ml Adenine).  Inoculations were incubated over night in a 30ºC shaker 
(200rpm).  Cultures were diluted to an optical density of approximately 0.2 at A600nm and 
incubated further until the optical density reached 0.4-0.8 (i.e. when the cells are still in 
log phase).   
2.4.2 Yeast transformation 
Cultured cells were transformed using a lithium acetate-based transformation procedure.  
Briefly, log phase cultures were pelleted by centrifugation at 5,000rpm for 5 minutes and 
resuspended in dH2O to wash away excess media.  Cells were centrifuged again and were 
resuspended in 2ml of 0.1M LiAc.  100µl of competent yeast cells were added to each 
DNA mixture, including 5µl salmon sperm DNA (~10µg/µl, Sigma), and approximately 
200ng of each plasmid (Gal4-DNA binding domain fusion protein in the pGBKT7 vector, 
and Gal4-activation domain fusion protein in the pGADT7 or pACTII vectors, all BD 
Biosciences).  600µl of 0.1M LiAc/40% PEG was added to each sample and vortexed.  
Transformation mixtures were then incubated at 30ºC for 30 minutes, followed by 
incubation at 42ºC for 15 minutes.  The transformed yeast were plated onto SD agar 
plates (7g/l Difco Yeast Nitrogen Base, 28g/l Agar, 2% Glucose and 20µg/ml Adenine) 
and incubated at 30ºC for 72 hours. 
2.4.3 Filter lift assay 
Transformed colonies were transferred onto Hybond-C Extra nitrocellulose membrane 
(Amersham Biosciences) and snap frozen in liquid nitrogen.  Membranes were then 
placed on filter-paper pre-soaked in filter lift solution (5ml Z Buffer (8.5g/l Na2HPO4, 
5.5g/l NaH2PO4, 0.7g/l KCl, 0.24g/l MgSO4, pH 7.0) 100mM β-mercaptoethanol and 
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50µl X-Gal at 100mg/ml) and incubated at 37ºC, noting the time taken for any colour 
changes.  
2.5 Cell culture  
2.5.1 HEK293 transfection 
HEK293 cell lines were provided and maintained by Caroline Dalgliesh (IHG, Newcastle 
University).  Cells were grown at 37ºC in 5% CO2 in Dulbecco’s MEM (DMEM) with 
glutamax-1 medium supplemented with 10% Foetal Bovine Serum (FBS) and 1% 
penicillin-streptomycin (all Invitrogen).  Cells were seeded 24 hours before transfection 
to be approximately 65% confluent upon transfection.  They were transfected using the 
GeneJammer transfection reagent (Stratagene) as per the manufacturer’s instructions.  
Cells were incubated for a further 24 hours before harvesting.  
2.5.2 HeLa transfection  
HeLa cell lines were provided and maintained by Caroline Dalgliesh (IHG, Newcastle 
University).  Cells were grown at 37ºC in 5% CO2 in DMEM with glutamax-1 medium 
supplemented with 10% FBS.  Cells were seeded into appropriate plates or dishes and 
cultured for 24 hours until they had reached 60% confluency.  Cells were transfected 
using Lipofectamine2000 (Invitrogen) according to the manufacturer's instructions. Cells 
were incubated for 24 hours before harvesting. 
2.5.3 Saos2 cells  
Saos2 cell lines were provided and maintained by Caroline Dalgliesh (IHG, Newcastle 
University).  Cells were grown at 37ºC in 5% CO2 in DMEM with glutamax-1 medium 
supplemented with 10% FBS.   
2.5.4 Murine embryonic fibroblasts (MEFs)  
Murine embryonic fibroblasts derived from wild-type embryos and Siah1a-/-Siah2-/- 
embryos were supplied by Professor David Bowtell (Peter MacCallum Cancer Centre, 
Australia).  MEFs were grown at 37ºC in 5% CO2 and cultured in DMEM supplemented 
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with 10% FBS, penicillin (500IU/ml), streptomycin (500µg/ml) (PenStrep from GIBCO) 
and 200µM β-mercaptoethanol.   
2.5.5 Generation of ASPP1 HEK293 stable cell line  
Flp-In HEK293 cells were supplied by Dr Nicholas Watkins and Dr Andrew Knox 
(Institute for Cell and Molecular Biosciences, Newcastle University).  Cells were 
cultured at 37ºC in 5% CO2 in DMEM with glutamax-1 supplemented with 10% FBS.   
These cells contain a flippase recognition target (FRT) site which is stably integrated 
along with a Blasticidin resistance gene in their genome.  Therefore, Blasticidin (final 
concentration 10µg/ml) was routinely added every third feed to ensure the FRT site was 
maintained in these cells.   
Cells were seeded 24 hours before transfection to be approximately 50% confluent upon 
transfection.  The pOG44 plasmid encoding the FRT recombinase was combined with the 
relevant pCDNA5 plasmid in a 9:1 ratio (2µg of DNA in total).  Cells were transfected 
using GeneJammer transfection reagent (Stratagene) according to the manufacturer’s 
instructions.   
In brief, for each transfection in a 6-well plate, 3µl of GeneJammer was added to 100µl 
of serum free DMEM and left to equilibrate at room temperature for 5 minutes.  This was 
then combined with the 2µg of DNA and incubated for a further 10 minutes at room 
temperature.  The complexes were then added to the cells in a dropwise manner.  Levels 
of confluency were checked 24 hours later and if very high (>70%), cells were split to 
50%.  48 hours after transfection, fresh medium was added and selection for transfectants 
began by adding 1µg/ml Hygromycin B (Sigma-Aldrich).  Cells were monitored daily 
and when many cells died and detached they were removed by washing with 1X PBS and 
medium was changed.  Hygromycin B selection was maintained and Blasticidin was 
routinely added every third feed.  Once cells were sufficiently established ASPP1-FLAG 
expression was induced by adding 1µg/ml Tetracycline (Sigma-Aldrich).   
2.5.6 Harvesting cells 
The growth medium was removed and cells were washed in 1X PBS (Invitrogen) to 
remove residual serum.  Cells were then treated wit
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incubated at 37ºC for 2 minutes to allow for detachment of adherent cells.   Following 
trypsinisation, an equal volume of growth medium was added to inactivate the trypsin 
and the cell suspension was collected and centrifuged at 8,000rpm for 2 minutes.  Cell 
pellets were washed with 1X PBS, centrifuged again and resuspended in 2X SDS sample 
loading buffer for Western analysis or IP lysis buffer for immunoprecipitation.     
2.5.7 Degradation assay 
This was carried out as per Venables et al., 2004. 
2.6 Computational analysis 
2.6.1 Sequence alignments 
Sequence alignments were carried out using the ClustalW program available online at 
http://www.ebi.ac.uk/clustalw/. 
2.6.2 BLAST searches 
Nucleotide similarity searches were carried out using the NCBI Basic Local Alignment 
Search Tool programme available online at http://www.ncbi.nlm.nih.gov/BLAST/. 
2.6.3 Molecular weight prediction  
The molecular weight of uncharacterised proteins or partial protein constructs was 
predicted using the scansite tool, available online at http://scansite.mit.edu/. 
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3.1 Introduction  
Previous studies have shown that Siah1a appears to play a crucial role in cell cycle 
control as Siah1a-/- mice are postnatally growth retarded and males are sterile due to 
meiotic arrest during spermatogenesis (Dickins et al., 2002).  Despite numerous 
biochemical studies which have led to the identification of various Siah co-factors and 
substrates, none of these interactions seem to relate to the observed Siah1a-/- mutant 
phenotype of male sterility.  A yeast 2-hybrid screen, carried out by Dr Julian Venables, 
using a human testes cDNA library identified a set of potentially interesting SIAH1 
interacting proteins (see introduction, Table 3).  In an attempt to better understand SIAH1 
function in the testes, the SIAH1 interacting proteins identified in this screen were further 
investigated. 
The primary objective was to establish whether or not any of these proteins were targets 
for SIAH1-mediated degradation.  To achieve this, the SIAH1 interaction domain for 
each protein was mapped using a yeast 2-hybrid approach, proteins were analysed for the 
presence of a SIAH-binding motif and the effect of SIAH1 on the stability of each 
interactor was assayed by expressing GFP-fusion constructs in cell culture and 
monitoring GFP levels when SIAH1 was over-expressed.  
By identifying likely SIAH1 targets for degradation we could then go on to study how 
these interactions affect cellular processes.   
3.2 Confirmation of specificity of hits from the SIAH1 yeast 2-hybrid screen  
Since the yeast 2-hybrid system is based on reconstitution of a functional transcription 
factor (in this case, the yeast Gal4 transcriptional activator), checking the auto-activation 
capacity of both the bait and target is crucial. The ability to initiate transcription, due to 
some underlying activating activity is present in approximately 5% of all proteins 
(Criekinge et al., 1999).  These proteins which can activate transcription by themselves 
are classified as false positives.  
In the yeast 2-hybrid screen carried out by Dr Julian Venables, full length SIAH1 was 
cloned into the pGBKT7 vector so that it is expressed as a fusion protein with the DNA 
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binding domain of Gal4 (Figure 4).  This construct was previously tested for auto-
activation and proven not to auto-activate (Thornton 2005).  Subsequently, this construct 
was used to screen a human testis cDNA-pACTII library and a number of hits were 
identified (Table 3).  
 
Figure 4. The SIAH1 yeast 2-hybrid screen.  The yeast 2-hybrid system uses two types of yeast 
expression plasmid.  One of the plasmids (pGBKT7) contains the Gal4 binding domain sequence fused to 
the coding sequence of the protein under investigation, in this case, SIAH1.  This protein acts as the ‘bait’. 
The second plasmid (pACTII) contains the Gal4 activation domain sequence fused to a protein coding 
sequence from a library of cDNAs (this is the ‘prey’).  The two plasmids are then co-transformed into the 
same cell.  Gal4- cells are used so they do not have any endogenous Gal4 activity.  As well as being Gal4-, 
the target cells are engineered to carry a reporter gene downstream of a Gal4 promoter.  In this screen, the 
reporter gene LacZ from E. coli was used, which encodes β-galactosidase.  Yeast colonies expressing this 
enzyme turn blue in the presence of a colourless substrate X-Gal.  β-galactosidase is expressed only if the 
unknown protein of the activation domain fusion interacts with the DNA binding domain fusion protein, 
thereby bringing the Gal4 activation and binding domains close together to switch on expression.  Figure 
modified from Griffiths (2000).  
To identify whether each of the fused prey-Gal4 activation domain proteins could 
activate transcription of the LacZ reporter gene alone, yeast strain Y190 was co-
transformed with each of the prey plasmids individually and empty pGBKT7 using a 
lithium acetate-based transformation procedure (see methods section 2.4.2).  If the 
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expression of the reporter gene was due to the prey alone then the LacZ reporter gene 
would be activated in the absence of the SIAH1 bait.  Resultant colonies were subjected 
to a filter-lift assay to determine the presence/absence of an interaction via X-Gal 
blue/white screening.  There were no observable blue colonies in the samples which were 
co-transformed with empty pGBKT7 (Figure 5). Therefore none of the SIAH1 interacting 
proteins appeared to auto-activate.  The Y190 strain of yeast used in this assay 
characteristically turns from white to red during growth due to an adenine- mutation.  The 
red pigment exhibited by adenine- mutants is a putative precursor which accumulates if 
grown in medium with low adenine.  Therefore, it is likely that the red SIAH1BP1 
colonies (Figure 5) were grown on medium containing an insufficient amount of adenine.    
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Figure 5. False positive analysis of hits from the SIAH1 yeast 2-hybrid screen.  Filters stained with X-
Gal are shown.  When there is no interaction, colonies remain white or red whereas positive interactions 
manifest as blue colonies.  SIAH1-pGBKT7 was tested against all positive hits from the two-hybrid screen 
as a positive control.  Empty bait plasmid pGBKT7 was used to test for auto-activation of prey plasmids.  
None of the SIAH1 interactors appeared to auto-activate. 
3.3 Mapping the SIAH1 interaction domains 
SIAH1 is a dimeric protein which can be divided into three regions – an N-terminal 
RING finger domain (amino acids 1-99), a central zinc-finger region (amino acids 99-
153) and a novel C-terminal substrate binding domain (amino acids 153-282) (Figure 6).  
The RING finger domain binds to specific E2 enzymes functioning as a platform to 
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position the charged E2 in close proximity to the target protein (Zheng et al., 2000).  The 
substrate binding domain is the region implicated in binding various substrate proteins, 
including the degraded proteins, DCC, N-CoR and Kid (see Table 1), as well as various 
co-factor proteins such as APC and SIP (see introduction, section 1.3.2).  In order to 
determine which region of SIAH1 interacts with each of the SIAH1 hits, deletion 
derivatives containing different regions of SIAH1 were tested in a yeast 2-hybrid screen 
against each of the interactors.     
 
Figure 6. SIAH1 domain structure.  SIAH1 consists of an N-terminal RING domain followed by two 
zinc finger motifs (ZnF) and a C-terminal substrate binding domain (SBD).  
3.3.1 Generation of partial SIAH1 constructs 
Full length SIAH1 and the SIAH ring finger domain (1-99) were previously cloned into 
the pGBKT7 Gal4 DNA binding domain vector (Thornton 2005).  However, the zinc 
finger region (99-153) and the substrate binding domain (153-282) constructs were only 
available in the pGADT7 Gal4-activation domain vector.  In order to test these constructs 
against the positive hits from the 2-hybrid screen (which were cloned into pACTII, a 
Gal4-activation plasmid), these partial SIAH1 sequences needed to be transferred to the 
pGBKT7 vector.  This was achieved via PCR-based cloning.     
PCR primers flanking the coding regions were used to amplify the partial SIAH1 
sequences from the pGADT7 vector (SIAH95-F and SIAH155-B, SIAH153-F and 
SIAH1protein-B).   PCR products were then digested with EcoRI/XhoI and ligated into 
complementary digested sites in pGBKT7.  The ligations were then re-cleaved with SalI, 
followed by dialysis (SalI cuts the part of the polylinker which is removed by EcoRI/XhoI 
digestion).  1µl of each of the ligation mixes was then transformed into E. coli DH5α by 
electroporation.  The resultant transformation mix was then plated out on LB plates 
containing the selective antibiotic kanamycin and incubated at 37ºC overnight.  Colonies 
were then screened by PCR using a vector specific forward primer (T7-F) and an insert 
specific reverse primer (SIAH155-B or SIAH1protein-B).  Insert positive colonies were 
further grown in LB-kanamycin overnight before plasmid purification. 
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3.3.2 Mapping interaction domains using the yeast 2-hybrid assay 
To identify the region of SIAH1 that recognises each of the interacting proteins, the three 
separate domains of SIAH1 were tested for their ability to bind each interactor.  Full 
length SIAH1 was also tested as a positive control.  Results are presented in Table 10. 
 
 
SIAH1 construct in pGBKT7 (amino acids) 
pA
C
TI
I 
 
SIAH1 Full 
length 
SIAH1(1-98) 
Ring finger 
domain 
SIAH1(99-153) 
Zinc finger 
region 
SIAH1(153-282) 
Substrate binding 
domain 
ASPP1 ++++ - - - 
CCDC92 ++++ - - +++ 
PHC2 ++++ + + + 
SIAH1BP1 ++++ - - - 
NELF-A ++++ - - ++ 
VAPA ++++ ++ +++ +++ 
ZC3H14 +++ - - - 
ZC3H11A ++++ - - +++ 
pACTII - - - - 
Table 10. Mapping of SIAH1 interaction domains.  Each interacting pACTII construct was tested 
against the partial SIAH1 constructs to elucidate the interacting region.  The table summarises the filter lift 
assay results.  Key, ++++ strong interaction, positive blue colour within 30 minutes, +++ positive blue 
colour observable within 2 h, ++ positive blue colour observable within 3 hours, + positive blue colour 
observable within 24 hours, - no noticeable interaction after 24 hours of exposure.   
ASPP1, SIAH1BP1 and ZC3H14 only interact with the full length SIAH1 protein in this 
assay.  VAPA and PHC2 interact with all three of the SIAH1 domains, whereas NELF-A, 
CCDC92 and ZC3H11A interact specifically with the substrate binding domain.  
Negative results for interaction between the empty pACTII activation domain plasmid 
and the various SIAH1 regions in pGBKT7 confirmed that the positive results were not 
due to auto-activation by the Gal4 DNA-binding domain SIAH1 fusions alone. 
3.4 Analysis of SIAH1 hits for presence of a SIAH-binding motif 
It has been reported that many SIAH binding proteins contain a common binding motif 
that may act as a degradation signal (House et al., 2003).  This core sequence, PxAxVxP, 
often referred to as the ‘degron motif’, was found to be conserved and functional in a 
number of SIAH-interacting proteins, (such as SIP, OBF-1 and TEIG-1 with a more 
degenerate consensus sequence found in N-CoR).  The crystal structure of SIAH 
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(residues 92-282) in a complex with a peptide containing this motif was later elucidated 
(Santelli et al., 2005; House et al., 2006).     
To ascertain whether or not this peptide sequence was present in our identified SIAH1 
interactors, we performed sequence analysis using ClustalW (Larkin et al., 2007).  
Because SIAH1 interacts with a diverse array of un-related proteins, only the fragments 
of four SIAH binding proteins which contain the acknowledged degron motif, were 
aligned with the full length protein sequences of each of our interactors (Figure 7).   
DCC             SEEAPSRTIPTACVRPT-HPLRSF------------------------------------  
OBF-1           HASSGAAPAPTAVVLPH-QPLATY------------------------------------  
SIP             KAELLDNEKPAAVVAPI-TTGYTV------------------------------------  
TIEG1           NVEAARKNIPCAAVSPN-RSKCER------------------------------------  
ASPP1           QGTVSSQPVPFSALGPTEKPGIEIGKVPPPIPGVGKQLPPSYGTYPSPTPLGPGSTSSLE 480 
 
DCC             -------------------------SEEAPS--------RTIPTACVRPTHPLRSF---- 
OBF-1           -------------------------HASSGA--------APAPTAVVLPHQPLATY---- 
SIP             -------------------------KAELLD--------NEKPAAVVAPITTGYTV---- 
TIEG1           -------------------------NVEAAR--------KNIPCAAVSPNRSKCER---- 
CCDC92          RASTIAYLTSQLHAAKKKLMSSSGTSDASPSGSPVLASYKPAPPKDKLPETPRRRMKKSL 210             
 
DCC             ---------------SEEAPSRTIPTACVRPTHPLRSF----------------------  
OBF-1           ---------------HASSGAAPAPTAVVLPHQPLATY----------------------  
SIP             ---------------KAELLDNEKPAAVVAPITTGYTV----------------------  
TIEG1           ---------------NVEAARKNIPCAAVSPNRSKCER----------------------  
PHC2            MTSGNGNSASSIAGTAPQNGENKPPQAIVKPQILTHVIEGFVIQEGAEPFPVGRSSLLVG 60 
                                  
DCC             ---------------SEEAPSRTIP-----------TACVRPTHPLRSF-----------  
OBF-1           ---------------HASSGAAPAP-----------TAVVLPHQPLATY-----------  
SIP             ---------------KAELLDNEKP-----------AAVVAPITTGYTV-----------  
TIEG1           ---------------NVEAARKNIP-----------CAAVSPNRSKCER-----------     
SIAH1BP1        VLGTLGTPGLVSPALTLAQPLGTLPQAVMAAQAPGVITGVTPARPPIPVTIPSVGVVNPI 360 
                                                              
DCC             -------------------SEEAPSRTIPTACVRPTHP---LRSF--------------- 
OBF-1           -------------------HASSGAAPAPTAVVLPHQP---LATY---------------  
SIP             -------------------KAELLDNEKPAAVVAPITT---GYTV---------------  
TIEG1           -------------------NVEAARKNIPCAAVSPNRS---KCER---------------  
NELF-A          LPAQF-KQRAPMYNSG-LSPATPTPAA-PTSPLTPTTP-PAVAPTTQTP-PVAMVAPQTQ 420 
 
DCC             ---------SEEAPSR---------TIP-TACVRPT----HPLRSF------------- 
OBF-1           ---------HASSGAA---------PAP-TAVVLPH----QPLATY------------- 
SIP             ---------KAELLDN---------EKP-AAVVAPI----TTGYTV------------- 
TIEG1           ---------NVEAARK---------NIP-CAAVSPN----RSKCER------------- 
VAPA            FTDVVTTNLKLRNPSDRKVCFKVKTTAPRRYCVRPNSGIIDPGSTVTVSVMLQPFDYDP 88 
 
DCC             ---------SEEAPSRTIPTA----CVRPTHP-----LRSF------------------- 
OBF-1           ---------HASSGAAPAPTA----VVLPHQP-----LATY------------------- 
SIP             ---------KAELLDNEKPAA----VVAPITT-----GYTV------------------- 
TIEG1           ---------NVEAARKNIPCA----AVSPNRS-----KCER------------------- 
ZC3H14          DAKCTKPDCPFTHVSRRIPVLSPKPAVAPPAPPSSSQLCRYFPACKKMECPFYHPKHCRF 700 
                                              
DCC             ---------------SEEAPSRTIPTACVRPTHPLRSF----------------------  
OBF-1           ---------------HASSGAAPAPTAVVLPHQPLATY----------------------  
SIP             ---------------KAELLDNEKPAAVVAPITTGYTV----------------------  
TIEG1           ---------------NVEAARKNIPCAAVSPNRSKCER---------------------- 
ZC3H11A         TVPEAENPRDSLVLPPTQSSSDSSPPEVSGPSSSQMSMKTRRLSSASTGKPPLSVEDDFE 780 
Figure 7. Sequence alignment of the SIAH binding motif in recognised SIAH interacting proteins and 
our identified SIAH1 interactors.  Alignments were generated with ClustalW.  Identical residues are 
highlighted in red columns. Conserved and semi-conservative residues are shown in green and yellow 
columns, respectively.  
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The ClustalW alignments revealed that the PHC2 protein contains the precise ‘PxAxVxP’ 
core degron motif.  ASPP1 and NELF-A contain a conserved version of the motif, in 
which both the N- and C-terminal prolines are identical in both alignments and two 
conserved substitutions are present in the central part of the motif.  CCDC92 and 
ZC3H11A contain a more degenerate motif, again with both the N- and C-terminal 
prolines identical in both alignments.  SIAH1BP1, VAPA, and ZC3H14 however, contain 
gaps in the core PxAxVxP alignment.  It is unlikely that these constitute SIAH binding 
motifs.  The crystal structure of the SIAH substrate binding domain bound to a peptide 
containing this motif has shown that key residues in the degron facilitate the interaction 
(Santelli et al., 2005; House et al., 2006).  Therefore insertions/deletions observed in the 
SIAH1BP1, VAPA, and ZC3H14 alignments are likely to affect the secondary structure 
of this region thus abrogating any possible interaction with the SIAH1 substrate binding 
domain.   
3.5 Assay for SIAH1 mediated degradation in cultured cells 
Several SIAH1-interacting proteins have been shown to act as substrates of SIAH1 
mediated degradation (see Table 1).  To determine whether or not the interaction with 
SIAH1 had direct consequences on the stability of our proteins of interest, each of the 
interactors were cloned into the pGFP3 vector to create in-frame GFP-fusion proteins (C-
terminal GFP tag).  These GFP-fusion proteins were then co-transfected into HEK293 
cells along with the SIAH1pCDNA3 expression vector or the empty pCDNA3 plasmid.  
The GFP-expression vector (pGFP3) was also included to act as a transfection control.  
The relative levels of the GFP-fusion protein were then monitored in the 
presence/absence of SIAH1.  The pGFP3 vector is a eukaryotic expression vector which 
has been shown to express well in cultured HEK293 cells (Venables et al., 2004). 
3.5.1 Generation of GFP-fusion protein constructs 
To create the GFP constructs, PCR primers were designed to amplify the clone sequence 
from the pACTII, yeast 2-hybrid vector (see appendix B).  In most cases the full length 
gene sequence was amplified.  A subset of the pACTII SIAH1 hits however were partial 
clones and therefore only partial sequences were amplified.  PCR products were digested 
and ligated into complementary digested sites in pGFP3 followed by selection on 
ampicillin-LB plates.  Colonies were screened by PCR using a target specific forward 
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primer and a pGFP3-specific reverse primer (pCDNArev).  Insert positive colonies were 
further grown overnight before plasmid purification.   
3.5.2 GFP-fusion protein expression in HEK293 cells  
To check that the GFP fusion proteins were the correct/expected size, each pGFP3-fusion 
plasmid was transfected into HEK293 cells.  Cells were incubated for 24 hours before 
checking for GFP fluorescence using fluorescence microscopy.  Following confirmation 
of GFP fluorescence, cells were harvested and subject to SDS-PAGE and Western blot 
analysis.  Blots were probed for GFP using the α-GFP antibody to ensure that the fusion 
proteins were of the correct size.  
The known/predicted molecular weight of each of the SIAH1 interactors is presented in 
Figure 8.  GFP is a 27kDa protein therefore addition of the GFP tag should cause a shift 
in migration of the resultant fusion proteins by approximately 27kDa.  It is important to 
bear in mind however that a subset of these interactors are partial clones and therefore 
will have a smaller molecular weight than expected.  
 
Figure 8. SIAH1 interacting GFP-fusion proteins. A Western blot of HEK293 cells transfected with the 
SIAH1 interacting GFP-fusion plasmid preparations.  Blots were probed with α-GFP primary antibody and 
HRP-conjugated α-mouse secondary antibody.  The migration of molecular weight markers is indicated on 
the right.  The table shows the known/predicted molecular weight of each of the proteins minus the GFP 
tag.  *Highlighted proteins represent partial clones.   
As expected, all of the fusion proteins, except ZC3H11A, appear to migrate slower than 
their predicted full size molecular weight, as a result of the GFP moiety.  The pGFP-
ZC3H11A clone however is partial, missing the N-terminal 1638bp’s (total CDS 
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2433bp’s).  The predicted molecular weight of the C-terminal half of the protein should 
be approximately half that of the full length protein (~44.5kDa).   Therefore, addition of 
GFP should result in a molecular mass of approximately 71.5kDa, which is indeed the 
case.   
The ASPPpGFP3 construct was previously created, sequenced and shown to run with the 
175kDa marker (Thornton 2005). 
3.5.3 In vivo degradation assay using HEK293 cells 
In order to determine whether or not SIAH1 targets any of these interactors for 
degradation, the GFP-fusion proteins and SIAH1pCDNA3 were co-transfected into 
HEK293 cells with the GFP expression vector internal standard to show the relative 
amount of the GFP-fusion protein.  Empty pCDNA3 plasmid was co-transfected in the 
minus SIAH1 controls.  Cell extracts were analysed by Western blot and probed with 
GFP antisera in an attempt to determine if any of these proteins were being destabilised 
in response to SIAH1 expression.  To ensure SIAH1 was being expressed and was 
functional, the same experiment was carried out using T-STAR protein, a known SIAH1 
substrate.  Previously Venables et al., (2004) had shown using a T-STAR-GFP fusion 
protein that SIAH1 bound T-STAR and targeted it for proteasome-dependent 
degradation.  Results are presented in Figure 9. 
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Figure 9. Representative Westerns of co-transfection assays to monitor SIAH1 interacting protein 
stability in the presence (+) and absence (-) of SIAH1.  Cells were harvested 24 hours after transfection 
and analysed by Western blotting.  Blots were probed with anti-GFP primary antibody and HRP-conjugated 
anti-mouse secondary antibody. The migration of molecular weight markers is indicated on the left of the 
Westerns.  The GFP control band migrates just above the 32.5kDa marker.  The graphs show the relative 
amount of the GFP-fusion proteins in each of the co-transfections.  Data is presented as the mean ± SD and 
is representative of two experiments. 
It is evident from the Westerns presented in Figure 9 that the levels of T-STAR, ASPP1, 
PHC2, NELF-A, ZC3H11A and ZC3H14 GFP-fusion proteins, relative to GFP, decrease 
when co-expressed with SIAH1.    However, when comparing the SIAH1BP1, CCDC92 
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and VAPA bands in the presence and absence of SIAH1, there does not appear to be any 
obvious affect.  To achieve a more quantitative result, Westerns were subjected to 
densitometry to determine the relative amount of each of the fusion proteins relative to 
GFP (see graphs in Figure 9).  Such a relative measurement means the assay is 
independent of the total amount of DNA co-transfected in each transfection, and hence 
the amount of protein in each sample. 
From the T-STAR data, we can see that the T-STAR-GFP protein levels were noticeably 
reduced in the presence of SIAH1.  Therefore, this implied that SIAH1 was being 
expressed efficiently.  
On the whole, all GFP-fusion protein levels were reduced when co-expressed with 
SIAH1.  However this effect was most noticeable in the ASPP1, PHC2, NELF-A, 
ZC3H11A and ZC3H14 transfections.   
3.6 Further mapping the SIAH1 binding site in ZC3H11A and ZC3H14  
The in vivo degradation assay showed that ZC3H11A and ZC3H14 were de-stabilised 
when co-expressed with SIAH1.  ZC3H11A contained a possible degenerate SIAH 
binding motif, however there was no recognisable motif found in ZC3H14.  If these are 
genuine SIAH1 targets, then this implies that SIAH1 can bind to proteins via a non-
canonical binding site. 
In attempt to map the SIAH1 binding sites in ZC3H11A and ZC3H14, constructs 
containing different regions of these proteins were generated and tested for their ability to 
interact with SIAH1 in the yeast 2-hybrid system.  
3.6.1 Generation of partial ZC3H11A and ZC3H14 constructs and mapping the SIAH1 
interacting region via yeast 2-hybrid 
ZC3H11A and ZC3H14 were first divided into two regions by PCR.  The PCR templates 
used were the pACTII clones originally pulled out of the SIAH1 yeast 2-hybrid screen.  
Both clones contained only the C-terminal half of the coding sequence.  ZC3H14 was 
divided in to amino acids 374-594 and 554-736.  ZC3H11A was divided into amino acids 
546-700 and 678-810 (see appendix for primer and cloning information).  Each PCR 
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product was cloned into the pGADT7 vector and each construct was then tested for 
interaction with full length SIAH1 protein in a directed yeast 2-hybrid assay (Figure 
10A). 
SIAH1 interacted with amino acids 546-700 of ZC3H11A and amino acids 374-594 of 
ZC3H14.  The SIAH1:ZC3H14 interaction however was slightly weaker in comparison 
to ZC3H11A.  In order to narrow down the SIAH1 binding site further, these interacting 
regions were again divided into two by PCR.   
ZC3H14 was divided in to amino acids 374-490 and 483-607.  ZC3H11A was divided 
into amino acids 546-633 and 625-706 (see appendix for primer and cloning 
information).  As before, PCR products were cloned into the pGADT7 vector and yeast 
2-hybrid assay was repeated (Figure 10B). 
 
Figure 10. Mapping of the ZC3H11A and ZC3H14 interaction domains with SIAH1.  Full length 
SIAH1-pGBKT7 was tested against partial ZC3H11A and ZC3H14 constructs to elucidate the interacting 
region. (A) The ZC3H pACTII clones were first divided into two, and each half tested for an interaction 
with SIAH1. (B) The positive SIAH1 interacting regions in turn were divided into two, and were tested in a 
second yeast 2-hybrid assay for their ability to interact with SIAH1. Empty bait plasmid, pGBKT7, was 
used to test for auto-activation of prey plasmids.  Filters stained with X-Gal are shown.  Positive 
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interactions manifest as blue colonies, while if no interaction is present, the colonies remain white or red.  
Key, +++ strong interaction, positive blue colour within 30 minutes, ++ positive blue colour observable 
within 1 hour, + positive blue colour observable within 2 hours, - no noticeable interaction after 24 hours of 
exposure.  
The SIAH1:ZC3H11A region was mapped down to 81 amino acids (625-706).  However, 
neither of the 374-490 (116 amino acids) or 483-607 (124 amino acids) ZC3H14 
constructs interacted with SIAH1.  This suggested that the SIAH1 binding site either lies 
in the region whereby this construct was divided, or there are secondary binding sites in 
the larger ZC3H14 fragment (374-594) that are required for a stable interaction.   It is 
also possible that these protein fragments do not fold correctly hence altering their ability 
to bind to other proteins.   
In order to determine whether or not there was a degenerate SIAH1 binding motif present 
in the ZC3H11A and ZC3H14 SIAH1-interacting fragments, sequence analysis was 
performed.  Again, the fragments of four SIAH binding proteins containing the 
acknowledged degron motif, were aligned with the ZC3H11A(625-706), and 
ZC3H14(374-594)  SIAH1-interacting fragments using ClustalW (see section 3.4 in this 
chapter).  Alignment results are presented in Figure 11 and Figure 12.               
DCC                 --------------SEEAPSRTIPTACVRP------THPLRSF-----------------  
OBF-1               --------------HASSGAAPAPTAVVLP------HQPLATY-----------------  
SIP                 --------------KAELLDNEKPAAVVAP------ITTGYTV-----------------  
TIEG1               --------------NVEAARKNIPCAAVSP------NRSKCER-----------------  
ZC3H11A(625-706)    GIGDSLLNVKCAAQTLEKRGKAKPKVNVKPSVVKVVSSPKLAPKRKAVEMHAAVIAAVKP  
                                     
  
OBF-1               --------------------- 
DCC                 --------------------- 
TIEG1               --------------------- 
SIP                 --------------------- 
ZC3H11A(625-706)    LSSSSVLQEPPAKKAAVAVVP  
Figure 11. Sequence alignment of the SIAH binding motif in recognised SIAH interacting proteins 
and the ZC3H11A(625-706) 81 amino acid SIAH1 interacting fragment.  Alignments were generated 
with ClustalW.  Identical residues and semi-conserved residues in the predicted SIAH binding site are 
highlighted in red and yellow columns, respectively.  
Chapter 3                                                                    An investigation into the interacting partners of SIAH1 
 
60 
 
DCC                 ------------------------------------------------------------ 
OBF-1               ------------------------------------------------------------ 
SIP                 ------------------------------------------------------------ 
TIEG1               ------------------------------------------------------------ 
ZC3H14(374-594)     VPQKQTLPVAPRTRTSQEELLAEVVQGQSRTPRISPPIKEEETKGDSVEKNQGTQQRQLL 60 
                                                                             
 
DCC                 ------------------------------------------------------------ 
OBF-1               ------------------------------------------------------------ 
SIP                 ------------------------------------------------------------ 
TIEG1               ------------------------------------------------------------ 
ZC3H14(374-594)     SRLQIDPVMAETLQMSQDYYDMESMVHADTRSFILKKPKLSEEVVVAPNQESGMKTADSL 120 
  
                                                                            
DCC                 ---------SEEAPSRTIPTA---CVR----PTHPLRSF---------------------  
OBF-1               ---------HASSGAAPAPTA---VVL----PHQPLATY---------------------  
SIP                 ---------KAELLDNEKPAA---VVA----PITTGYTV---------------------  
TIEG1               ---------NVEAARKNIPCA---AVS----PNRSKCER---------------------  
ZC3H14(374-594)     RVLSGHLMQTRDLVQPDKPASPKFIVTLDGVPSPPGYMSDQEEDMCFEGMKPVNQTAASN 180 
 
 
DCC                 ---------------------------------------- 
OBF-1               ---------------------------------------- 
SIP                 ---------------------------------------- 
TIEG1               ---------------------------------------- 
ZC3H14(374-594)     KGLRGLLHPQQLHLLSRQLEDPNGSFSNAEMSELSVAQKP 220 
Figure 12. Sequence alignment of the SIAH binding motif in recognised SIAH interacting proteins 
and the ZC3H14(374-594) 220 amino acid SIAH1 interacting fragment.  Alignments were generated 
with ClustalW.  Identical residues are highlighted in red columns. Conserved and semi-conservative 
residues in the predicted SIAH binding site are shown in green and yellow columns, respectively.  
A second potential SIAH1 binding motif, different to the one previously identified 
(section 3.4 of this chapter) was found in the 81 amino acid ZC3H11A SIAH1-interacting 
fragment.  In contrast, no obvious SIAH1 binding motif was found in the 220 amino acid 
ZC3H14 SIAH1-interacting fragment as there were gaps in the core PxAxVxP alignment. 
3.7 Summary and discussion  
Several interesting SIAH1 interacting proteins were identified in the yeast 2-hybrid 
screen carried out by Dr Julian Venables.  These included proteins involved in 
transcriptional regulation (NELF-A, PHC2, SIAH1BP1), vesicle trafficking (VAPA), 
apoptosis (ASPP1) and regulation of mRNA splicing and stability (T-STAR, ZC3H14).   
A directed yeast 2-hybrid assay revealed that a number of these interactors (CCDC92, 
NELF-A and ZC3H11A) bound specifically to the substrate binding domain of SIAH1, 
the region implicated in binding its various target proteins.  ASPP1, SIAH1BP1 and 
ZC3H14 interacted with full length SIAH1 protein only, however it is possible that these 
proteins primarily interact with the SIAH1 SBD in vivo and the RING-finger or central 
zinc finger regions are necessary for stabilising the interaction.   
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Protein sequence analysis revealed that some of these hits (PHC2, ASPP1 and NELF-A) 
contained a conserved SIAH binding motif, which is present in a number of known 
SIAH-interacting proteins (House et al., 2003).  The presence of a putative binding motif 
in these SIAH1 interactors substantiates the likelihood that these proteins are genuine 
interactors in vivo.  However, because this is such a small motif, it is possible that its 
presence may simply be a coincidence.  Also, a poor alignment does not necessarily 
signify that a protein is not a genuine SIAH1 substrate because not all of the recognised 
SIAH1 substrates contain this motif (see later).   
When analysing the stability of each of the hits when co-expressed with or without 
SIAH1, it was observed that protein levels on the whole, were reduced when co-
expressed with SIAH1.  This may be due to competition for transcription and 
translational machinery when both the SIAH1 and GFP-fusion plasmids are present in the 
cell.  However, empty pCDNA plasmid was co-transfected in minus SIAH1 controls 
suggesting that the observed affect is more likely to be due to SIAH1 mediated 
breakdown.  Quantitative analysis revealed that co-expression of SIAH1 had the most 
noticeable effect on levels of ASPP1, PHC2, NELF-A, ZC3H11A and ZC3H14.     
As noted in the introduction to this thesis (section 1.3.2), not all SIAH1 interacting 
proteins are targets for SIAH1 mediated ubiquitination and breakdown as SIAH proteins 
can bind cofactors/adaptors which bridge the interaction between SIAH and its target for 
destruction.  For example APC and SIP function as bridging proteins, physically linking 
SIAH with β-catenin, resulting in β-catenin ubiquitination and degradation (Liu et al., 
2001).   SIP contains a recognised SIAH1 binding domain and binds to the SIAH SBD, 
however its stability is unaffected by this interaction (Matsuzawa et al., 2001; House et 
al., 2003). 
However, proteins which interact with the substrate binding domain of SIAH1, contain a 
conserved SIAH binding motif and, more importantly, are notably reduced when co-
expressed with SIAH1, are likely to be targets for SIAH1 mediated degradation.    
Taking into consideration the data so far, the most likely candidates for SIAH1 targeted 
destruction identified from the SIAH1 testes yeast 2-hybrid screen include, PHC2, a 
polycomb protein which is part of a multimeric, chromatin associated complex involved 
in homeotic gene regulation; NELF-A, a component of the negative elongation factor 
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complex which negatively regulates RNA polymerase II; ASPP1, a protein required for 
the induction of apoptosis by p53-family proteins; and ZC3H11A, a recently identified 
member of the mRNA export complex, known as the TREX complex (Dufu et al., 2010).  
Further mapping of the SIAH1 binding site in ZC3H14 and ZC3H11A revealed a 
potential SIAH1 binding site in the ZC3H11A SIAH1-interacting region however, no 
obvious motif was found in ZC3H14 when the ClustalW alignment method was used. 
The SIAH binding motif has only been identified in around half of the functionally 
diverse SIAH binding proteins so far (Santelli et al., 2005).  Proteins in which no obvious 
motif has been identified include substrates such as Synaptophysin, mGlutR1 (House et 
al., 2003), TRIM proteins (Fanelli et al., 2004) and cofactors such as APC (House et al., 
2003).  It is possible that there is a different consensus motif in these SIAH interacting 
proteins and ZC3H14.   However, further mapping of the SIAH interacting region in 
these proteins, alignment analysis and mutational analysis is required.   
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4.1 Introduction 
As a result of our previous studies, NELF-A, one of the hits from the SIAH1 yeast 2-
hybrid screen, was found to interact specifically with the SIAH1 substrate binding 
domain.  NELF-A contains a putative conserved SIAH binding motif and levels of 
NELF-A-GFP fusion protein were notably reduced when co-expressed with SIAH1, 
comparable to the published SIAH1 substrate, human T-STAR.  Each piece of evidence 
to date implied that NELF-A was a target for SIAH1-mediated degradation.  
The NELF-A protein is a member of a highly conserved, multi-subunit complex known 
as the negative elongation factor (NELF) protein complex.  This complex is composed of 
four subunits.  These are named the A subunit (66kDa), B subunit (62kDa), C/D subunits 
(60/59kDa), and the E subunit (46kDa), all of which appear to be ubiquitously expressed 
(Mariotti et al., 2000; Narita et al., 2003).  NELF-C/D are translation variants of the same 
mRNA (Gilchrist et al., 2008).  
The importance of the NELF complex is highlighted by the implication of some of its 
subunits in the etiology of various diseases.  NELF-A is encoded by the WHSC2 gene 
which was first identified as a candidate gene for Wolf-Hirschhorn syndrome, a multiple 
malformation disorder characterised  by a range of developmental defects (Wright et al., 
1999).  NELF-B, also known as COBRA1 (cofactor of BRCA1), is a breast/ovarian 
cancer susceptibility gene (Ye et al., 2001; Narita et al., 2003; Aiyar et al., 2004) and 
reduced NELF-B expression correlates with poor prognosis in breast cancer (Sun et al., 
2008a).  RNAi against NELF-E in Drosophila has been shown to cause developmental 
defects or lethality depending on where the RNAi was expressed.  Thus like NELF-A, 
absence of NELF-E also affects development (Enerly et al., 2002).  
In vitro biochemical and tissue culture based studies have demonstrated that this multi-
subunit complex acts together with DRB-sensitivity inducing factor (DSIF) and stalls 
elongating RNA polymerase II (RNAPII), resulting in a pause in transcription 
(Yamaguchi et al., 1999; Yamaguchi et al., 2002).  Transcription is the process through 
which a DNA sequence is copied to produce a complementary RNA, and transcription of 
protein coding genes is carried out by the multi-subunit enzyme RNAPII.  The NELF 
complex and DSIF achieve transcriptional pausing by binding to RNAPII and nascent 
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RNA via their various subunits (summarised in Figure 13) (Narita et al., 2003; Yung et 
al., 2009).   
 
Figure 13. NELF- and DSIF- induced stalling of elongating RNAPII.  NELF subunits are light grey.  
The functionally active NELF complex consists of a heterotetramer of one of each subunit bound to each 
other and to other factors in the configuration shown.  NELF-A binds to elongating RNAPII on one surface 
and to NELF-C on another, while NELF-B is sandwiched between NELF-C and NELF-E and another 
surface of NELF-E binds to short nascent RNA transcripts protruding from the active site of RNAPII.  The 
tethering of the NELF-E to nascent transcript and elongation complex restricts the movement of RNAPII.   
Figure compiled  from information from Narita et al., (2003) and Yung et al., (2009).   
It is often assumed that RNAPII initiation is the rate-limiting step in gene expression, 
however it is emerging that the elongation step of transcription is a crucial control point 
in transcriptional regulation for a subset of genes, requiring the recruitment of multiple 
proteins.  Hence, the identification of potential regulators of this level of gene expression 
is of great interest.    Mechanisms controlling transcriptional elongation are reviewed by 
Shilatifard (2004); Saunders et al., (2006) and Price (2008).   
Generally, NELF and DSIF pause elongating RNAPII approximately 20-50 base pairs 
downstream from the transcription start site, after transcription initiation and promoter 
clearance (Wu et al., 2005; Gilchrist et al., 2008; Lee et al., 2008a).  Genes which contain 
these poised polymerases are designated ‘potentially active’ and studies which have 
measured the distribution of poised RNAPII across the Drosophila and human genomes 
have revealed that that they predominantly locate to developmental control genes, such as 
those encoding homeodomain proteins and genes which respond to developmental or 
environmental cues (e.g., wnt, notch and TGFβ) (Aida et al., 2006; Gilchrist et al., 2008).  
Thus the NELF complex plays a very important role in regulating the pattern of genes 
expressed during development and differentiation, however very little is known of how 
this complex is manipulated to give rise to selective gene activation or repression. 
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As the Siah1a mutant mouse is growth retarded and the male mouse is sterile, Siah1a 
evidently plays an important role in regulating cell growth and differentiation. Thus it is 
possible that SIAH proteins may mediate an additional layer of transcriptional regulation 
of the various NELF- regulated developmental control genes by modulating stability of 
NELF-A and the NELF complex.  
We wanted to further characterise the SIAH1:NELF-A interaction and determine whether 
or not SIAH1 could regulate NELF-A stability in vivo.  To do this, the SIAH binding site 
in NELF-A was mapped and further investigated in vivo via GST pull down.  
Experiments were carried out in order to determine whether or not NELF-A was 
ubiquitinated and endogenous NELF-A protein was analysed in mouse testes tissue and 
Siah deficient cells.  We also wanted to establish whether or not the other members of the 
Siah family could regulate NELF-A stability and to do this, levels of NELF-A-GFP 
fusion protein were monitored when each of the three murine Siah proteins were over-
expressed.   
4.2 Assay to determine whether or not GFP-tagged NELF-A is regulated by the 
proteasome  
The in vivo degradation assay described in chapter 3 (section 3.5.3) revealed that levels of 
NELF-A-GFP fusion protein were notably reduced when co-expressed with SIAH1.  
However, as noted in the discussion (chapter 3, section 3.7), this observed reduction may 
be due to SIAH1 mediated poly-ubiquitination of NELF-A-GFP and proteasomal 
breakdown, or it may be a result of reduced expression due to competition for 
transcriptional and translational machinery when both expression plasmids are present in 
the cell.  
To distinguish between these two possibilities, the stability of NELF-A-GFP fusion 
protein was assayed in the presence and absence of the peptide aldehyde MG132, a 
potent inhibitor of proteasome function.  If NELF-A-GFP is targeted by SIAH1 for 
proteasomal breakdown then we would expect levels of the protein to stabilise in the 
presence of MG132.   
Essentially, the in-vivo degradation assay described in chapter 3 (section 3.5.3) was 
repeated.  NELF-ApGFP3 and SIAH1pCDNA3 were co-transfected into HEK293 cells 
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with a GFP expression vector internal standard to show the relative amount of the NELF-
A-GFP fusion protein.  24 hours after transfection cells were incubated with or without 
the proteasome inhibitor MG132 for 7 hours.  Cell extracts were then analysed by 
Western blot probing with GFP antisera (Figure 14). 
 
Figure 14. GFP-tagged NELF-A is stabilised by MG132.  24 hours after transfection, cells were 
incubated with or without 40µM MG132 for 7 hours.  Cell lysates were prepared and samples were 
separated on 10% SDS PAGE.  Levels of GFP-tagged NELF-A were measured by immunoblotting with α-
GFP and HRP-conjugated anti-mouse secondary antibody.  The migration of molecular weight markers is 
indicated on the left of the Western.  The graph shows the relative amount of NELF-A-GFP fusion protein 
in each of the co-transfections.   
Consistent with regulation by a proteasome dependent mechanism, NELF-A-GFP fusion 
protein was more stable with MG132 incubation when co-expressed with SIAH1. 
4.3 Comparison of the human and mouse NELF-A protein sequence  
Given that human NELF-A is a SIAH1 substrate, our next question was could the same 
protein interaction take place in the mouse and perhaps contribute to the Siah1a-/- mutant 
phenotype.  As mentioned in the introduction to this thesis (section 1.4), an investigation 
into the interaction between T-STAR and SIAH1 by Venables and colleagues (2004) 
revealed that human T-STAR efficiently bound to SIAH1 resulting in its proteasomal 
degradation.  However, mouse T-STAR was neither bound nor degraded by SIAH1. 
Comparative sequence analysis of mouse T-STAR with the SIAH1-binding region in 
human and primate T-STAR proteins revealed that the SIAH binding motif evolved 
specifically in the primate lineage and is absent in the mouse.  Hence, defects in 
modulation of T-STAR protein stability by SIAH1 could not help explain the mouse 
Siah1a-/- mutant phenotype. 
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It was previously reported that the WHSC2 gene, encoding NELF-A, is a highly 
conserved gene with the human and mouse genes showing 84.2% identity at the 
nucleotide level and the encoded proteins are 93.3% identical at the amino acid level 
(Wright et al., 1999).  In order to determine whether or not the putative SIAH1 binding 
site identified in NELF-A (chapter 3, section 3.4) was conserved between humans and 
mice, the human and mouse NELF-A protein sequences were aligned using ClustalW 
(Figure 15).  This revealed that unlike T-STAR, the predicted SIAH1 binding site 
identified in NELF-A is identical in humans and mice. 
Mouse  MASMRESDTGLWLHNKLGATDELWAPPSIASLLTAAVIDNIRLCFHRLSSAVKLKLLLGT 60 
Human  MASMRESDTGLWLHNKLGATDELWAPPSIASLLTAAVIDNIRLCFHGLSSAVKLKLLLGT 60 
       ********************************************** ************* 
 
Mouse  LHLPRRTVDEMKAALMDIIQLATLDSDPWVLMVADILKSFPDTGSLNLDLEEQNPNVQDI 120 
Human  LHLPRRTVDEMKGALMEIIQLASLDSDPWVLMVADILKSFPDTGSLNLELEEQNPNVQDI 120 
       ************.***:*****:*************************:*********** 
 
Mouse  LGELREKVSECEASAMLPLECQYLNKNALTTLAGPLTPPVKHFQLKRKPKSATLRAELLQ 180 
Human  LGELREKVGECEASAMLPLECQYLNKNALTTLAGPLTPPVKHFQLKRKPKSATLRAELLQ 180 
       ********.*************************************************** 
 
Mouse  KSTETAQQLKRSAGVPFHAKGRGLLRKMDTTTPLKGIPKQAPFRSPTTPSVFSPSGNRTP 240 
Human  KSTETAQQLKRSAGVPFHAKGRGLLRKMDTTTPLKGIPKQAPFRSPTAPSVFSPTGNRTP 240 
       ***********************************************:******:***** 
 
Mouse  IPPSRTPLQKERGVKLLDISELNTVGAGREAKRRRKTLDTEVVEKPTKEETVVENATPDY 300 
Human  IPPSRTLLRKERGVKLLDISELDMVGAGREAKRRRKTLDAEVVEKPAKEETVVENATPDY 300 
       ****** *:*************: ***************:******:************* 
 
Mouse  AAGLVSTQKLGSLNSEPTLPSTSYLPSTPSVVPASSYIPSSETPPAPPSREASRPPEEPS 360 
Human  AAGLVSTQKLGSLNNEPALPSTSYLPSTPSVVPASSYIPSSETPPAPSSREASRPPEEPS 360 
       **************.**:*****************************.************ 
 
Mouse  APSPTLPTQFKQRAPMYNSGLSPATPAPAAPTSPLTPTTPPAVTPTAQTPPVAMVAPQTQ 420 
Human  APSPTLPAQFKQRAPMYNSGLSPATPTPAAPTSPLTPTTPPAVAPTTQTPPVAMVAPQTQ 420 
       *******:******************:****************:**:************* 
 
Mouse  APAPVQQQPKKNLSLTREQMFAAQEMFKTANKVTRPEKALILGFMAGSRENPCPEQGDVI 480 
Human  APA--QQQPKKNLSLTREQMFAAQEMFKTANKVTRPEKALILGFMAGSRENPCQEQGDVI 478 
       ***  ************************************************ ****** 
 
Mouse  QIKLSEHTEDLPKADGQGSTTMLVDTVFEMNYATGQWTRFKKYKPMTNVS 530 
Human  QIKLSEHTEDLPKADGQGSTTMLVDTVFEMNYATGQWTRFKKYKPMTNVS 528 
       ************************************************** 
Figure 15. Sequence alignment between human and mouse NELF-A protein.  The alignment was 
generated using ClustalW.  The putative SIAH binding motif is highlighted by the red box.  .  “*”residues 
represent those that are identical the alignment. “:” represent conserved substitutions and “.” represent 
semi-conservative substitutions. 
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4.4 Immunodetection of NELF-A in mouse tissues 
WHSC2 expression was analysed in human tissues by Mariotti and colleagues (2000) via 
Northern blot.  They found it was expressed in all human tissues examined and was most 
abundant in the heart and placenta.  Narita et al., (2003) also examined expression of 
WHSC2 and the other three NELF subunits by Northern blot and again found they were 
expressed in all human tissues examined.  To our knowledge, however, NELF-A protein 
abundance in both human and mouse tissues has not been analysed.   
As SIAH proteins affect protein rather than mRNA stability we hoped to gain an insight 
of the relative stability of NELF-A protein in varying tissues by comparing NELF-A 
protein levels with the published mRNA expression results.  In order to analyse this, a 
NELF-A specific antibody was purchased (Santa Cruz, H-240).  Due to the limited 
availability of human tissues samples we sought to analyse protein levels of NELF-A in 
various murine tissues.  Although the NELF-A polyclonal antibody was raised against 
amino acids 92-300 mapping near the N-terminus of NELF-A of human origin we were 
confident that it would detect both human and mouse proteins due to the high degree of 
protein sequence identity (see alignment Figure 15).  
Various mouse tissues were dissected and homogenised in 2x sample loading buffer.  
Samples were then boiled and proteins were separated by 7% SDS-PAGE.  NELF-A 
protein abundance was analysed by Western blot probing with the α-NELF-A polyclonal 
antibody.  For a loading control, the blot was also probed with a β-actin specific antibody 
(Figure 16).   
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Figure 16. Analysing abundance of NELF-A protein in multiple mouse tissues.  Tissue lysates were 
prepared, and the level of NELF-A was measured by immunoblotting with α-NELF-A and anti-β-actin 
antibodies.  Antibody binding was detected using HRP-conjugated α-rabbit secondary antibody.  The 
migration of molecular weight markers is indicated on the right.  The graph shows the relative amount of 
NELF-A protein in each tissue compared to the β-actin loading control. 
NELF-A protein was most abundant in mouse lung, heart, liver and testis.  Protein levels 
were moderate in the kidney and NELF-A was least abundant in the brain and spleen.  In 
contrast to this result, although no quantitative data is shown, the Northern blot published 
by Mariotti et al., (2000) shows that NELF-A mRNA levels in the human brain are higher 
than or approximately equal to those in the liver, lung and kidney.  This may imply that 
NELF-A protein is less stable in the brain, potentially due to rapid turnover by the 
proteasome in these tissues.  Alternatively, the WHSC2 gene encoding NELF-A may be 
differentially expressed in mouse and human tissues. 
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4.5 Immunodetection of NELF-A in mouse testes  
As discussed previously, the murine Siah1a protein is known to play an essential role in 
male germ cell development as targeted deletion of this gene results in meiotic arrest 
during spermatogenesis.   To further investigate Siah1 expression during meiosis, 
Venables and colleagues (2004) performed Western blots with a SIAH1 antibody on 
extracts from different purified mouse germ cell populations.  The SIAH1 antibody used 
could detect both human SIAH1 and mouse Siah1a proteins as they differ by only one 
amino acid.  They found Siah1 was strongly expressed in spermatocytes (meiotic cells) 
but not spermatids (post-meiotic cells). 
As noted in the introduction (chapter 1, section 1.3) mice contain a second, almost 
identical copy of the Siah1a gene, Siah1b.   This gene however, resides on the X 
chromosome which is shut down during meiosis.  Therefore the Siah1 protein expressed 
in murine spermatocytes is likely to represent Siah1a, not Siah1b. 
Our initial analysis of NELF-A protein expression in various mouse tissues confirmed 
that NELF-A was expressed in the testes which is consistent with its isolation from the 
testis cDNA library used for the SIAH1 yeast 2-hybrid screen.  In order to determine 
whether or not Siah1 and NELF-A protein were present in the same cell types in the 
testis, the precise localisation of NELF-A protein was analysed in mouse testes sections 
by immunohistochemistry.   
Murine testis sections (prepared by Dr Ingrid Ehrmann, IHG, Newcastle University) were 
dewaxed and microwaved in citrate buffer to expose antigens.  Sections were then stained 
using the α-NELF antibody and the DAB detection system (see methods, section 2.3.7).  
Staining was visualised by light microscopy (Figure 17). 
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Figure 17. Images of testis sections from wild-type mice immunostained with NELF-A.  (A and B) 
Mouse testis sections were probed with NELF-A antisera and NELF-A was detected using biotin-
conjugated α-rabbit secondary antibody and the DAB system. Brown staining indicates NELF-A protein, 
and blue staining is the haematoxylin counterstain which stains nuclei.  (C and D) Mouse testes sections 
stained with biotin-conjugated α-rabbit secondary antibody alone and haematoxylin counterstained.  Scale 
bars are equal to 200µm in A and C and 100µm in B and D.  SE: seminiferous epithelium; Spg: 
spermatogonia; Spc: spermatocyte; Spd: Spermatids at differing stages of differentiation, including round 
and elongating spermatids; Spz: spermatozoon. 
It was clear from the images presented in Figure 17 that NELF-A protein was present in 
the nuclei of a large proportion of developing germ cells within the testes.  The nuclear 
localisation is consistent with NELF-A’s role as a regulator of RNAPII.   To gain a 
clearer picture of the specific populations of germ cells in which NELF-A was present, 
the images were sent to Professor Philippa Saunders (MRC Human Reproductive 
Sciences Unit, Edinburgh, UK) a specialist in male germ cell development.  Professor 
Saunders concluded that NELF-A protein was present in the nuclei of pachytene 
spermatocytes and round spermatids, and was absent in elongate spermatids and most 
spermatogonia.  The pachytene stage occurs during meiosis I (primary spermatocytes) 
and is the point where spermatocytes begin to synthesise large amounts of mRNAs and 
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proteins permitting them to sustain two consecutive rounds of cell division (Geremia et 
al., 1977; Monesi et al., 1978). 
Thus unlike Siah1a which seems to be expressed mainly in meiotic cells (i.e. 
spermatocytes) NELF-A is expressed in both meiotic and mitotic cells.  Since Siah1a and 
NELF-A are co-expressed in a subset of cells it is possible that Siah1a could regulate 
NELF-A in these cell types.  Determination of the precise points at which Siah1a and 
NELF-A expression is switched on and off during spermatogenesis however, would 
require more in depth analysis.  Unfortunately, the SIAH1 antibodies available to us did 
not work by Western blot or immunohistochemistry, therefore we were unable to co-stain 
the testes sections.  
4.6 Mapping the SIAH1 binding site in NELF-A  
Analysis of the NELF-A protein sequence revealed a putative SIAH binding site 
encompassing amino acids 381-405 which is conserved between humans and mice (see 
section 4.3).  To determine which part of NELF-A is recognised by SIAH1, four 
constructs containing different regions of NELF-A were generated by PCR and tested in 
a directed yeast 2-hybrid assay for their ability to bind SIAH1 protein.  
4.6.1 Generation of partial NELF-A constructs 
NELF-A was divided into four regions – the N-terminal region (amino acids 1-248, using 
primers WHSC2-F and WHSC2(744)R), the central region (amino acids 248-317, using 
primers WHSC2(744)F and WHSC2(951)B), the C-terminal region including the PST-
rich domain (amino acids 317-528, using primers WHSC2(951)F and WHSC2-B), and 
the PST-rich domain alone (amino acids 317-427, using primers WHSC2(951)F and 
WHSC2(1281)B)  (see Figure 18).   The PCR products were then digested with 
EcoRI/XhoI and ligated into complementary digested sites in the pGADT7 yeast 2-hybrid 
vector.  The ligations were then re-cleaved with BamHI followed by dialysis.  1µl of each 
of the ligation mixes was then transformed into E. coli DH5α cells by electroporation.  
The resultant transformation mix was then plated out onto LB plates containing 
ampicillin and incubated at 37ºC overnight.  Colonies were screened by PCR using a 
vector specific forward primer (T7-F) and an insert specific reverse primer.  Insert 
positive colonies were further grown in LB-ampicillin overnight before plasmid 
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purification.  To confirm that the pGADT7 clones contained the correct sequences, each 
construct was sequenced from the 5′ end using the T7-F sequencing primer.   
 
Figure 18. Schematic diagram of the NELF-A protein and summary of yeast 2-hybrid results.  The N-
terminal HDAg homology region (amino acids 89 to 248) is essential for interaction with RNAPII and the 
C-terminal half of the protein includes a region which is rich in proline (P), serine (S), and threonine (T) 
residues.  The putative SIAH binding motif (amino acids 381-405) lies within this PST-rich region (↓).  
Smaller constructs outlined below were cloned independently into the pGADT7 vector, and were assayed 
for an interaction with SIAH1 via the yeast 2-hybrid assay.  Primers used for cloning are shown as red 
arrows.   
4.6.2 Mapping the NELF-A:SIAH1 interacting region using the yeast 2-hybrid assay 
The four partial NELF-ApGADT7 clones shown in Figure 18 were tested against the 
pGBKT7 vector alone to assay for auto-activation, and against full length SIAH1-
pGBKT7.  As a positive control, full length NELF-ApACTII was tested against full 
length SIAH1-pGBKT7.   Results are presented in Figure 19. 
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Figure 19. Mapping of the NELF-A interaction domain with SIAH1.  Full length SIAH1-pGBKT7 was 
tested against partial NELF-A constructs to identify the interacting region. Empty bait plasmid, pGBKT7, 
was used as a control to test for auto-activation of prey plasmids.  Filters stained with X-Gal are shown.  
Positive interactions manifest as blue colonies while if no interaction is present, the colonies remain white 
or red.  Key, +++ strong interaction, positive blue colour within 10 minutes, ++ positive blue colour 
observable within 30 minutes, + positive blue colour observable within 1 hour, - no noticeable interaction 
after 2 hours of exposure.  
A strong, positive interaction with SIAH1 was detected with constructs 317-427 and 317-
528.  This mapped to the PST-rich region of the NELF-A protein.  This is the region of 
the protein which contains the putative SIAH1 degron motif that we previously identified 
(chapter 3, section 3.4).  Negative results for interaction between the empty pGBKT7 
vector and the various NELF-A regions in pGADT7 confirmed that the positive results 
were not due to auto-activation by the Gal4 AD-NELF-A fusions alone. 
4.7 Assaying the NELF-A:SIAH2 interaction via yeast 2-hybrid 
Some SIAH substrates such as DCC are targeted for proteolytic degradation by both 
SIAH1 and SIAH2 proteins (Hu et al., 1997b).  However in some cases, the biochemical 
functions SIAH1 and SIAH2 are unique to the individual family member.  For example 
the central regulator of cellular responses to stress and cytokines, TRAF2, is targeted for 
proteasomal degradation by SIAH2 but not SIAH1 (Habelhah et al., 2002).  Identifying 
substrates which are uniquely degraded by SIAH1 may help explain why, in contrast to 
the Siah2 mutant, which is largely phenotypically normal, the Siah1a mutant mouse is 
growth retarded and males are sterile. 
Therefore SIAH2 was assayed for its ability to interact with NELF-A via yeast 2-hybrid.  
A SIAH2 clone was available in pACTII, which is a Gal4 activation domain plasmid 
(Venables et al., 2004).  In order to test whether or not SIAH2 interacts with NELF-A, 
full length NELF-A and its partial sequences needed to be transferred from pGADT7 (as 
this is also a Gal4 activation domain plasmid) to the pGBKT7 vector, which contains the 
Gal4 DNA binding domain sequence.   
NELF sequences were amplified by PCR and digested as previously described (see 
section 4.6.1).  In this case however, products were ligated into EcoRI/SalI sites of the 
pGBKT7 yeast 2-hybrid vector.  Ligations were re-cleaved with SalI, transformed into E. 
coli DH5α and the transformations were plated out on LB agar containing Kanamycin.  
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To confirm that positive clones contained the correct sequence, each construct was 
sequenced.  Each NELF-A construct was then tested for ability to interact with SIAH2 in 
a yeast 2-hybrid assay. Results are presented in Figure 20.  
 
Figure 20. Mapping of the NELF-A interaction domain with SIAH2.  Full length SIAH2-pACTII was 
tested against partial NELF-A constructs to identify the interacting region. Empty bait plasmid, pACTII, 
was used to test for auto-activation of prey plasmids.  Filters stained with X-Gal are shown.  Positive 
interactions manifest as blue colonies while if no interaction is present, the colonies remain white or red.  
Key, +++ strong interaction, positive blue colour within 1 hour, ++ positive blue colour observable within 2 
hours, - no noticeable interaction after 24 hours of exposure. 
The full length NELF-A protein did not interact with SIAH2, however the minimal PST-
rich domain (amino acids 317-427) containing the SIAH binding motif did.  Often, sub-
domains of proteins interact better than full length clones, perhaps due to the lack of 
certain folding constraints.  In the yeast 2-hybrid system, the full-length fusion proteins 
may not fold correctly consequently altering their confirmation.  Alternatively, in order to 
interact, they may require certain post-translational modifications (e.g. phosphorylation 
or glycosylation), which may not occur properly, or at all in the yeast system.  Also, some 
proteins, when expressed in yeast, are not be targeted to the nucleus, they may be toxic to 
the cell, or they may also be unstable and degraded by yeast proteins.  Thus, it remains 
possible that SIAH2 and NELF-A interact in vivo.  The C-terminal (amino acids 317-528) 
region of NELF-A was found to auto-activate when cloned in frame with the activation 
domain of Gal4 (encoded for by empty pACTII).  
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4.8 Confirmation of the interaction between NELF-A and SIAH1 in vitro  
The next step was to confirm that the interaction between NELF-A and SIAH1 was a 
genuine molecular interaction, caused by direct protein-protein contact rather than any 
yeast bridging proteins.  This was achieved via a GST in vitro pull-down assay.  Firstly, 
the PST-rich region of NELF-A was cloned into the pGEX5X1 vector to create a GST-
fusion gene.  The encoded fusion protein was then expressed in E. coli BL21 cells, and 
used to specifically pull down radiolabelled, in vitro-translated, SIAH1.  A similar 
experiment was previously carried out to confirm the interaction between SIAH1, and the 
RG-rich region of human T-STAR containing the SIAH1 binding site (Venables et al., 
2004).  Because this was known to work, T-STAR(RG) was used as a positive control.   
4.8.1 Generation of partial NELF-A-GST fusion protein 
The PST-rich region of NELF-A (amino acids 317-427) which was found to interact with 
SIAH1 via yeast 2-hybrid was amplified by PCR from the NELF-ApACTII clone (using 
primers WHSC2(951)F and WHSC2(1281)B) and cloned into the EcoRI/XhoI sites of the 
pGEX5X1 GST fusion vector.  To confirm that the pGEX5X1 clone contained the correct 
sequence, it was sequenced from the 5′ end using the pGEX5 sequencing primer.  T-
STAR(RG) was previously cloned into pGEX5X1 (Venables et al., 2004).  Both 
recombinant plasmids were then transformed into E. coli BL21 cells, via the calcium 
chloride transformation procedure and were expressed overnight using Instant TB 
medium (see methods, section 2.3.8).  Total BL21 cell lysate samples from the overnight 
cultures are shown in Figure 21A. 
The molecular weight of the T-STAR RG-rich domain and the NELF-A PST-rich domain 
was estimated using the Scansite tool (see methods, section 2.6.3).  The predicted 
molecular weight of T-STAR(RG) was 8kDa, and NELF-A(317-427) was 11.5kDa (both 
predictions were based on the absence of phosphate groups).  GST is a 25kDa protein, 
therefore the expected sizes of the T-STAR(RG) and NELF-A(317-427) GST-fusion 
proteins were 33kDa and 36.5kDa, respectively.   
Strong bands for T-STAR(RG)-GST and NELF-A(317-427)-GST were evident in the 
overnight induction samples showing that the GST-fusion proteins expressed well (see 
overnight (O/N) culture lanes in Figure 21).  The proteins migrated a little slower than 
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their expected molecular weight, however proteins often run a little larger or smaller than 
their calculated molecular weight and deviations of up to 5kDa are not unusual.  
4.8.2 Testing solubility and purification of T-STAR and NELF-A GST-fusion proteins 
For use in a GST-pull-down assay, it is important that the GST fusion protein is soluble.  
Hence, bacterial cell pellets from the overnight cultures were lysed and sonicated, 
followed by a 10 minute centrifugation step to pellet any insoluble material (see methods, 
section 2.3.8.3).   To test solubility, samples of total cell lysate, taken before the 
centrifugation step, and samples of soluble supernatant, taken after centrifugation, were 
analysed on a coomassie-stained SDS-PAGE gel (Figure 21A).    
 
 
Figure 21. Testing solubility of the T-STAR(RG) and NELF-A(317-427) GST fusion proteins and 
purification using glutathione agarose. (A) Samples taken after the overnight (O/N) induction are shown 
along with total BL21 cell lysates and soluble cell lysates expressing GST fusion proteins. (B) GST-fusion 
proteins bound to glutathione agarose.  Samples were boiled in 2X loading buffer and analysed on a 
coomassie stained, 10% SDS-PAGE gel.  The sizes of molecular weight markers in kDa are indicated on 
the left.  
For both fusion proteins, strong bands of the approximate expected size were present in 
both the non-pelleted, total cell lysate, and in the soluble supernatant from the centrifuged 
sample (Figure 21A), confirming that both fusion proteins were soluble.  
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These proteins were then purified from the soluble cell lysates using glutathione agarose 
beads (methods, section 2.3.8.3).  To check purification, a sample of GST-fusion-bound 
beads were again analysed via SDS-PAGE (Figure 21B).  Evidently, incubation with 
glutathione agarose beads, resulted in isolation of large amounts of T-STAR(RG)-GST 
and NELF-A(317-427)-GST.  
4.8.3 In vitro transcription and translation of SIAH1 
The SIAH1pGBKT7 plasmid (encoding the full length SIAH1 coding sequence, 
downstream of a T7 promoter) was used as a template to generate radiolabelled SIAH1 
protein via an in vitro transcription and translation technique (see methods, section 2.3.4).  
A T7 Luciferase control plasmid was also used to make luciferase protein for a negative 
control.  Both products were analysed by SDS-PAGE and autoradiography (see input 
lanes in Figure 22).  Strong bands of the expected size of full length SIAH1 (34kDa) and 
Luciferase (61kDa) proteins were detected.   
4.8.4 In vitro pull-down 
Equal amounts of radiolabelled SIAH1 and luciferase were added to equal amounts of T-
STAR and NELF-A GST-fusion bound agarose beads.  Glutathione agarose beads 
attached to GST alone were used as a negative control.  Samples were incubated for 1 
hour, with rotation at room temperature, to allow protein binding.  The beads were then 
pelleted by centrifugation and washed to remove any unbound protein.   Reactions were 
analysed on an SDS-PAGE gel and visualised by autoradiography (Figure 22). 
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Figure 22. In vitro pull-down of radiolabelled SIAH1 by T-STAR and NELF-A.  Glutathione agarose 
beads bound to GST fusions of the RG-rich region of T-STAR and the PST-rich region of NELF-A were 
added to in vitro-translated SIAH1 or luciferase proteins. After binding, samples were washed, boiled and 
separated by SDS-PAGE prior to autoradiography.  T-STAR(RG) and NELF-A(PST) fusion proteins 
efficiently pulled down in vitro-translated SIAH1.   
The positive control, T-STAR(RG)-GST-fusion protein efficiently pulled down 
radiolabelled SIAH1, as expected.  A similar signal was evident with the NELF-A(317-
427)GST fusion protein.  This is consistent with the yeast 2-hybrid data, showing that the 
PST-rich region of NELF-A is capable of binding full length SIAH1 protein.  The weaker 
lower bands may be due to translational initiation at secondary methionine codons (AUG) 
within the SIAH1 coding sequence.  The stronger, upper bands appear to be the correct 
size for full length SIAH1.  The negative control, GST alone, pulls down a small amount 
of SIAH1 protein, however the signal is negligible compared to that of T-STAR(RG) and 
NELF-A(317-427).  Under the same conditions, only minor amounts of the negative 
control luciferase protein were pulled down by each GST-fusion protein.   
4.9 Assay for SIAH1-mediated ubiquitination of NELF-A in cultured cells 
Confirmation of the specific interaction between SIAH1 and NELF-A in vitro and results 
from our in vivo degradation assays (section 4.2) implied that this interaction resulted in 
proteasomal degradation of over-expressed NELF-A-GFP fusion protein.  If this was 
indeed the case, then we would presume that this was mediated by polyubiquitination.  
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To test this possibility, ectopically expressed NELF-A-GFP fusion protein was 
immunoprecipitated using the GFP antibody after co-expression with or without SIAH1 
and incubation with the proteasome inhibitor MG132 to prevent degradation of 
ubiquitinated protein.    
In the experiments described, one 6 well plate of approximately 60% confluent HEK293 
cells were used for each immunoprecipitation.  Two plates were transfected with NELF-
ApGFP3 alone, and in another two plates NELF-ApGFP3 was co-expressed with 
SIAH1pCDNA.  24 hours after transfection one of each of these plates of cells was 
treated with the proteasome inhibitor MG132 for 5 hours.  By immunoprecipitating 
NELF-A-GFP fusion protein from cells in which SIAH1 was not overexpressed we 
aimed to establish whether or not there was sufficient endogenous SIAH1 activity in the 
cell to mediate NELF-A-GFP ubiquitination.   
Following confirmation of GFP fluorescence, all plates were harvested and cell lysates 
prepared (see methods 2.3.10).  Half of the cell lysate from each transfection were 
incubated with the α-GFP antibody overnight and the other half without antibody as a 
negative control.  The following day cell lysates +/- GFP antibody were incubated with 
protein A Dynabeads and immunoprecipitated.  Immunoprecipitates were then subjected 
to Western blot analysis using α-GFP antibody to confirm the IP was successful (Figure 
23A). 
As shown in Figure 23A NELF-A-GFP appears to be stabilised when MG132 was 
present (compare lanes 1 with 2 and 2 with 3), however there appears to be more NELF-
A-GFP when co-expressed with SIAH1 (compare lanes 1 with 3 and 2 with 4).  It is 
important to bear in mind, that there is no loading control on this Western.  Therefore, we 
cannot ascertain anything with regards to protein levels from this IP.  Interestingly, a 
higher molecular-weight smear characteristic of polyubiquitinated products was detected 
in all four IP lanes and this smear was strongest in cells in which SIAH1 was co-
expressed and cells were treated with MG132.  This was consistent with the hypothesis 
that SIAH1 mediates polyubiquitination of NELF-A-GFP fusion protein.   
In order to confirm that the observed smear was due to ubiquitinated NELF-A-GFP 
fusion protein, the blot was stripped and re-probed with an anti-ubiquitin antibody.  
However, despite re-running samples, repeating Westerns and testing varying 
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concentrations of antibody we failed to detect any protein on these immunoprecipitations 
using the ubiquitin antibody (data not shown).  As we did not have a positive control for 
this experiment (an expression construct for a proven SIAH1 target for 
polyubiquitination), we were unable to determine whether this was because NELF-A-
GFP was not ubiquitinated or if it was simply due to the antibody having deteriorated.  
In an attempt to resolve this issue, we utilised an HA-tagged ubiquitin expression 
construct, HA-UbpCDNA3 (purchased from Professor Yue Xiong, Lineberger Cancer 
Centre, University of North Carolina, USA) and the experiment described above was 
repeated.  This time however, the HA-UbpCDNA3 was co-transfected and cells were 
incubated with the proteasome inhibitor MG132 for 6 hours rather than 5 in the hope that 
more ubiquitinated species would accumulate, making it easier to detect.  Again, 
immunoprecipitates were then subjected to Western blot analysis using α-GFP antibody 
to ensure that NELF-A-GFP immunoprecipitated successfully (Figure 23B). 
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Figure 23. Immunoprecipitation of NELF-A-GFP fusion protein in attempt to detect SIAH1 
mediated ubiquitination of ectopically expressed NELF-A.  (A) HEK293 cells were co-transfected with 
NELF-ApGFP3 and SIAH1pCDNA or empty pCDNA vector in the minus SIAH1 controls.  24 hours after 
transfection cells were incubated in the presence or absence of 50µM MG132 for 5 hours. (B)  HEK293 
cells were co-transfected with NELF-ApGFP3, SIAH1pCDNA5 and HA-UbpCDNA3 as indicated.  24 
hours after transfection cells were incubated in the presence or absence of 60µM MG132 for 6 hours.  In 
both experiments lysates were immunoprecipitated with α-GFP antibody and Protein A Dynabeads or 
beads only as a negative control.  After washing, samples were eluted by boiling in sample loading buffer. 
Immunoprecipitates and controls were separated on 7% SDS PAGE followed by immunoblotting with α-
GFP and HRP-conjugated α-mouse secondary antibody to visualise NELF-A-GFP.  The asterisks highlight 
non-specific bands. The question marks highlight the higher molecular weight NELF-A-GFP band 
observed when both NELF-ApGFP3 and SIAH1pCDNA were co-expressed and cells were incubated with 
MG132.   
Similar to the previous experimental result (Figure 23A), it was clear that levels of 
NELF-A-GFP fusion protein were again stabilised in the presence of the proteasome 
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inhibitor MG132 (compare lanes 3 and 4 in Figure 23B) and a higher molecular weight 
band was also clearly observed (highlighted by the arrow and question mark).  In order to 
determine whether or not the band represented a ubiquitinated form of NELF-A-GFP 
protein, this Western was stripped and re-probed with an α-HA antibody.  However, once 
again we failed to detect any bands on these samples using the α-HA antibody despite 
repeated attempts (data not shown).   
Therefore this data showed that the NELF-A-GFP fusion protein was modified in the 
presence of the proteasome inhibitor when SIAH1 was co-expressed, however we were 
unable to confirm that this modification was due to addition of a ubiquitin tag. 
4.10 Assay for GFP-tagged NELF-A:RNAPII interaction in the presence/absence of 
SIAH1 
As mentioned in the introduction to this chapter, the four subunits of the NELF complex 
interact with one another, DRB-sensitivity inducing factor (DSIF) and RNA polymerase 
II (RNAPII) to stall elongating RNAPII (summarised in Figure 13).  The NELF-A protein 
in particular has been shown to be essential for RNAPII binding and transcriptional 
pausing, associating with RNAPII via its HDAg homology region (amino acids 89-248, 
see Figure 18) (Yamaguchi et al., 2001; Narita et al., 2003).   
In our previous experiment we found that overexpression of SIAH1 results in 
modification (possibly ubiquitination) of NELF-A-GFP fusion protein.  This led us to 
hypothesise that this modification could affect the ability of NELF-A to associate with 
RNAPII and/or other subunits of the NELF complex.  In order to test this hypothesis and 
determine whether or not the NELF-A-GFP fusion protein and/or its modified species 
were able to interact with RNAPII in vivo, HEK293 soluble cell lysates (input), 
immunoprecipitations (IP: anti-GFP antibody) and controls (IP: protein A Dynabeads 
only) from the experiment described in the previous section (4.9) were subject to SDS-
PAGE and Western blot probing with an antibody specific to the carboxy-terminal 
domain (CTD) of RNAPII (Figure 24). 
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Figure 24. Testing co-immunoprecipitation of NELF-A-GFP and RNAPII in HEK293 cells.  HEK293 
cells were co-transfected with NELF-ApGFP3 and SIAH1pCDNA or empty pCDNA vector in the minus 
SIAH1 controls.  24 hours after transfection cells were incubated in the presence or absence of 50µM 
MG132 for 5 hours, then harvested and cell lysates prepared.  Soluble HEK293 cell lysates were incubated 
either with or without α-GFP antibody and protein A Dynabeads.  After washing, samples were eluted by 
boiling in sample loading buffer.  Soluble cell lysates (input), and IP samples were separated on 7% SDS 
PAGE and probed with α-GFP and HRP-conjugated α-mouse secondary antibody (upper blots).  Blots were 
then stripped and re-probed with α-RNAPIICTD and α-mouse HRP-conjugated secondary antibodies 
(lower blots). The migration of molecular weight markers is indicated on the right.   
RNAPII, running above the 175kDa marker was detected in the soluble HEK293 cell 
lysates (input) and it was evident that treatment with the proteasome inhibitor MG132 
resulted in RNAPII stabilisation.    This was not unexpected as a number of studies have 
shown that stalled or arrested RNAPII is ubiquitinated and degraded (Somesh et al., 
2005; Somesh et al., 2007).  The smears observed are likely to represent breakdown 
products of RNAPII as they are more stable in the presence of MG132.  
There was no RNAPII detected in the NELF-A-GFP IP lanes.  Therefore, in this 
experiment, ectopically expressed NELF-A-GFP fusion protein did not co-
immunoprecipitate with RNAPII, either when co-expressed with SIAH1 or in the 
presence of MG132.  It remains possible that these proteins form a complex in vivo, 
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however, the amount of NELF-A-GFP immunoprecipitated may be insufficient to detect 
this interaction.   
4.11 Analysing NELF-A stability and localisation in Siah1a-/-2-/- cells 
In experiments to date in this thesis, the effect of SIAH1 on target protein stability has 
been investigated through over-expression studies.  To further characterise the 
physiological function of SIAH proteins and understand how they affect NELF-A protein 
stability in vivo, we utilised mouse embryonic fibroblasts (MEFs) which lack Siah1a and 
Siah2 genes.  Murine embryonic fibroblasts derived from wild-type embryos and Siah1a-
/-Siah2-/- embryos were kindly supplied by Professor David Bowtell (Peter MacCallum 
Cancer Centre, Australia).  Generation of these MEFs is described in Frew et al., (2002).  
4.11.1 Siah gene expression analysis in Siah1a-/-2-/- cells 
Before commencing with analysis of NELF-A protein abundance in wild-type and 
Siah1a-/-2-/- cells we first wanted to ensure the cells were the correct genotype and 
confirm that the Siah1a-/-2-/- cells lack Siah2 and Siah1a mRNA transcripts.  To do this 
reverse transcriptase PCR (RT-PCR) analysis was performed.  Primers were designed to 
amplify the region between the targeting construct and the Siah1a and Siah2 coding 
sequence (Figure 25).   
 
 
Figure 25. Siah1a and Siah2 gene targeting strategy summarised from Dickins et al., (2002) and Frew 
et al., (2003). (A) The Siah1a coding region resides on a single exon.  The targeting vector was designed to 
replace the coding region with a neomycin resistance gene, leaving only the first 22 codons intact. (B) The 
Siah2 gene was inactivated by insertion of a neomycin resistance gene into exon IV.  This insertion 
truncates the Siah2 protein reading frame at codon 180.  The primers used for RT-PCR are shown as red 
arrows.  For Siah1a, the forward primer (Siah1a-F) lies within the first 66 nucleotides (encoding the first 22 
codons) of the coding region and the reverse primer (Siah1a-R) is within the coding sequence which was 
replaced by the neomycin resistance gene.  The Siah2 forward primer (Siah2-F) lies within the first 540 
nucleotides (encoding the first 180 codons) of the coding region and again the reverse primer (Siah2-R) is 
within the coding sequence which is replaced by the neomycin resistance gene.  The Siah1a and Siah2 RT-
PCRs were expected to yield products of 153 and 214 nucleotides, respectively. 
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To establish whether or not Siah1a and Siah2 were expressed in the MEFs, RNA was 
extracted from the wild-type and the Siah1a-/-2-/- cells.  For a positive control, RNA was 
extracted from mouse testes tissue as expression of both Siah1a and Siah2 in murine 
testis has been reported (Della et al., 1995; Venables et al., 2004).   Expression was 
measured by RT-PCR and results are presented in Figure 26A. 
 
Figure 26. Analysis of Siah1a and Siah2 expression in murine embryonic fibroblasts and murine 
testes.  (A) RNAs were analysed by RT-PCR using Siah1a-F, Siah1a-R and Siah2-F, Siah2-R.  (B) MspI 
digest of RT-PCR products.  MspI cuts the Siah1a 153bp PCR product into 99bp and 54bp fragments.  
MspI does not cut Siah1b or Siah2.  All samples were analysed by electrophoresis on 2% agarose gels.   
The DNA markers are shown on the left. 
RT-PCR analysis confirmed the absence of Siah2 mRNA in Siah1a-/-2-/- cells (Figure 
26A).  However the presence/absence of Siah1a required further investigation.  Unlike 
humans, which have two SIAH genes (SIAH1 and SIAH2), mice have three highly 
conserved Siah genes Siah1a, Siah1b and Siah2 (see chapter 1, section 1.3).  As you can 
see from the Siah1a/1b alignment presented in Figure 27, these genes encode very similar 
proteins.  Due to the high degree of similarity of the Siah1a and Siah1b gene coding 
sequences, it is very likely that the Siah1a primers amplified the Siah1b coding sequence.   
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Figure 27. Sequence alignment between murine Siah1a and Siah1b.  The nucleotide sequence 
alignments are presented in the upper panel and the protein sequence is shown below.  The Siah1a-F and 
Siah1a-R primers used for RT-PCR and the MspI site (CCGG) are highlighted.  Both Siah1a and Siah1b 
are 282-amino-acid proteins with 97% homology.  “*” residues are identical in both proteins. “:” represents 
a conserved substitution and “.” represents a semi-conservative substitution.  The RING finger domain 
(amino acids 1-99) is highlighted in green.  The zinc-finger region (amino acids 99-153) is highlighted in 
yellow and the substrate binding domain (amino acids 153-282) is highlighted in red. 
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In order to distinguish between Siah1a and Siah1b PCR products, a varying restriction 
enzyme site in the Siah1a and Siah1b coding sequences was identified.  There is an MspI 
restriction enzyme site present within the Siah1a amplified coding region, which is 
absent in Siah1b (Figure 27).  Therefore the RT-PCR products were digested with MspI 
(Figure 26B).  This MspI digest (Figure 26B) showed that, as expected, the double knock 
out MEFs do not express Siah1a and the 153bp band observed represents Siah1b.  It also 
confirms that all 3 murine Siah genes are expressed in the testes.   
To further confirm the identity of the Siah1a RT-PCR product shown in Figure 26A, the 
PCR product was purified using the Qiagen PCR purification kit and sequenced.   
Approximately 100bp of sequence was obtained from the 5′ end using the Siah1a-F 
primer.  A  BLAST search revealed that this PCR product matched the Siah1b coding 
sequence.  
Interestingly, the Siah1b RT-PCR product appeared to be stronger in the double knockout 
MEFs than in the wild-type cells and once the products were digested with MspI the 
153bp Siah1b band appeared to be absent in the wild-type cells (Figure 26B).  This led us 
to speculate that in the absence of Siah1a and/or Siah2, Siah1b expression is up-regulated 
in order to compensate for the lack of Siah function.  To further analyse Siah1b 
expression in the wild-type and Siah1a-/-2-/- MEFs, Siah1b specific primers were designed 
for RT-PCR.  The forward primer was designed from the Siah1b 5′UTR, which has no 
homology to Siah1a and the reverse primer from within the coding sequence.  For a 
loading control, HPRT (Hypoxanthine Phosphoribosyltransferase) specific primers were 
also designed as the HPRT gene is reported as a constitutively expressed housekeeping 
gene (Pernas-Alonso et al., 1999).  It was ensured that both sets of primers had the same 
annealing temperature and they were designed to span an intron allowing us to 
distinguish between gDNA and RNA. 
RNA was extracted from four separate cell harvests of wild-type and the Siah1a-/-2-/- cells 
and Siah1b expression was measured by RT-PCR using the Siah1b and HPRT specific 
primers.  Results are presented in Figure 28. 
Chapter 4                                                                Further investigation into the SIAH1:NELF-A interaction 
 
90 
 
 
Figure 28. Analysis of Siah1b expression in murine embryonic fibroblasts and murine testes.  (A) 
RNA from four separate cell harvests were analysed by RT-PCR using Siah1b-F, Siah1b-R and HPRT-F, 
HPRT-R primers.  Samples were separated on a 2% agarose gel.  The DNA markers are shown on the left.  
The graph shows the relative amount of Siah1b mRNA in wild-type and the Siah1a-/-2-/- MEFs.  Data is 
presented as the mean ± SD and is representative of the four cell harvests shown. 
The Siah1b specific RT-PCR analysis revealed that there was no significant difference in 
Siah1b expression in wild-type and Siah1a-/-2-/- cells.  
4.11.2 NELF-A stability in Siah1a-/-2-/- cells 
If SIAH1 and potentially SIAH2 were primarily responsible for controlling levels of 
NELF-A in the cell, then we would expect to find elevated levels of NELF-A protein in 
cells which lack Siah1a and Siah2. 
In order to determine whether or not this was the case, and to establish whether or not the 
stability of NELF-A protein in the MEFs was dependent on the proteasome, confluent 
T25 flasks of wild-type and Siah1a-/-2-/- MEFs were incubated with the proteasome 
inhibitor MG132 for 5 hours. Control samples (minus MG132) were also harvested and 
lysed in 2x sample loading buffer.  Total cell lysates were separated by SDS-PAGE and 
analysed by Western blot (Figure 29) probing with the antibody specific to NELF-A and 
α-tubulin for a loading control. 
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Figure 29. NELF-A protein levels in Siah deficient MEFs.  Exponentially growing wild-type and 
Siah1a-/-2-/- mutant MEFs were incubated with or without 60µM MG132 for 5 hours.  Cell lysates were 
prepared, and the level of NELF-A was measured by immunoblotting with α-NELF-A antibody, and an 
anti-α-tubulin antibody for a loading control.  Antibody binding was detected using HRP-conjugated α-
rabbit and α-mouse secondary antibodies, respectively.  Two separate cell harvests (1-2) are presented.  The 
migration of molecular weight markers is indicated on the left.   
Germani et al., (2000) report that α-tubulin is a SIAH1 interacting protein, however they 
found no evidence of variation in α-tubulin levels in cells over-expressing SIAH1 and no 
difference in the presence of proteasome inhibitors.   This was consistent with our results 
and so α-tubulin was considered to be a suitable loading control.  When comparing 
NELF-A protein abundance in wild-type and Siah1a-/-2-/- MEFs, steady state levels 
appear similar (Figure 29).  Clearly there was little difference in NELF-A protein in wild-
type cells compared to Siah1a-/-2-/- null cells and NELF-A protein stability was not 
affected by incubation with the proteasome inhibitor, MG132.   
4.11.3 Comparison of NELF-A distribution in wild-type and Siah1a-/-2-/- MEFs  
In order to gain some insight as to whether or not NELF-A was in some way 
differentially regulated in the presence and absence of Siah proteins, precise localisation 
of endogenous NELF-A protein was visualised by immunofluorescence.  Wild-type and 
Siah1a-/-2-/- null MEFs were fixed in methanol and stained with the α-NELF-A antibody 
(Figure 30). 
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Figure 30. Localisation of NELF-A in wild-type and Siah1a-/-2-/- MEFs.  Cells were fixed, permeabilised 
and stained with α-NELF-A.  NELF-A was visualised with an Alexa Flour-488 (green) conjugated α-rabbit 
secondary antibody.  DNA was visualised with DAPI (blue).  Images were generated by fluorescence 
microscopy.  Scale bars represent 20µM.  
Consistent with previous studies on NELF-localisation, NELF-A protein localised to the 
nucleus, although a small amount of cytoplasmic staining was observed.  There did not 
appear to be any difference in NELF-A localisation in wild-type or Siah1a-/-2-/- null cells. 
4.12 Siah1b expression in mouse tissues 
As mentioned in the introduction to this thesis (section 1.3) three highly conserved 
murine Siah genes have been identified  (Siah1a, Siah1b and Siah2), whereas only two 
human homologs, SIAH1 and SIAH2, have been identified (Della et al., 1993).   So far, 
investigations have focused primarily on the human SIAH1:NELF-A protein interaction.  
Analysis of Siah gene expression in the Siah1a-/-2-/- double knockout MEFs showed that 
these cells express Siah1b (section 4.11.1).  Siah1b knockout mice have been reported to 
have an embryonic lethal phenotype suggesting, although this gene is murine-specific, it 
plays an essential role in development (Frew et al., 2002).  Given that the Siah1a and 
Siah1b proteins are very similar (see alignment Figure 27), we speculated that they are 
likely to have overlapping functions and Siah1b could provide sufficient Siah activity in 
the Siah1a-/-2-/- cells to allow normal stability of NELF-A.  
Aside from the phenotype of the Siah1b knockout which was briefly noted in the study 
by Frew et al., (2002), Siah1b is rarely mentioned in the literature and no Siah1b 
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substrates have been reported.   This is possibly because this is a murine specific gene 
and its high sequence homology to Siah1a makes it difficult to distinguish between the 
two.  As we were confident that the primers used for RT-PCR in section 4.11.1 were 
specifically amplifying Siah1b, we used these to analyse Siah1b expression in various 
mouse tissues.       
RNA was extracted from various murine tissues by Miss Emily Jones (MSc Medical 
Genetics student, IHG, Newcastle University) and Siah1b expression was analysed by 
RT-PCR using the Siah1b and HPRT specific primers.  Results are presented in Figure 
31. 
 
Figure 31. Analysis of Siah1b expression in multiple mouse tissues.  RNA from the tissues shown was 
analysed by RT-PCR using Siah1b-F, Siah1b-R and HPRT-F, HPRT-R primers.  Samples were analysed by 
electrophoresis on a 2% agarose gel.  The DNA markers are shown on the left.   
RT-PCR results revealed that Siah1b was predominantly expressed in the murine testes.  
Weak expression was also detected in muscle, thymus and kidney.  Thus, unlike the other 
Siah proteins which are reportedly ubiquitously expressed, Siah1b expression appears to 
be restricted to particular tissues.  Its elevated expression in the testes suggested that 
Siah1b, like Siah1a, may play an important role in the testes.  This result however was 
quite surprising as the Siah1b gene resides on the X chromosome and most of the gene 
activity on the X chromosome is shut down in male meiotic cells.  Thus, either the Siah1b 
gene remains active during meiosis or the expression detected is from the non-meiotic 
cells in the testes.  
4.13 Assaying murine Siah mediated degradation of NELF-A in cultured cells 
To determine whether or not NELF-A stability is controlled by Siah1b we performed an 
experiment analogous to the SIAH1 degradation assay described in chapter 3 (section 
3.5.3).   In this case, the NELF-A-GFP fusion construct was co-transfected into HEK293 
cells with empty GFP-expression vector and either a Siah1a, Siah1b or Siah2 eukaryotic 
Chapter 4                                                                Further investigation into the SIAH1:NELF-A interaction 
 
94 
 
expression construct.   The levels of NELF-A-GFP fusion protein could then be assayed 
in the presence/absence of the murine Siah homologs (1a, 1b and 2).  Siah1a and Siah2 
eukaryotic expression constructs (in the pKH3 vector) were previously provided by 
Professor David Bowtell (Peter MacCallum Cancer Centre, Australia).  These constructs 
encode the full length Siah1a/Siah2 coding sequence, downstream of a human 
cytomegalovirus (CMV) promoter.   A Siah1b expression construct, however, was not 
available, which we therefore created. 
4.13.1 Generation of Siah1b mammalian expression construct 
Siah1b was PCR amplified from a full length clone purchased from the mammalian 
genome collection (Siah1b image ID; 30053109) using primers Siah1b(F) and Siah1b(R).  
PCR products were digested with EcoRI/XhoI and ligated into complementary sites in 
pCDNA3.1, a mammalian expression plasmid which also contains a CMV promoter.    
The ligation was re-cleaved with EcoRV, followed by dialysis, transformation and 
selection on ampicillin-LB plates.  Colonies were screened by PCR using Siah1b(F) and 
pCDNArev.  Insert positive colonies were further grown overnight before plasmid 
purification.  To confirm that the pCDNA clone contained the correct Siah1b sequence it 
was sequenced from the 5′ end using the T7-F primer. 
4.13.2 In vivo murine Siah degradation assay using HEK293 cells 
In order to determine which of the murine Siah proteins affect NELF-A stability, NELF-
ApGFP3 and the murine Siah expression plasmids (Siah1a-pKH3, Siah1b-pCDNA, 
Siah2-pKH3) were co-transfected into HEK293 cells with the GFP expression vector to 
show the relative amount of the NELF-A-GFP fusion protein.  SIAH1-pCDNA was also 
tested as a positive control.  Cell extracts were analysed by Western blot and probed with 
GFP antibody.  To ensure the murine Siah proteins and the human SIAH1 protein were 
being expressed and were functional, the same experiment was carried out using a known 
SIAH1 substrate, T-STAR (Venables et al., 2004).  Results are presented in Figure 32. 
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Figure 32. Western blot analysis of co-transfection assays to monitor the stability of NELF-A and T-
STAR GFP-fusion proteins in the presence of murine Siah proteins in HEK293 cells.  NELF-ApGFP3 
and the murine Siah expression plasmids (Siah1a-pKH3, Siah1b-pCDNA, Siah2-pKH3) were co-
transfected into HEK293 cells along with empty GFP expression vector.  Cells were harvested 24 hours 
after transfection. Cell lysates were separated on 7% SDS PAGE and analysed by Western blot.  Blots were 
probed with α-GFP antibody and HRP-conjugated anti-mouse secondary antibody. The migration of 
molecular weight markers is indicated on the left.  The graphs show the relative amount of the GFP-fusion 
proteins in each of the co-transfections.  
As expected, levels of NELF-A and T-STAR GFP-fusion proteins were reduced in the 
presence of human SIAH1 (compare lanes 1 and 5).  A similar affect was observed in the 
presence of the murine Siah1a and Siah2 proteins.  However, co-expression of Siah1b did 
not appear to have any effect on NELF-A or T-STAR protein stability.  This suggested 
that either Siah1b was not functional as an E3 ubiquitin ligase, or that it was not 
efficiently expressed.  Since the expression vectors used encoded non-tagged Siah1a, 
Siah1b and Siah2 proteins it was not possible to confirm that they were expressed.  
4.13.3 In vivo murine Siah degradation assay using 3T3 cells 
Considering Siah1a and Siah1b proteins are highly homologous, we were surprised to 
find that these proteins did not have a similar affect on NELF-A and T-STAR GFP-fusion 
stability.  Given that Siah1b is a murine specific protein, and no equivalent Siah1b gene 
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has been identified in humans, we speculated that this protein may require a murine 
specific partner protein to target substrates for degradation which is not present in 
HEK293 cells.  Alternatively, because Siah1b is not normally expressed in HEK293 
cells, it may mis-localise.  In order to determine whether or not this was the case, the in 
vivo murine Siah degradation assay described above (section 4.13.2) was repeated in a 
mouse cell line.  As we had previously shown that Siah1b is expressed in murine 
embryonic fibroblasts (section 4.11.1) we chose to use mouse embryonic fibroblast 3T3 
cells for this experiment.  Results are presented in Figure 33. 
 
Figure 33. Westerns of co-transfection assays to monitor the stability of NELF-A and T-STAR GFP 
fusion proteins in the presence of murine Siah proteins in 3T3 cells.  Cells were harvested 24 hours 
after transfection.   Cell lysates were separated on 7% SDS PAGE and analysed by Western blot.  Blots 
were probed with α-GFP antibody and HRP-conjugated anti-mouse secondary antibody. The migrations of 
molecular weight markers are shown and the graphs show the relative amount of the GFP-fusion proteins in 
each of the co-transfections.  
Again, as in HEK293 cells, Siah1b did not appear to have any effect on the stability of 
NELF-A or T-STAR GFP-fusion proteins in the murine 3T3 cell line (compare lanes 1 
and 4).  In this experiment, neither SIAH1, Siah1a or Siah2 appeared to affect NELF-A-
GFP stability, however they efficiently de-stabilised the T-STAR GFP-fusion protein.  It 
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is possible that SIAH1, Siah1a and Siah2 require a co-factor protein to target NELF-A for 
degradation which is not expressed in 3T3 cells.  However this experiment was only 
performed once therefore repeats of this experiment are required to confirm this 
observation.    
4.13.4 Generation of FLAG-tagged murine Siah proteins  
Results to date from our transient expression experiments revealed that Siah1a and Siah2 
proteins efficiently destabilised the ectopically expressed NELF-A and T-STAR GFP-
fusion proteins but no effect on protein stability was observed for Siah1b.   This could be 
for several reasons, for example, Siah1b may not function as an E3 ubiquitin ligase, or 
alternatively, it may not being efficiently expressed in cells.  Due to the lack of Siah 
specific antibodies, we were unable to determine whether or not the Siah proteins were 
being efficiently expressed.  To remedy this we chose to tag Siah1a, Siah1b and Siah2 
with the FLAG epitope.  The three murine Siah genes were cloned into both the N-
terminal and C-terminal p3XFLAG-CMV expression vectors as we were concerned that 
adding the FLAG epitope to either the C-terminal substrate binding domain or the N-
terminal RING finger domain may affect Siah function.  
Murine Siah primers were designed to ensure the FLAG peptide sequence would be in 
frame with the Siah coding sequences.  For cloning into the N-terminal FLAG vector, 
reverse primers included the Siah STOP codon and for cloning in the C-terminal FLAG 
vector, the STOP codon was omitted.  Due to the very high sequence 
homology/similarity between the Siah1a and Siah1b coding sequences, the same reverse 
primers were used for cloning (see appendix for further primer and cloning information). 
Siah1b was amplified from the full length Siah1b image clone (ID; 30053109) and 
Siah1a and Siah2 were amplified from the Siah1a-pKH3 and Siah2-pKH3 vectors, 
respectively.  PCR products were digested with EcoRI/XbaI and ligated into 
complementary sites in the N-terminal and C-terminal vectors p3XFLAG-CMV.  The 
ligations were re-cleaved with BglII, followed by dialysis, transformation into E. coli 
DH5α cells and selection on ampicillin-LB plates.  Colonies were screened by PCR using 
CMV-F and the Siah specific reverse primers.  Plasmids were purified from insert 
positive colonies and then sequenced to ensure they contained the correct sequence. 
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4.13.5 In vivo degradation assay using murine Siah-FLAG tagged clones. 
In order to determine whether or not the murine Siah-FLAG tagged clones were 
functional the experiment described in section 4.13.2 was repeated. This time however, 
the cells were co-transfected with NELF-ApGFP3 and the FLAG-tagged Siah clones and 
in the minus Siah controls (-) empty FLAG vector was co-transfected.  Also, because 
SIAH1 protein is known to regulate its own stability (Hu et al., 1999; Lorick et al., 1999), 
we also assayed Siah-FLAG protein and NELF-A-GFP protein stability in the presence 
and absence of the proteasome inhibitor MG132.  24 hours after transfection HEK293 
cells expressing the FLAG-tagged Siah proteins and NELF-A-GFP were treated with or 
without MG132 for 6 hours before they were harvested. Again, cell extracts were 
analysed by Western blot and probed with the α-GFP antibody. To ensure that the Siah-
FLAG fusion proteins were being expressed the blot was re-probed with α-FLAG 
antibody.  Results are presented in Figure 34. 
 
Figure 34. Westerns of co-transfection assays to monitor the stability of NELF-A-GFP fusion 
proteins in the presence of murine Siah FLAG-tagged proteins in HEK293 cells. 24 hours after 
transfection, cells were incubated with or without 60µM MG132 for 6 hours.  Cell lysates were prepared 
and samples were separated on 12% SDS PAGE.  Levels of GFP-tagged NELF-A and FLAG-tagged Siah 
proteins were measured by immunoblotting with α-GFP and α-FLAG primary antibodies and HRP-
conjugated anti-mouse secondary antibody.  The migration of molecular weight markers is indicated on the 
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left of the Westerns.  The graph shows the relative amount of the GFP-fusion proteins in each of the co-
transfections.  The data in the graphs is presented as the mean ± SE and is representative of two 
experiments.  
Both Siah1a and Siah1b are 282-amino-acid proteins and have a molecular weight of 
31kDa.  Siah2 is a slightly larger 325-amino acid protein with a molecular weight of 
34kDa.  We can see from Figure 34 that addition of the 3xFLAG epitopes (which consists 
of 22 amino acids, DYKDHDGDYKDHDIDYKDDDDK) shifts protein migration by 
~10kDa as expected and the Siah FLAG-tagged proteins migrate just above the GFP 
loading control band.   
From the graph (Figure 34) we can see that in the presence of N-terminal-FLAG tagged 
Siah1a and Siah2, NELF-A-GFP stability is reduced.   However, when co-expressed with 
C-terminal FLAG-tagged Siah1a, and both N- and C-terminal-FLAG tagged Siah1b, 
levels of NELF-A-GFP are elevated compared to minus Siah controls.  Co-expression 
with the C-terminal Siah2 had no effect on NELF-A-GFP stability.  As expected, NELF-
A-GFP protein was stabilised by MG132 consistent with it being regulated by a 
proteasome dependent mechanism.   
Aside from NELF-A-GFP protein stability, it was clear from the Western that the Siah1a 
and Siah2 N-terminal-FLAG tagged proteins were stabilised by MG132, whereas the C-
terminal clones and both the Siah1b clones were not.   Therefore addition of the FLAG-
tag to the C-terminal SBD domain prevents Siah1a and Siah2 from auto-regulating 
themselves and NELF-A-GFP.  It perhaps not surprising that the C-terminal FLAG-
tagged clones do not affect NELF-A-GFP stability as addition of the FLAG-tag to the 
substrate binding domain of the protein is likely to interfere with ligase-substrate 
interaction.  The N-terminal FLAG-tagged proteins however are functional in de-
stabilising NELF-A-GFP and in regulating their own stability.   
Again, these experiments support our previous data showing that Siah1b does not 
regulate the stability of NELF-A-GFP fusion protein.  As a result of using the FLAG 
epitope to detect expression levels of transfected Siah proteins we were certain that they 
were being efficiently expressed.  We also found that unlike Siah1a and Siah2, Siah1b 
does not auto-regulate its own stability suggesting that Siah1b is not functioning as an E3 
ligase. 
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4.14 Assay for Siah1b:NELF-A interaction  
Our in vivo degradation assays show that Siah1b, unlike Siah1a, does not affect the 
stability of T-STAR- or NELF-A-GFP fusion proteins.  Given that Siah1a and Siah1b 
contain the exact same substrate binding domain, it seemed surprising that they do not 
have similar targets or function.  We therefore wanted to determine whether or not 
Siah1b could actually interact with NELF-A and T-STAR.  In order to do this, a Siah1b 
yeast 2-hybrid construct containing the full length Siah1b sequence was generated and 
tested via a directed yeast 2-hybrid assay for its ability to bind to the SIAH1 interacting 
proteins NELF-A and T-STAR.  
4.14.1 Generation of Siah1b yeast 2-hybrid construct 
Siah1b was amplified by PCR and digested as described previously (section 4.13.1).  The 
digested PCR product was ligated into complementary EcoRI/SalI sites in the pGBKT7 
Y2H vector.  The ligation was re-cleaved with SalI, followed by dialysis, transformation 
and selection on Kanamycin-LB plates.  Colonies were screened by PCR using the T7-F 
primer and Siah1b(R).  Insert positive colonies were further grown overnight before 
plasmid purification.   
4.14.2 Testing for Siah1b:NELF-A interaction via yeast 2-hybrid 
The Siah1b pGBKT7 clone expresses full length Siah1b as a fusion protein with the DNA 
binding domain of Gal4.  This protein was tested for its ability to interact with full length 
NELF-A and T-STAR via a yeast 2-hybrid assay (NELF-A and T-STAR clones in the 
pACTII Y2H vector were previously isolated by Dr Julian Venables).  The full length 
SIAH1 protein was also tested to act as a positive control.  Results are presented in 
Figure 35. 
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Figure 35. Testing for interaction with Siah1b.  Siah1b-pGBKT7 was assayed for its ability to interact 
with NELF-A and T-STAR. SIAH1-pGBKT7 was tested as a positive control.  Empty bait plasmid, 
pACTII, was used to test for auto-activation of Siah1b-pGBKT7.  Filters stained with X-Gal are shown.  
Key, +++ strong interaction, positive blue colour within 30 minutes, ++ positive blue colour observable 
within 1 hour, + positive blue colour within 24 hours, - no noticeable interaction after 24 hours of exposure. 
As expected, an interaction between the human SIAH1 protein and NELF-A and T-
STAR was detected.  The SIAH1pGBKT7, NELF-A and T-STAR-pACTII constructs 
were previously tested for auto-activation and proven not to auto-activate (see chapter 3, 
section 3.2).  A strong interaction between Siah1b, NELF-A and T-STAR was also 
observed and a negative result for interaction between the empty pACTII vector and the 
Siah1b-pGBKT7 construct shows that this construct does not auto-activate.  
4.15 Testing Siah1b mediated-inhibition of NELF-A degradation  
The Siah1b yeast 2-hybrid result shows that Siah1b can bind to NELF-A and T-STAR, 
however unlike the other Siah proteins it does not target these proteins for degradation.  
In the in vivo degradation assay using the FLAG-tagged Siah constructs (section 4.13.5) 
we also observed that levels of NELF-A-GFP fusion protein were in fact elevated when 
co-expressed with Siah1b compared to the minus Siah controls (whereby empty FLAG-
vector was co-transfected). These results prompted us to hypothesise that by binding to 
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NELF-A, Siah1b may inhibit the binding of other Siah proteins and hence prevent its 
degradation.   
It is also possible that Siah1b inhibits Siah1a and Siah2 activity by forming a 
heterodimer.  Siah proteins have been shown to form homo- or heterodimers with other 
Siah proteins through their C-terminal domain (Hu et al., 1999).  Recently, a novel splice 
variant of human SIAH1, designated as SIAH-1S (Mei et al., 2007), was identified and it 
was found that SIAH-1S was able to interact with SIAH1 to form a heterodimer or with 
itself to form a homodimer.   However, unlike SIAH1:SIAH1, neither SIAH1:SIAH1-1S 
nor SIAH-1S:SIAH-1S could degrade the previously identified SIAH substrate, β-
catenin.  Thus, SIAH-1S acts as a dominant-negative inhibitor of SIAH1.   
To determine whether or not Siah1b was inhibiting Siah-mediated degradation, 
expression plasmids encoding murine Siah genes were co-transfected in pair-wise 
combinations along with NELF-ApGFP3, and the levels of NELF-A-GFP fusion protein 
were analysed.  
In this experiment, NELF-ApGFP3 and equal amounts of either SIAH1pCDNA3, Siah1a-
pKH3, Siah1b-pCDNA, or Siah2-pKH3 were co-transfected in varying combinations into 
HEK293 cells.  The GFP expression vector was also transfected to act as an internal 
standard and show the relative amount of the NELF-A-GFP fusion protein.  24 hours 
after transfection, and upon confirmation of GFP fluorescence, cells were harvested and 
cell extracts were analysed by Western blot and probed with GFP antisera (Figure 36).    
Chapter 4                                                                Further investigation into the SIAH1:NELF-A interaction 
 
103 
 
 
Figure 36. Examining the stability of NELF-A-GFP fusion protein in the presence of pair wise 
combinations of ectopically expressed Siah proteins.  24 hours after transfection, cell lysates were 
prepared and samples were separated by 10% SDS PAGE and analysed by Western blot.  Levels of GFP-
tagged NELF-A were assayed by probing with α-GFP and HRP-conjugated anti-mouse secondary 
antibodies.  On the left of the Western the migrations of molecular weight markers are shown.  The graph 
shows the relative amount of NELF-A-GFP fusion protein in each of the co-transfections in the Western 
presented.   
It was clear from this assay that NELF-A-GFP fusion protein was most abundant in cells 
co-transfected with a double dose of the Siah1b expression vector (lane 8) and was least 
abundant in cells co-transfected with either a double dose of Siah1a or Siah2 expression 
vectors (lanes 5 and 10).  Although there is no negative control in this experiment (e.g. 
cells transfected with empty expression vector), results are consistent with previous 
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experiments whereby Siah1a and Siah2 efficiently degrade NELF-A-GFP and Siah1b 
does not.  When Siah1b is co-expressed with SIAH1, Siah1a or Siah2, levels of NELF-A-
GFP are approximately equal to or more than that observed with the SIAH1/SIAH1, 
Siah1a/Siah1a and Siah2/Siah2 pairs.  Therefore, the data suggests that Siah1b may have 
inhibitory effect on SIAH1, Siah1a or Siah2 mediated degradation of NELF-A-GFP, 
however the basis of this requires further investigation.     
4.16 Immunoprecipitation of murine Siah-FLAG tagged proteins 
Results to date implied that N-terminal FLAG-tagged Siah1a and Siah2 target NELF-A-
GFP fusion protein for proteasome-mediated destruction.  In an attempt to determine 
whether or not the ectopically expressed Siah proteins functionally interact with 
endogenous NELF-A protein, we utilised the Siah FLAG-epitope in order to carry out an 
immunoprecipitation experiment.     
To assay for an in vivo interaction with NELF-A, each of the N-terminal FLAG-tagged 
Siah clones were transfected into HEK293 cells.  Because ligase-substrate interactions in 
vivo are likely to be transient, immunoprecipitations were carried out in the presence and 
absence of the proteasome inhibitor, MG132.   In previous experiments we had shown 
that N-terminal FLAG-tagged Siah1a and Siah2 were stabilised by MG132 which then 
strengthens the likelihood of detecting an interaction (section 4.13.5).  24 hours after 
transfection HEK293 cells expressing the N-terminal FLAG-tagged Siah proteins were 
treated with or without MG132 for 6 hours.   Cells were harvested and FLAG-tagged 
proteins were immunoprecipitated using α-FLAG affinity resin (see methods, section 
2.3.11).  Immunoprecipitated samples were washed, electrophoresed on 10% SDS-
PAGE, and analysed by Western blot, firstly probing with a monoclonal antibody against 
the FLAG epitope to determine whether or not the IP was successful (Figure 37).
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Figure 37. Immunoprecipitation of N-terminal FLAG-tagged murine Siah proteins and testing for 
co-immunoprecipitation with endogenous NELF-A.  24 hours after transfection, cells were incubated 
with or without 60µM MG132 for 6 hours.  Cell lysates were then prepared and incubated with α-FLAG 
affinity resin. After washing, samples were boiled, electrophoresed on a 10% SDS-polyacrylamide gel and 
analysed by immunoblotting with α-FLAG antibody and HRP-conjugated anti-mouse secondary antibody 
(upper blot).  The blots were then re-probed with α-NELF-A antibody and HRP-conjugated anti-rabbit 
secondary antibody (lower blot). The migration of molecular weight markers is shown on the left. 
It was clear from the Western probed with α-FLAG antibody (Figure 37, upper blot) that 
Siah1a, Siah1b and Siah2 immunoprecipitated successfully.  Consistent with previous 
experimental results, the Siah1a and Siah2 immunoprecipitations were more efficient in 
the presence of MG132 showing that these proteins auto-regulate their own stability, 
whereas Siah1b did not.   
The Siah1a protein band differs slightly in size when comparing the input and IP lanes in 
both the presence and absence of MG132.  This was often observed in IP experiments 
and suggests that the protein has been modified in some way (e.g. de-phosphorylation, 
de-ubiquitination etc) as a result of immunoprecipitation.  Alternatively, the migration of 
bands may be affected by the varying buffers/salt concentrations in the input and 
immunoprecipitation samples.  Also, a lower molecular weight band running just below 
the 32.5kDa marker was evident in each of the IP lanes.  Because this band was present 
in the IP lanes only it is likely that this is an artefact from the α-FLAG affinity resin.   
To determine whether or not endogenous NELF-A protein interacts with the FLAG-
tagged Siah proteins, the same blot was then re-probed with α-NELF-A antibody.  The 
83kDa NELF-A band was clearly observable in the input and IP supernatant lanes, and 
absent from the IP lanes, thus NELF-A did not co-immunoprecipitate with ectopically 
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expressed Siah proteins, neither in the presence or absence of MG132.  This is perhaps 
not surprising given that the Siah-NELF-A interaction is likely to be transient.   
4.17 Mutating Siah1b  
As shown in the Siah1a/1b alignment (Figure 27), there are only six amino acid 
differences between the Siah1a and Siah1b proteins (summarised in Table 11). Three of 
these amino acid differences locate to the N-terminal RING-finger domain of the protein 
and the other three amino acid differences locate to the central zinc finger region.  
To determine whether there was a particular residue or residues responsible for rendering 
Siah1b non-functional with regard to controlling NELF-A-GFP stability, site-directed 
mutagenesis was performed to make point mutations and thus sequentially revert each of 
the 6 differing amino acids which have accumulated in Siah1b since it diverged from 
Siah1a. 
Amino acid Siah1a Siah1b Protein domain 
5 T - Threonine A – Alanine 
RING-Finger Domain 10 P – Proline S – Serine 
27 G - Glycine D – Aspartic Acid 
101 A - Alanine S – Serine 
Zinc –Finger Region 102 S – Serine A – Alanine 
113 E – Glutamic Acid K – Lysine 
Table 11. Amino acid differences between Siah1a and Siah1b.   
To make each of the 6 point mutations, two oligonucleotide primers were designed, each 
primer pair complementary to opposite strands of the Siah1b-FLAG vector.  These 
oligonucleotide primers were then extended during temperature cycling by PfuTurbo 
DNA polymerase (see methods, section 2.1.12).  PfuTurbo DNA polymerase replicates 
both plasmid strands with high fidelity without displacing the mutant oligonucleotide 
primers. Following temperature cycling, the products were then treated with DpnI, an 
endonuclease which specifically cuts methylated and hemimethylated DNA.  DpnI 
therefore digests the parental DNA template, leaving the newly synthesised mutation-
containing DNA intact.  Each DNA product containing the desired mutation was then 
purified using the Qiagen PCR purification kit and transformed into E. coli DH5α cells 
by electroporation.  The resultant transformation mix was then plated out on LB plates 
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containing the selective antibiotic ampicillin and incubated at 37ºC overnight.  Plasmids 
were purified from colonies and mutations were verified by DNA sequencing.   
4.17.1 Assaying ability of Siah1b mutants to degrade NELF-A in vivo 
To determine whether any of the six single amino acid substitutions between the Siah1a 
and Siah1b proteins were responsible for the differing activity with regard to controlling 
NELF-A-GFP fusion protein stability, each of the Siah1b mutants described in the 
previous section were co-transfected with the NELF-ApGFP3 expression plasmid into 
HEK293 cells, and the levels of NELF-A-GFP fusion protein were analysed.  
As a positive control the N-terminal FLAG-tagged Siah1a expression vector was co-
transfected and in the minus Siah control (-) empty FLAG vector was co-transfected.  
The GFP expression vector was also transfected to act as an internal standard and show 
the relative amount of the NELF-A-GFP fusion protein.  24 hours after transfection and 
upon confirmation of GFP fluorescence, cells were harvested and cell extracts were 
analysed by Western blot probing with α-GFP antibody and α-FLAG antibody to ensure 
the Siah proteins were being efficiently expressed (Figure 38).   
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Figure 38. Co-transfection experiment to assay the ability of Siah1b mutants to degrade NELF-A-
GFP fusion protein in HEK293 cells.  24 hours after transfection, cell lysates were prepared.  Samples 
were separated by 10% SDS-PAGE and analysed by Western blot.  Levels of GFP-tagged NELF-A were 
assayed by probing with α-GFP and HRP-conjugated anti-mouse secondary antibodies. To visualise Siah 
protein expression, the blot was re-probed with α-FLAG antibody and HRP-conjugated anti-mouse 
secondary antibody (lower blot).  On the left of the Western the migrations of molecular weight markers 
are shown.  The graph shows the relative amount of NELF-A-GFP fusion protein in each of the co-
transfections compared to the GFP loading control.   
Co-expression of none of the six different Siah1b mutants resulted in a reduction of 
NELF-A-GFP protein levels to the equivalent level of that observed when co-expressed 
with the functional E3 ligase Siah1a, however a reduction was observed when co-
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expressed with Siah1b mutant D27G.  In contrast, NELF-A-GFP protein was more stable 
when co-expressed with Siah1b and mutants A5T, S10P, S101A, A102S and K113E 
when compared to the minus Siah control (-).  Although repeats of this experiment are 
required in order to determine whether or not these results are statistically significant, 
preliminary results suggest that a single amino acid substitution is not solely responsible 
for the differing functional activity between Siah1a and Siah1b. 
4.17.2 Assaying ability of Siah1b mutants to auto-regulate themselves 
As noted in the literature and consistent with our findings, the SIAH1 protein targets 
itself for proteasomal degradation.  Studies by Hu and Fearon (1999) revealed that an 
intact N-terminal RING finger domain is essential for this function as point mutations 
and deletion of the RING finger domain lead to stabilisation of the SIAH1 protein.    As a 
result of our experiments, we found that the murine Siah1a and Siah2 proteins also auto-
regulate their own stability, however the closely related Siah1b protein did not.  Because 
three of the six differing amino acids between Siah1a and Siah1b locate to the RING 
finger domain (Table 11), we speculated that these differences were responsible for the 
observed differences in stability. 
To investigate whether or not the six amino acid substitutions between Siah1a and Siah1b 
proteins could affect Siah1b stability, levels of FLAG-tagged wild-type Siah1b and the 
Siah1b mutants were measured in the presence and absence of the proteasome inhibitor 
MG132. 
The N-terminal FLAG tagged Siah1b clones were co-transfected with empty GFP vector 
to act as transfection and loading control into HEK293 cells.  N-terminal FLAG-tagged 
Siah1a was also transfected as a positive control as we had previously shown that this 
protein is stabilised by MG132.  24 hours after transfection HEK293 cells expressing the 
N-terminal FLAG-tagged Siah proteins were treated with or without MG132 for 6 hours.   
Following confirmation of GFP fluorescence cells were harvested and subjected to SDS-
PAGE and Western blot analysis (Figure 39).   
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Figure 39. Co-transfection assay to monitor the stability of Siah1b mutants. 24 hours after transfection, 
cells were incubated with or without 60µM MG132 for 6 hours.  Cell lysates were prepared and samples 
were separated by 10% SDS-PAGE.  Levels of FLAG-tagged Siah proteins and the GFP loading control 
were measured by immunoblotting with α-FLAG and α-GFP primary antibodies, and HRP-conjugated anti-
mouse secondary antibody.  The migration of molecular weight markers is indicated on the left of the 
Western.  The graph shows the relative amount of the FLAG-tagged Siah protein in the presence and 
absence of the proteasome inhibitor MG132.  The data in the graphs is representative of an average of two 
Westerns and is presented as the mean ± SE.  
A number of samples in the Western shown in Figure 39 did not separate well 
(particularly Siah1b D27G).  Therefore samples were electrophoresed a second time on 
10% SDS-PAGE and were again analysed by Western blot (Western not shown).  Both 
Westerns were analysed using ImageQuant (Version 5.2) and an average of results is 
presented in the graph in Figure 39.   As expected, the Siah1a protein was stabilised in 
the presence of MG132.  A slight stabilisation was also observed for Siah1b, however 
this was negligible comparable to Siah1a.  Levels of Siah1b mutants A5T, S101A and 
K113E were unaffected by the addition of MG132, whereas mutants S10P, D27G and 
A102S appeared to be more stable in the absence MG132.   
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Overall these experimental results imply that the individual reversion of each of the six 
amino acid changes in Siah1b, which have accumulated since it diverged from Siah1a, 
were insufficient to restore its ability to target itself for proteasomal degradation.   
4.18 Summary and discussion  
At the beginning of this chapter we hypothesised that Siah proteins may mediate an 
additional layer of transcriptional regulation of the various NELF- regulated 
developmental control genes by modulating stability of NELF-A.  Thus, in order to 
further characterise the SIAH1:NELF-A interaction and determine whether or not Siah 
proteins regulate NELF-A stability in vivo we carried out a number of experiments.  
These included mapping of the SIAH binding site in NELF-A and confirmation via GST 
pull down; IP experiments to determine whether or not NELF-A was ubiquitinated; 
analysis of NELF-A protein localisation in mouse testes tissue and Siah deficient cells 
and analysis of NELF-A stability in the presence of the murine family of Siah proteins 
We confirmed that a genuine molecular interaction occurred in vitro, mapping to the 
PST-rich region of NELF-A which contains a conserved SIAH binding motif.  SIAH2, 
the SIAH1 homolog also bound to the PST-rich region of NELF-A, but not the full-
length protein in a yeast 2-hybrid experiment.  Consistent with this, Narita and colleagues 
(2003) aiming to better understand the interactions of the NELF complex at a molecular 
level found that C-terminal deletions of NELF-A, including the PST-rich region, did not 
affect the assembly of the NELF complex, however they hypothesised  that this region 
may contribute to the stability of the DSIF/NELF/RNAPII complex.   
The stability of NELF-A-GFP fusion protein was found to be dependent on the 
proteasome as protein levels increased in the presence of the proteasome inhibitor 
MG132.  Since this data suggested that SIAH1 targeted NELF-A-GFP for proteasomal 
degradation, immunoprecipitation experiments were carried out to investigate whether or 
not SIAH1 mediates ubiquitination of NELF-A-GFP fusion protein.  Results from these 
experiments however remained inconclusive.  A modified, larger molecular weight 
NELF-A-GFP fusion protein was detected when SIAH1 was co-expressed and MG132 
was present.  However, due to lack of a suitable positive control, we were unable to 
determine whether or not this modification was a result of ubiquitination.   
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I would like to note that ubiquitination of proteins is inherently difficult to detect.  This is 
due to the rapid proteasomal degradation of ubiquitinated species and also, ubiquitination 
can often be rapidly reversed by the action of a large family of deubiquitinating enzymes 
(DUBs).  Although we addressed the problem of the proteolytic activities of the 
proteasome by using the inhibitor MG132, there may be DUBs in the cell that 
specifically de-ubiquitinate NELF-A.  The majority of DUBs are cysteine proteases, 
therefore addition of cysteine protease inhibitors to the cell may improve our chances of 
detecting modified substrates. 
Also, as noted in the introduction to this thesis (section 1.2.1) various polyubiquitin chain 
types have been described and it is unlikely that ubiquitin antibodies are able to detect 
free-ubiquitin, mono-ubiquitin and the various types of polyubiquitin chain conjugates 
with equal affinity.  Thus, it is possible that a different ubiquitin antibody would detect 
the modified NELF-A-GFP species.  Proteins modified with polyubiquitin chains are 
usually detected as higher molecular weight smears on Western blots, however we 
observed a discrete higher molecular weight band (Figure 23).  If this is indeed a result of 
modification with ubiquitin then the presence of a discrete band suggests that the protein 
was mono or di-ubiquitinated rather than polyubiquitinated.  The ubiquitin monomer has 
a molecular weight of 8.6kDa, therefore it is possible that the observed higher molecular 
weight band could represent a mono or di-ubiquitin tagged protein.   In general, SIAH 
proteins are reported to polyubiquitinate substrates, however there was one exception 
published by Lee et al., (2008b) whereby SIAH1 was found to facilitate the mono and di-
ubiquitination of α-synuclein which is commonly found in neurodegenerative inclusion 
bodies.  SIAH1-mediated ubiquitination of α-synuclein did not target it for degradation 
by the proteasome, but instead appeared to promote α-synuclein aggregation. 
Another possibility is that the NELF-A-GFP protein was modified by a ubiquitin like 
protein (see introduction, section 1.2.2).  For example, modification with the UBL 
SUMO has been shown to affect protein stability, however, a distinct set of E1, E2 and 
E3 enzymes appear to be required for sumoylation.  It is interesting to note though that 
SIAH1 and SIAH2 were found to interact with UbcH9, an E2 enzyme that catalyzes 
conjugation of SUMO, not ubiquitin, via yeast 2-hybrid (Desterro et al., 1997; Hu et al., 
1997b).  Although there is no evidence in the literature of SIAH proteins facilitating 
sumoylation, it is an intriguing possibility.  It is also possible that other pathways may be 
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activated in the presence of SIAH1 and MG132 which results in a differing type of post-
translational modification of NELF-A-GFP (e.g. phosphorylation).    
Although SIAH1 was able to efficiently target ectopically expressed NELF-A for 
proteasomal degradation, analysis of endogenous levels of NELF-A protein in HEK293 
cells revealed that endogenous protein was stable and unaffected by both MG132 
incubation and SIAH1 over expression (data not shown).  We were also unable to detect 
an interaction between FLAG-tagged Siah proteins and endogenous NELF-A via co-
immunoprecipitation.  These results suggest that these proteins do not interact under 
normal cellular conditions.  It is possible that SIAH proteins may serve to limit NELF-A 
only at certain stages in the cell cycle.  Interestingly, a study by Yung et al., (2009) which 
followed the movement of fluorescently labelled NELF-A via live cell fluorescence 
microscopy showed that NELF bodies were present in the nucleus throughout most of the 
cell cycle, except that they disappeared shortly before entering mitosis and reappeared 
after completion of cytokinesis.  Therefore it would be interesting to monitor NELF-A 
protein levels throughout the cell cycle.     
Alternatively, SIAH proteins may simply serve to target NELF-A which is in excess of 
cellular requirements.  It is likely that the majority of NELF-A within the cell is present 
with the NELF complex, inaccessible to SIAH proteins.  There may be some sort of 
trigger required that results in dissolution of the NELF complex to make NELF-A 
accessible to SIAH1-mediated ubiquitination.   
Investigation in to NELF-A protein localisation in the testes revealed that NELF-A was 
present in pachytene spermatocytes and round spermatids and experiments by Venables 
et al., (2004) revealed that Siah1a is also expressed in spermatocytes, but not spermatids.  
Potentially, Siah1a regulates NELF-A which is being expressed in spermatocytes and 
once Siah1a expression is switched off in the spermatids, NELF-A is stable.  The precise 
points at which Siah proteins and NELF-A are present during meiosis I and/or meiosis II 
however is unknown, and further investigation is required.   
Analysis of NELF-A protein in the MEFs by Western and cell staining revealed that 
steady-state levels of NELF-A were similar in wild-type and the Siah1a-/-2-/- null cells.  
This showed that the NELF-A protein was not exclusively regulated by either Siah1a 
and/or Siah2.  In the absence of Siah proteins alternative pathways or other regulators of 
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NELF-A may be activated or it may be subject to degradation by another E3 ligase.  
There are a number of acknowledged Siah substrates which have been found to be 
regulated by alternate pathways and E3 ligases other than SIAH proteins.  β-catenin, for 
example, was primarily believed to be regulated by the Wnt signalling pathway, however 
Matsuzawa and Reed (2001) and Liu et al., (2001) later found that β-catenin could also 
be destroyed by SIAH1 (Polakis 2001).  HIPK2, another SIAH1 target, has also been 
shown to be regulated by alternate ubiquitin ligases, including WSB-1 and Fbx3 (Choi et 
al., 2008; Shima et al., 2008), and it appears that HIPK2 is regulated by multiple E3 
ligases according to cellular needs (Kim et al., 2009). 
We initially predicted that the most likely candidate to additionally control NELF-A 
protein in the mouse was the Siah1a murine homolog, Siah1b.  Analysis of Siah1b 
expression in mouse tissues and MEFs revealed that Siah1b was most highly expressed in 
the testes and was expressed in both wild-type and Siah1a-/-2-/- null cells.  This prompted 
us to hypothesise that Siah1b could replace Siah function and compensate for the lack of 
Siah1a and Siah2 in the Siah1a-/-2-/- null cells.  However, our in vivo degradation assays 
revealed that Siah1b, unlike SIAH1, Siah1a and Siah2, had no affect on GFP-tagged 
NELF-A or T-STAR stability.  Also, unlike the other Siah proteins Siah1b did not auto-
regulate its own stability.   
Given that Siah1a and Siah1b proteins are so similar it was surprising to find that Siah1b 
had diverged in function.  The six amino acid differences between Siah1a and Siah1b 
reside in the RING finger domain and the central zinc finger region.  There are no amino 
acid differences between the SIAH1, Siah1a and Siah1b substrate binding domains, thus 
it was not unexpected to find that Siah1b, like SIAH1 also bound to NELF-A and T-
STAR in the yeast 2-hybrid assay.   
It is unlikely that the amino acid changes that have accumulated in Siah1b simply render 
this protein non-functional, as in an attempt to generate Siah1b knockout mice, Bowtell 
and colleagues found that Siah1b was essential for viability during embryonic 
development (Frew et al., 2002).   As Siah1b was capable of binding to NELF-A we 
hypothesised that Siah1b may act as a competitor and play an important role in the cell by 
preventing Siah1/2-mediated degradation.   
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The RING finger domain binds to E2 ubiquitin-conjugating enzymes and functions as 
part of a scaffold to optimally position substrate and E2 for ubiquitin transfer (Hu et al., 
1999; Zheng et al., 2000).  As a result of these varying residues it is possible that Siah1b 
binds to differing E2s or other modifying enzymes which are perhaps absent from 
HEK293 and murine 3T3 cells.  Alternatively, the Siah1b RING finger and/or zinc finger 
region may bind to a protein which prevents or inhibits its ability to bind to and 
ubiquitinate particular substrates.  It is also possible that Siah1b protein may have 
evolved to assist in the conjugation of UBL proteins, rather than ubiquitin.   
Individual reversion of each of the six amino acid changes which have accumulated in 
Siah1b since it diverged from Siah1a had no affect on Siah1b’s auto-regulatory activity.  
With regard to controlling NELF-A-GFP stability, co-expression the six different Siah1b 
mutants did not decrease NELF-A-GFP protein levels to the equivalent level of that 
observed when co-expressed with Siah1a, however a reduction was observed when co-
expressed with Siah1b mutant D27G.  Although repeats of this experiment are required in 
order to determine whether or not this is a statistically significant result, preliminary 
results suggest that multiple amino acid differences between Siah1a and Siah1b are 
responsible for their differing activities.   
Co-expression of none of the six different Siah1b mutants resulted in a reduction of 
NELF-A-GFP protein levels to the equivalent level of that observed when co-expressed 
with the functional E3 ligase Siah1a, however a reduction was observed when co-
expressed with Siah1b mutant D27G.  In contrast, NELF-A-GFP protein was more stable 
when co-expressed with Siah1b and mutants A5T, S10P, S101A, A102S and K113E 
when compared to the minus Siah control (-).  Although repeats of this experiment are 
required in order to determine whether or not these results are statistically significant, 
preliminary results suggest that a single amino acid substitution is not solely responsible 
for the differing functional activity between Siah1a and Siah1b. 
Overall these experiments revealed that SIAH1, Siah1a and Siah2 proteins but not Siah1b 
preferentially down-regulate the levels of ectopically expressed NELF-A protein and the 
endogenous cellular NELF-A protein was largely stable under parallel conditions.  Also, 
we were unable to detect an interaction between NELF-A-GFP and RNAPII by 
immunoprecipitation and we suspect that the GFP-tagged NELF-A protein does not 
participate in the formation of a functional NELF complex. 
Chapter 4                                                                Further investigation into the SIAH1:NELF-A interaction 
 
116 
 
It remains possible that Siah proteins, excluding Siah1b, do mediate transcriptional 
regulation by modulating stability of NELF-A and the NELF complex.  However, further 
understanding of what triggers disassociation of the NELF complex is required. 
 Chapter 5. Further investigation into the interaction between SIAH1 
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5.1 Introduction 
One of the interacting proteins identified in the SIAH1 yeast 2-hybrid screen included a 
tumour suppressor protein known as ASPP1 (Apoptosis Stimulating Protein of p53).  In 
chapter 3 ASPP1 was found to interact specifically with full length SIAH1 protein, it 
contained a conserved SIAH binding motif and levels of ASPP1-GFP fusion protein were 
notably reduced when co-expressed with SIAH1.  Therefore, evidence to date implied 
that ASPP1 was a target for SIAH1-mediated degradation.  
The ASPP1 protein, encoded by the PPP1R13B gene, is a member of a family of proteins 
that share common domains at their N-termini, including an ankyrin-repeat domain, an 
SH3 domain and proline rich domain (hence, ASPP is also an acronym for the ankyrin 
repeats, SH3 domain, and proline rich domains that characterise the family).  The family 
consists of three members, ASPP1, ASPP2 and iASPP, reviewed by Sullivan and Lu, 
(2007).   
ASPP1 and ASPP2, also known as 53BP1 and 53BP2/53BP2L (made from splicing 
variants of the same gene) were originally identified in a yeast 2-hybrid screen aiming to 
identify p53 interactors, and were shown to bind to wild-type but not mutant p53 protein 
in vitro (Iwabuchi et al., 1994).  They were later found to interact with p53 in vivo and 
regulate its activity (Samuels-Lev et al., 2001).  Subsequently, ASPP1 and ASPP2 were 
found to interact with other key proteins involved in apoptosis and cell growth.  These 
include the p53 family members, p63 and  p73 (Bergamaschi et al., 2004; Robinson et al., 
2008), the apoptotic regulator Bcl-2 (Naumovski et al., 1996), p65, a subunit of the 
apoptotic regulator NFκB (Yang et al., 1999), and APCL (Nakagawa et al., 2000) among 
others (see Table 12 in chapter 6 for a comprehensive list of ASPP1 and ASPP2 
interacting proteins).  To date however, the most studied function of the ASPP family 
proteins is their ability to bind to and regulate p53.  ASPP1 and ASPP2 are activators of 
p53-dependent apoptosis but not cell cycle arrest (Samuels-Lev et al., 2001).  They bind 
to the DNA binding domain of p53 and enhance its ability to selectively bind to 
promoters of pro-apoptotic genes and stimulate their expression (Iwabuchi et al., 1998; 
Samuels-Lev et al., 2001; Patel et al., 2008) .  The mechanism of how they accomplish 
this however, is not clear.  It may be achieved by changing the protein conformation of 
p53 itself or by recruiting other transcription factors or chromatin remodelling enzymes.   
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In contrast, the third ASPP family member, iASPP, is a key inhibitor of p53-mediated 
apoptosis, summarised in Figure 40 (Bergamaschi et al., 2003).   
 
Figure 40. Regulation of p53-dependent apoptosis by ASPP proteins.  After stress such as DNA 
damage, p53 is up regulated and stabilised.  Binding of ASPP1 or ASPP2 results in transactivation of pro-
apoptotic genes such as Bax and PIG3 resulting in cell death.  iASPP prevents this, instead allowing 
proliferation to occur.  Figure modified from Braithwaite et al., (2006). 
The most common p53 mutations observed in human cancer map to the 200-amino acid 
core DNA binding domain which overlaps with the ASPP binding region.  Elucidation of 
the crystal structure of the C-terminal portion of ASPP2 bound to the p53 core domain 
revealed that a number of these frequently mutated residues in p53 disrupt the 
ASPP2:p53 interaction (Gorina et al., 1996).  Thus, this interaction plays an important 
role in p53 cancer biology and one mechanism by which wild-type p53 is tolerated in 
human cancer is through loss of ASPP activity.  Both ASPP1 and ASPP2 are frequently 
down-regulated in human breast cancer (Samuels-Lev et al., 2001), leukaemia (Liu et al., 
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2004) and tumour cell lines (Liu et al., 2005).  Low ASPP2 mRNA levels have also been 
linked to poor clinical outcome in lymphoma patients (Lossos et al., 2002) and ASPP2 
heterozygous mice are tumour prone (Kampa et al., 2009a).    
Given the pro-apoptotic functions of ASPP1 and ASPP2, it must be important to keep 
ASPP activity in check as any disruption may result in impaired apoptosis and tumour 
formation.  Much of the literature on the ASPP proteins focuses predominately on 
ASPP2, and a number of publications have shown that ASPP2 levels increase following 
UV irradiation and treatment with the clinically utilised bortezomib and chemotherapy 
agents which induce DNA damage (Lopez et al., 2000; Zhu et al., 2005).  However, the 
mechanisms controlling ASPP1 and ASPP2 protein levels and function are poorly 
understood.     
As discussed in the introduction to this thesis (section 1.3.3) SIAH1 is a p53 inducible 
gene and appears to play a role in the p53-mediated response.  A number of groups 
observed that overexpression of SIAH1 often results in apoptosis or cell cycle arrest 
however the exact way in which SIAH1 controls the outcome is undefined.  It is possible 
that SIAH1 contributes to the decision by regulating levels of the pro-apoptotic protein 
ASPP1. 
Interestingly, a report published by Zhu and colleagues (2005) revealed that ASPP2 was 
regulated by a proteasome dependent mechanism.  They found that treatment of cells 
with proteasomal inhibitors increased ASPP2 protein levels but not RNA and they also 
showed that ASPP2 was ubiquitinated.  The E3 ligases responsible for ASPP2 
ubiquitination however remain unknown.   Given that ASPP1 and ASPP2 share 48% 
identity (Slee et al., 2003) we were keen to further characterise the interaction between 
SIAH1 and ASPP1 and we also wanted to determine whether or not SIAH1 could 
regulate ASPP2 stability.   
In this chapter I describe experiments which address these issues.  Levels of ASPP2-GFP 
fusion protein were monitored when SIAH1 was overexpressed and the ASPP2 protein 
sequence was analysed for the presence of a SIAH binding site.  The SIAH1 interacting 
regions were mapped in both ASPP1 and ASPP2 and in order to gain a better idea of how 
SIAH proteins regulate ASPP stability in vivo, an ASPP1 polyclonal antibody was 
purified and levels of endogenous ASPP1 protein were analysed in Siah deficient cells. 
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5.2 Assay to determine whether or not GFP-tagged ASPP1 and ASPP2 are regulated 
by SIAH1 and the proteasome 
Previous experiments suggested that ASPP1-GFP was modulated by proteasomal 
degradation as levels of ASPP1-GFP fusion protein were reduced when co-expressed 
with the E3 ubiquitin ligase, SIAH1 (chapter 3, section 3.5.3).  Given that the ASPP1 and 
ASPP2 proteins are 48% similar, and Zhu and colleagues (2005) revealed that ASPP2 
was regulated by a proteasome dependent mechanism, we hypothesised that SIAH1 may 
also target ASPP2 for proteasomal breakdown.  In order to analyse this ASPP1pGFP3, 
ASPP2pGFP3 and SIAH1pCDNA3 were co-transfected into HEK293 cells.  The GFP 
expression vector was also co-transfected to show the relative amounts of GFP-tagged 
ASPP protein.  24 hours after transfection, cells were incubated with or without the 
proteasome inhibitor MG132 for 7 hours.  Cell extracts were then analysed by Western 
blot (Figure 41). 
 
Figure 41. GFP-tagged ASPP1 and ASPP2 are stabilised by MG132.  24 hours after transfection, cells 
were incubated with or without 60µM MG132 for 7 hours.  Cell lysates were prepared and samples were 
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separated on 7% SDS PAGE.  Levels of GFP-tagged ASPP were measured by immunoblotting with α-GFP 
and HRP-conjugated anti-mouse secondary antibody.  The migration of molecular weight markers is 
indicated on the left of the Western.  The graphs show the relative amount of the GFP-fusion protein in 
each of the co-transfections.   
Consistent with our previous results, co-expression with SIAH1 resulted in reduced 
ASPP1-GFP stability and a similar effect was observed on the stability of ASPP2-GFP.  
Also ASPP1- and ASPP2-GFP fusion proteins were stabilised in the presence of MG132.  
Therefore these results suggest that SIAH1 targets both of these proteins for proteasomal 
breakdown. 
5.3 Analysis of ASPP2 protein sequence for presence of a SIAH-binding motif 
Results from our in vivo degradation assay described in section 5.2 suggest that SIAH1 
can target the ASPP2 protein for proteasomal breakdown.  This prompted us to analyse 
the ASPP2 protein sequence in order to determine whether or not it contains a SIAH-
binding motif.  Sequence analysis was performed using ClustalW as described previously 
(chapter 3, section 3.4). 
 
DCC           -------------------------SEEAPSRTIPTACVRPTHPLRSF------------  
OBF-1         -------------------------HASSGAAPAPTAVVLPHQPLATY------------ 
SIP           -------------------------KAELLDNEKPAAVVAPITTGYTV------------      
TIEG1         -------------------------NVEAARKNIPCAAVSPNRSKCER------------  
ASPP2         PKPAGQQPRVLLSPSIPSVGQDQTLSPGSKQESPPAAAVRPFTPQPSKDTLLPPFRKPQT 480 
 
Figure 42. Sequence alignment of the SIAH binding motif in recognised SIAH interacting proteins 
and ASPP2.  Alignments were generated with ClustalW.  Identical residues in the core motif are 
highlighted in red columns. Only the sequence encompassing the identified SIAH binding motif is shown.   
The ClustalW alignment revealed that the ASPP2 protein contains the precise 
‘PxAxVxP’ core SIAH binding motif encompassing amino acids 445-468 (Figure 42). 
We then went on to confirm that this predicted binding motif was completely conserved 
between humans and mice by aligning the human and mouse ASPP2 protein sequences 
using ClustalW (Figure 43).   
 
Human         TVVPSMGTKPKPAGQQPRVLLSPSIPSVGQDQTLSPGSKQESPPAAAVRPFTPQPSKDTL 471 
Mouse         IAATSVGAKLKPAGPQARMLLSPGAPSGGQDQVLSPASKQESPPAAAVRPFTPQPSKDTF 599 
               ...*:*:* **** *.*:****. ** ****.***.**********************: 
 
Figure 43. Partial sequence alignment between the human and mouse ASPP2 proteins.  Alignment 
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was generated using ClustalW.  Only the sequence encompassing the identified SIAH binding motif (red 
box) is shown.  “*”residues represent those that are identical in the alignment. “:” represent conserved 
substitutions and “.” represent semi-conservative substitutions. 
5.4 Mapping the SIAH1 binding site in ASPP2 
Analysis of the ASPP2 protein sequence revealed that it contained a precise SIAH 
binding motif (between amino acids 445-468) which was conserved between humans and 
mice (see Figure 43).  To determine which part of the ASPP2 protein was bound by 
SIAH1, partial constructs containing the N-terminal and C-terminal regions of ASPP2 
were generated and the encoded proteins were tested for their ability to interact with 
SIAH1 in a directed yeast 2-hybrid assay. 
5.4.1 Generation of partial ASPP2 yeast 2-hybrid constructs  
ASPP2 was divided in to two halves, an N-terminal half, including amino acids 1-556, 
and a C-terminal half, including amino acids 556-1005.  This was achieved via PCR 
using an ASPP2 expression plasmid encoding the full length ASPP2 CDS as a PCR 
template (gift from Professor Xin Lu, Ludwig Institute for Cancer Research, University 
of Oxford, UK).  PCR products were cloned into the pGADT7 vector (see appendix for 
primer and cloning information).  To confirm that the pGADT7 clones contained the 
correct sequence, both constructs were sequenced from the 5′ end using the T7-F 
sequencing primer.   
5.4.2 Mapping the SIAH1 interacting region in ASPP2 via yeast 2-hybrid 
The two ASPP2pGADT7 clones described above were tested against the pGBKT7 vector 
alone, to assay for auto-activation, and against full length SIAH1-pGBKT7.  Results are 
from the yeast 2-hybrid assay presented in Figure 44 and are summarised in Figure 48.   
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Figure 44. Mapping the SIAH1 interaction region in ASPP2.  Full length SIAH1-pGBKT7 was tested 
against two partial ASPP2 constructs to identify the interacting region. Empty bait plasmid, pGBKT7 was 
used to test for auto-activation of prey plasmids.  Filters stained with X-Gal are shown.  Positive 
interactions manifest as blue colonies while when no interaction is present, the colonies remain white or 
red.  Key, +++ strong interaction, positive blue colour within 30 minutes, ++ positive blue colour 
observable within 1 hour, + positive blue colour observable within 4  hours, - no noticeable interaction after 
24 hours of exposure.  
A strong, positive interaction with SIAH1 was detected with the N-terminal ASPP2 
construct (amino acids 1-563).  It is this half of the protein which contains the SIAH-
binding motif previously identified (section 5.3).  Negative results for an interaction 
between the empty pGBKT7 vector and the two ASPP2-pGADT7 clones confirmed that 
the positive result was not due to auto-activation by the Gal4-activation domain ASPP2 
fusions alone. 
5.5 Mapping the SIAH1-binding site in ASPP1  
Previous analysis of the ASPP1 protein sequence revealed a putative conserved version 
of the SIAH-binding site encompassing amino acids 420-444 (see chapter 3, section 3.4).  
In order to determine whether or not this putative SIAH1 binding site was conserved 
between humans and mice, the human and mouse ASPP1 protein sequences were aligned 
using ClustalW (Figure 45).  This revealed that unlike the motif identified in ASPP2, the 
putative motif in ASPP1 was only partially conserved between humans and mice.   
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Human         QGTVSSQPVPFSALGPTEKPGIEIGKVPPPIPGVGKQLPPSYGTYPSPTPLGPGSTSSLE 480 
Mouse         QGAISSQPLPLSALGATEKLGIEIGKGPPPIPGVGKPLPPSYGTYPSSGPLGPGSTSSLE 478 
              **::****:*:****.*** ****** ********* **********. *********** 
 
Figure 45. Partial sequence alignment between the human and mouse ASPP1 proteins.  Alignment 
was generated using ClustalW.  Only the sequence encompassing the putative SIAH binding motif which is 
highlighted by the red box is shown. “*”residues represent those that are identical in the alignment. “:” 
represent conserved substitutions and “.” represent semi-conservative substitutions. 
5.5.1 Mapping the SIAH1 interacting region in ASPP1 via yeast 2-hybrid 
In order to determine which part of ASPP1 was recognised by SIAH1, Dr Jared Thornton 
previously generated partial ASPP1 yeast 2-hybrid constructs (Thornton 2005) and tested 
these in a directed yeast 2-hybrid assay for their ability to interact with full-length 
SIAH1.  I repeated this assay in order to confirm results and further map the interacting 
region.  Results are presented in Figure 46. 
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Figure 46. Mapping the SIAH1 interaction domains in ASPP1.  Full length SIAH1-pGBKT7 was tested 
against partial ASPP1 constructs to elucidate the interacting region. Empty bait plasmid, pGBKT7, was 
used to test for auto-activation of prey plasmids.  Filters stained with X-Gal are shown.  Positive 
interactions manifest as blue colonies while colonies remain white or red when there is no interaction.  Key, 
+++ strong interaction, positive blue colour within 10 minutes, ++ positive blue colour observable within 
30 minutes, + positive blue colour observable within 1 hour, - no noticeable interaction after 24 hours of 
exposure.  
Surprisingly, no interaction was detected between full length ASPP1 and SIAH1 in this 
assay.  However, this was detected in the yeast 2-hybrid assay described in chapter 3, 
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sections 3.2 and 3.3.  The only difference between these two assays is that the ASPP1 
coding sequence was in the pACTII plasmid rather than pGADT7, both of which contain 
the Gal4 activation domain fused to ASPP1 CDS.  It is possible that the pGADT7 clone 
had deteriorated.  SIAH1 however, was also pulled out of a yeast 2-hybrid screen aiming 
to identify ASPP1 interacting proteins in the testes (see next chapter, section 6.2), thus 
we were confident that the full length proteins interact and this was an anomalous result.     
Two different regions of ASPP1, amino acids 87-352 and 532-760, were found to interact 
with SIAH1 and this was consistent with Dr Jared Thornton’s results (Thornton 2005).   
Negative results for an interaction between the empty pGBKT7 vector and the various 
ASPP1 fragments in pGADT7 confirmed that the positive interactions were not due to 
auto-activation by the Gal4-activation domain ASPP1 fusions alone.  
5.5.2 Confirmation of the interaction between ASPP1 and SIAH1 in vitro 
It was confirmed that the ASPP1:SIAH1 interactions were genuine molecular interactions 
by BSc students Anthony J. Cutts and Robin Humphrey (Human Genetics, Newcastle 
University) who performed an in vitro GST pull-down assay (data not shown).  They 
cloned the two SIAH1 interacting ASPP1 fragments (amino acids 87-352 and 532-760) 
into the pGEX5X1 vector to create GST-fusion proteins.  They then expressed these in E. 
coli BL21 cells and used these to specifically pull down radiolabelled, in vitro-translated 
SIAH1.  Therefore, we were confident that the ASPP1:SIAH1 interactions detected in our 
yeast 2-hybrid assay were due to direct protein-protein contact rather than yeast bridging 
proteins. 
5.6 Further mapping of the SIAH1 binding site in ASPP1 
Previous experiments confirmed that SIAH1 interacts with amino acids 87-352 and 532-
760 of ASPP1.  However, the original analysis of the ASPP1 protein sequence for the 
presence of a SIAH-binding motif identified a putative site within amino acids 420-444 
(chapter 3, section 3.4), which lies in-between the two SIAH1 interacting fragments.   
In order to further narrow down the SIAH1 binding sites in ASPP1, constructs containing 
different regions of the two interacting fragments were generated and tested for their 
ability to interact with SIAH1 in the yeast 2-hybrid system.  
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5.6.1 Generation of partial ASPP1 yeast 2-hybrid constructs  
The two SIAH1 interacting fragments (87-352 and 532-760) were divided into two 
regions by PCR.  An ASPP1-V5 expression plasmid encoding the full length ASPP1 
CDS was used as a template for PCR (gift from Professor Xin Lu, Ludwig Institute for 
Cancer Research, University of Oxford, UK).  The 87-352 SIAH1 interacting region was 
divided into amino acids 86-216 and 208-355.  The 532-760 SIAH1 interacting region 
was divided into amino acids 525-620 and 613-760 (see appendix for primer and cloning 
information).  Each PCR product was cloned into the pGADT7 vector and we confirmed 
that the pGADT7 clones contained the correct sequences by sequencing from the 5′ end 
using the T7-F sequencing primer.   
5.6.2 Further mapping of the SIAH1 interacting region in ASPP1 via yeast 2-hybrid 
Each construct described above was then tested for interaction with full length SIAH1 
protein in a directed yeast 2-hybrid assay.  Full length ASPP1 was also tested as a 
positive control.  Results are shown in Figure 47. 
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Figure 47. Further mapping the SIAH1 interaction region in ASPP1.  Full length SIAH1-pGBKT7 was 
tested against partial ASPP1 constructs to further narrow down the interacting region. Empty bait plasmid, 
pGBKT7, was used to test for auto-activation of prey plasmids.  Filters stained with X-Gal are shown.  
Positive interactions manifest as blue colonies while colonies remain white or red when there is no 
interaction.  Key, +++ strong interaction, positive blue colour within 30 minutes, ++ positive blue colour 
observable within 1 hour, + positive blue colour observable within 4  hours, - no noticeable interaction after 
24 hours of exposure.  
SIAH1 interacted strongly with full length ASPP1 and amino acids 208-355, and a weak 
interaction was detected with amino acids 525-620.  Results are summarised in Figure 48. 
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Figure 48. Schematic diagram of the ASPP1 and ASPP2 proteins and summary of the yeast 2-hybrid 
results.  ASPP1 and ASPP2 proteins have a similar modular structure and the domain organisation of both 
proteins is shown.  Domains include ubiquitin-like (ULD), glutamine-rich (Gln), proline-rich (Pro), ankyrin 
repeats (ANK) and Src homology 3 (SH3) domains. Smaller constructs outlined below were assayed for an 
interaction with SIAH1 via yeast 2-hybrid. SIAH1 interacting fragments are red.  
Sequence analysis was performed in order to determine whether or not there was a 
degenerate SIAH1 binding motif present in the two ASPP1 SIAH1-interacting fragments.   
Again, fragments of four SIAH binding proteins containing a confirmed SIAH binding 
motif were aligned with ASPP1(208-355) and ASPP1(525-620) using ClustalW (see 
chapter 3, section 3.4).  No clear SIAH binding motif was identified in either of these 
fragments (data not shown).  However when the full length ASPP1 and ASPP2 protein 
sequences were aligned, the precise SIAH1 binding motif present in ASPP2 aligns within 
the 525-620 ASPP1 region which interacts weakly with SIAH1 via yeast 2-hybrid (Figure 
49).  Therefore SIAH1 may interact with both ASPP1 and ASPP2 in similar regions. 

ASPP1         IQQRIS--------------VPPSPTYPPAGPPAFPAGDSKPELPLTVAIRPFLADKG-S 562 
ASPP2         LSTVVPSMGTKPKPAGQQPRVLLSPSIPSVGQDQTLSPGSKQESPPAAAVRPFTPQPSKD 469 
              :.  :.              *  **: *..*     : .** * * :.*:*** .: . . 
 
Figure 49. Partial sequence alignment between ASPP1 and ASPP2 proteins.  Alignment was generated 
using ClustalW.  Only the sequence encompassing the SIAH binding motif identified in ASPP2 (red box) is 
shown.  “*”residues represent those that are identical in the alignment. “:” represent conserved substitutions 
and “.” represent semi-conservative substitutions. 
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5.7 ASPP1 polyclonal antibody purification 
Experiments to date revealed that levels of both GFP-tagged ASPP1 and ASPP2 were 
notably reduced when co-expressed with SIAH1 and this effect was reversed by 
proteasome inhibition.  In order to determine whether or not SIAH proteins normally 
target ASPP proteins for proteasomal degradation in vivo, we wanted to examine levels of 
endogenous ASPP proteins. 
Unfortunately an ASPP2 antibody was not available to us.  However, a polyclonal 
antibody specific to ASPP1 was previously generated by Dr Jared Thornton and it was 
formerly shown to work well on Western blots (Thornton 2005).  This antibody was 
raised in sheep by injecting a GST-tagged ASPP1 specific epitope (amino acids 357-
532).  Due to limited stocks of the purified antibody however, I first had to re-affinity 
purify the polyclonal antibody from crude serum.   
Total IgG was first separated from sheep serum (injected with purified ASPP1(357-532)-
GST protein) by Agata Rozanska (IHG, Newcastle University) using caprylic acid.  
Epitope-specific antibodies were then affinity purified against an ASPP1-histidine fusion 
peptide coupled to a SulfoLink column (see methods, section 2.3.9.2).  By using a His-
tagged peptide derived from the pET32 vector (encoding the same ASPP1 specific 
epitope, amino acids 357-532) rather than the GST-tagged immunising peptide we 
ensured that the purified IgG was specific to the ASPP1 epitope, not the GST-tag. 
5.7.1 Purification of ASPP1(357-532) His-fusion protein 
The ASPP1(357-532)pET32a plasmid was transformed into E. coli BL21 cells via the 
calcium chloride transformation procedure (see methods, section 2.3.8.1).  The pET32a 
plasmid contains six His-tag peptides fused with the thioredoxin protein.  The empty 
vector was also transfected as a positive control.  Single colonies were selected and 
expression was induced overnight in Instant TB medium (see methods, section 2.3.8.2).  
Total BL21 cell lysate samples from the overnight cultures are shown in Figure 50A.  
Following induction strong bands were observed corresponding to the predicted size of 
either ASPP1(357-532)-His-thioredoxin (approximately 35kDa) or His-thioredoxin 
(approximately 20kDa).   
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A solubilisation assay was previously carried out by Dr Jared Thornton showing that the 
ASPP1 epitope was predominantly soluble under native conditions (Thornton 2005).  To 
ensure this was the case, lysed cells were centrifuged to pellet any insoluble material.  
After centrifugation, samples of soluble supernatant were taken and analysed on a 
SimplyBlue stained SDS-PAGE gel (Figure 50B).  Bands of the correct size were present 
in the soluble fraction, indicating that as expected both proteins were soluble. 
The His-tagged ASPP1(357-532) peptide was then  purified from soluble cell lysate using 
ProCatch His resin under native conditions (see methods, section 2.3.8.4).  The peptide 
was then eluted with imidazole, which displaces histidine and the elution process was 
repeated three times to recover as much of the purified peptide as possible.  To check 
purification, a sample of each elution was analysed via SDS-PAGE (Figure 50C).  It was 
clear that sufficient amounts of pure ASPP1(357-532)-His protein were obtained for 
subsequent purification of α-ASPP1-specific IgG
 
Figure 50. Preparation of the His-tagged ASPP1 antigenic peptide for affinity purification. (A) 
Bacterial expression of the ASPP1(357-532)-His fusion peptide.  ASPP1(357-532)pET32a and empty 
pET32a plasmids were transformed into E. coli BL21 bacteria.  Transformed bacteria were cultured and 
expression from the plasmids was induced overnight using instant TB medium.  Before (pre-induction) and 
after the induction (O/N culture), aliquots of BL21 cells were harvested, lysed in 2X loading buffer, 
resolved on 10% SDS-PAGE  and visualised with SimplyBlue SafeStain. (B) Testing solubility of His-
fusion peptides.  Induced cells lysates were subject to centrifugation and the soluble supernatant was 
visualised on the SimplyBlue stained gel. (C) Purification of the ASPP1(357-532)-His peptide.  The 
peptide was purified using ProCatch His resin. After washing, bound peptide was eluted by adding 1ml of 
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elution buffer.  The elution process was repeated three times and protein samples from each elution were 
analysed by SDS-PAGE.  Molecular weight markers are indicated on the left of each gel. 
5.7.2 ASPP1-specific IgG purification  
Purified ASPP1(357-532)-His fusion protein was reduced with DTT to provide free 
sulfhydryls for linking the peptide to a SulfoLink column.  ASPP1(357-532)-His was 
bound to the SulfoLink agarose and washed to wash off any un-bound protein (see 
methods, section 2.3.9.2).   
Caprylic acid-purified total IgG (purified by Agata Rozanska, IHG) was passed through 
the ASPP1-epitope coated column.  The column was then washed before elution of α-
peptide specific antibodies first under acidic conditions followed by neutralisation of the 
column and subsequent elution under alkaline conditions.  Fractions were collected, 
immediately neutralised and assayed for protein content via a Bradford assay (see 
methods, section 2.3.9.2).   High levels of IgG protein eluted in acid fractions 3 and 4.  
Positive fractions were dialysed overnight against 1X PBS.  Sodium azide was added 
(final concentration 0.05%) to the purified IgG to prevent bacterial infection and glycerol 
was added (final concentration 10%) to prevent freeze/thaw damage. 
5.7.3 Characterisation of the α-ASPP1 antiserum by Western blotting and pre-
absorption 
Following purification, acid fractions 3 and 4 were tested for their ability to recognise full 
length ASPP1 by Western blot.   Total protein was prepared from non-transfected 
HEK293 cells and cells transfected with the ASPP1pGFP3 expression plasmid.  Proteins 
were electrophoresed on 7% SDS-PAGE followed by immunoblotting with the α-ASPP1 
antibody (Figure 51). 
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
Figure 51. Analysis of the α-ASPP1 antiserum, acidic fractions 3 and 4 by Western Blot.  Fractions 3 
and 4 eluted from the SulfoLink column under acidic conditions were tested against HEK293 cells 
transfected with ASPP1-GFP (Lane 1), or non-transfected HEK293 cells (Lane 2).  Protein samples were 
boiled, electrophoresed on a 7% SDS-polyacrylamide gel and analysed by immunoblotting with α-ASPP (1 
in 500 dilution) and HRP-conjugated anti-sheep secondary antibody.  On the left of the Westerns the 
migrations of molecular weight markers are shown. The asterisks highlight potential smaller ASPP1 
isoforms or ASPP1 degradation products. 
The α-ASPP1 antibody fractions 3 and 4 detected three protein bands in cells transfected 
with ASPP1-GFP and two protein bands in non-transfected cells (Figure 51).  Clear 
bands were observed at the expected sizes for both the endogenous ASPP1 protein and 
ASPP1-GFP fusion protein (expected sizes 175kDa and 202kDa respectively) and these 
were detected with approximate equal affinity with both the acidic fractions.  The smaller 
protein bands (*) were also observed with Dr Jared Thornton’s purified α-ASPP1 
antibody (Thornton, 2005).  It is likely that these are ASPP1 degradation products or are 
representative of proteins made from alternatively spliced ASPP1 transcripts.  However, 
these bands may also be due to the antibody binding non-specifically to a different 
protein.  
Following detection of a protein of the expected size of ASPP1 and ASPP1-GFP fusion 
protein in non-transfected and transfected cells, pre-absorption assays were carried out to 
determine if the detected protein was indeed ASPP1 (see methods, section 2.3.9.3).  If the 
protein bands resulted from the α-ASPP1 antiserum recognising ASPP1 protein, then 
prior binding of the antiserum to the ASPP1(357-532)-His fusion peptide before 
immunoblotting should eliminate or diminish the signal.  This pre-absorption assay was 
carried out by pre-incubating the α-ASPP1 antiserum with ProCatch His resin coated 
with the ASPP1(357-532)-His fusion protein.  As a control, a mock pre-absorption assay 
was carried out using an unrelated peptide, an RBM-histidine peptide attached to 
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ProCatch His resin which was used to generate an α-RBM antibody (Elliott et al., 1998).  
Both acid fractions 3 and 4 were tested on a Western blot of non-transfected and 
transfected HEK293 cells (transfected with ASPP1-GFP).  Results are presented in 
Figure 52. 
 
Figure 52. Western blots of pre-absorption assays to test the specificity of the α-ASPP1 antiserum, 
acidic fractions 3 and 4.  Total protein from HEK293 cells transfected with ASPP1-GFP (lane 1) and non-
transfected cells (lane 2) were prepared, resolved on 7% SDS-PAGE and analysed by Western blotting.  
Blots were probed with α-ASPP1 antiserum (no pre-absorption), the α-ASPP1 antiserum pre-incubated 
with the ASPP1(357-532)-His fusion coated resin (pre-absorption), and the α-ASPP1 antiserum pre-
incubated with an RBM-histidine fusion coated resin (mock pre-absorption).  Antibody binding was 
detected using a HRP-conjugated α-sheep secondary antibody. 
Upon pre-absorption with the ASPP1(357-532)-His coated resin, no bands were 
observable for acid fraction 4 and a substantial decrease in band intensity was observed 
with acid fraction 3 (Figure 52).  Therefore, this implies that the bands detected in non-
transfected and transfected HEK293 cells are specific to the ASPP1 protein.  
Mock pre-absorption with the ProCatch His resin coated in RBM-His peptide had no 
effect on the detection of ASPP1 using acid fraction 3.  This further confirmed that the 
loss of signal in the pre-absorbed assay was due to the specific sequestration of the 
antibody by the epitope and not non-specific binding to the ProCatch His resin.  Band 
intensity however was decreased when acid fraction 4 was mock pre-absorbed which may 
be due to poor protein transfer in this region of the gel during Western blotting.  A 
stronger signal was observed when using α-ASPP1 acid fraction 3 therefore this antibody 
was used in subsequent experiments. 
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5.8 Analysing ASPP1 stability in Siah1a-/-2-/- cells 
Since we purified the α-ASPP1 polyclonal antibody which detected both ASPP1 and 
ASPP1-GFP on Western blot, we utilised this to examine endogenous ASPP1 protein 
levels in Siah1a-/-Siah2-/- mouse embryonic fibroblasts (MEFs).  These cells were 
introduced in the previous chapter and were used to analyse the stability of NELF-A 
protein (see chapter 4, section 4.11).  By comparing ASPP1 protein levels in wild-type 
and Siah null cells we hoped to determine whether or not Siah proteins were primarily 
responsible for targeting ASPP1 for proteasomal degradation in vivo.  
Confluent T75 flasks of wild-type and double mutant MEFs were harvested and lysed in 
2x sample loading buffer.  Total cell lysates were subject to SDS-PAGE and were 
analysed by Western blot (Figure 53) probing with the α-ASPP1 antibody. 
 
Figure 53. ASPP1 protein levels in Siah deficient MEFs.  Cell lysates from wild-type and Siah1a-/-2-/- 
mutant MEFs were prepared, and the level of ASPP1 was measured by immunoblotting with α-ASPP1 
antibody and HRP-conjugated α-sheep secondary antibody.  The migration of molecular weight markers is 
indicated on the left of the Western.  The graph shows the relative amount of ASPP1 protein in wild-type 
and mutant MEFs compared to the α-tubulin loading control.  Data is presented as the mean ± SE and is 
representative of 3 separate cell harvests. 
When comparing ASPP1 protein abundance in wild-type and Siah1a-/-2-/- MEFs by 
Western blot, steady state levels appeared similar.  To gain a more quantitative result, 
four separate cell harvests were subjected to Western blot analysis (a representative 
Western shown in Figure 53) and protein levels were quantified using ImageQuant 
(Version 5.2).  These results, presented in the graph in Figure 53, show that there is a 
trend towards increased ASPP1 stability in Siah1a-/-2-/- null cells.  However further 
Chapter 5          Further investigation into the interaction between SIAH1 and the tumour suppressor 
proteins ASPP1 and ASPP2 
 
137 
 
analysis is required in order to determine whether or not this result is of statistical 
significance. 
5.9 Summary and discussion 
In order to determine whether or not SIAH1 could regulate both ASPP1 and ASPP2 
protein stability, levels of GFP-tagged ASPP1 and ASPP2 were analysed in the presence 
and absence of SIAH1.  We found that ASPP1- and ASPP2-GFP tagged proteins were 
reproducibly destabilised by co-expression of human SIAH1, and protein destabilisation 
was MG132-sensitive, indicating this resulted from SIAH1-mediated targeting to the 
proteasome.  Analysis of the ASPP2 protein sequence revealed that it contained the 
precise SIAH binding motif which is found in a number of known SIAH-interacting 
proteins (House et al., 2003), and we mapped the SIAH1:ASPP2 interaction to the N-
terminal half of ASPP2 which contains this motif.  These findings support the study 
published by Zhu et al., (2005) who report that proteasomal degradation modulates 
ASPP2 protein levels and apoptotic function.  The ASPP1 protein was not mentioned in 
this study and prior to our studies the regulatory mechanism controlling ASPP1 stability, 
and the E3 ligases responsible for targeting ASPP2 for proteasomal degradation, were 
unknown.   
Further characterisation of the SIAH1:ASPP1 interaction via yeast 2-hybrid mapping 
revealed that there were two regions of ASPP1 capable of interacting with SIAH1.  
Sequence comparison between full length ASPP1 and ASPP2 proteins indicated that the 
binding site identified in ASPP2 overlaps with one of the ASPP1:SIAH1 interacting 
fragments (amino acids 525-620) containing a conserved version of this motif.   No 
obvious SIAH1 binding motif was found in the second ASPP1:SIAH1 interacting 
fragment (amino acids 208-355), suggesting that there is an unknown secondary SIAH 
binding motif present in ASPP1.  Although the interaction between SIAH1 and the 
ASPP1 interacting fragments were confirmed via GST-pull down by BSc students 
Anthony J. Cutts and Robin Humphrey (Human Genetics, Newcastle University), it is 
unknown as to whether SIAH1 could simultaneously interact with both of these regions 
of ASPP1 in vivo. 
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Both ASPP1 and ASPP2 proteins have a similar modular structure.  They both contain an 
ubiquitin-like (ULD) domain and glutamine-rich (Gln) domain at their N-terminus and 
proline-rich, ankyrin-repeat and SH3 domains at their C-terminus (see Figure 48).  The 
C-terminal region is highly conserved amongst all of the ASPP family members (ASPP1, 
ASPP2 and iASPP) and interactions with all known ASPP1 and ASPP2 interacting 
proteins (including p53 and Bcl2) are mediated through the ankyrin repeats and SH3 
domains (Naumovski et al., 1996; Trigiante et al., 2006).  The N-terminal domain is only 
conserved between ASPP1 and ASPP2 and not much is known about what this region of 
the protein does except that it is required for pro-apoptotic function (Samuels-Lev et al., 
2001).  Tidow and colleagues (2007), who solved the structure of the ASPP2 N-terminal 
domain by NMR, suggest that the N-terminus is responsible for binding to other proteins 
in the apoptotic network.  Interestingly, unlike all of the known ASPP1 and ASPP2 
interactors, we found that SIAH1 binds to the proline-rich domain of ASPP1 and the N-
terminal regions of the ASPP1 and ASPP2 proteins.  Thus SIAH proteins may be able to 
interact with ASPP1 and ASPP2 whilst they are in a complex with other proteins 
resulting in their polyubiquitination and proteasomal degradation.   
While it has been established that the ASPP2 protein is ubiquitinated, as would be 
expected for a proteasomal substrate, this remains to be determined for ASPP1.  Zhu and 
colleagues (2005) show that it is the central region of ASPP2 which is ubiquitinated and 
this region is rich in lysine residues that could serve as ubiquitin conjugation sites.  
Consistent with their findings, the SIAH binding motif we identified in ASPP2 also 
locates to the central region (amino acids 445-468). 
In order to gain a better idea of how SIAH proteins regulate ASPP stability in vivo, 
ASPP1 protein levels were analysed in the wild-type and the Siah1a-/-2-/- null MEFs using 
the ASPP1 polyclonal antibody which we purified.  Western blot analysis revealed that 
there was slightly more ASPP1 protein in the Siah1a-/-2-/- null cells compared to the wild-
type controls.  These observations suggest that Siah1a and/or Siah2 are directly involved 
in regulating ASPP1 stability however more repeats of this experiment are required to 
determine whether or not this will achieve statistical significance.    
It is of interest to note that the ASPP1:SIAH1 interaction was originally identified in the 
SIAH1 testes yeast 2-hybrid screen and analysis of ASPP1 localisation in mouse testes 
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section by Dr Jared Thornton found that it was expressed in round spermatids and 
spermatocytes (Thornton et al., 2006).  Given that spermatocytes were found to apoptose 
after meiotic arrest in the Siah1a-/- mutant mouse (Dickins et al., 2002) it is possible that 
in the absence of Siah1a in testes, ASPP1 protein accumulates and promotes apoptosis.     
As a result of our experiments, our data suggests that ASPP1, like ASPP2, is also 
regulated by the proteasome and that the E3 ligase SIAH1 may be candidate in 
controlling this process.  However the signals which promote these interactions and 
subsequent degradation remain to be determined.   
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6.1 Introduction 
As discussed in the introduction to the previous chapter, ASPP1 and ASPP2 have been 
reported to bind to and modulate the behaviour of p53 and its family members, p63 and 
p73 (Bergamaschi et al., 2004; Robinson et al., 2008).  In addition to p53, several other 
ASPP interacting proteins have been identified, many of which are involved in 
modulating apoptosis and cell growth (summarised in Table 12).  The majority of these 
interacting proteins were identified as ASPP2 or 53BP2 (a splicing variant of ASPP2) 
interacting partners and often determination of a potential interaction with ASPP1 was 
not studied.    
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Putative 
Interactor 
Interaction identified 
with 
ASPP1/ASPP2/53PB2 
Putative function or pathway interaction References 
E2F1, 
E2F2, 
E2F3 
ASPP1 and  ASPP2 
promoters 
E2F1, E2F2 and E2F3 are transcription factors 
which bind to the ASPP1 and ASPP2 
promoters and up regulate their expression 
(Chen et al., 
2004; Fogal et 
al., 2005; 
Hershko et al., 
2005) 
PP1γ1    53BP2 53BP2 inhibits PP1 phosphatase activity (Helps et al., 
1995) 
p53, p63, 
p73 
53BP2, ASPP1, ASPP2 ASPP1 and ASPP2 stimulate p53, p63 and 
p73 transcriptional activity and apoptotic 
function 
(Iwabuchi et al., 
1994; Samuels-
Lev et al., 2001; 
Bergamaschi et 
al., 2004) 
14-3-3’s ASPP2/53BP2 ASPP2/53BP2 associate with 14-3-3 proteins 
during interphase, however the  functional 
outcome of this association is unknown 
(Meek et al., 
2004) 
APCL 53BP2 APCL appears to regulate cytoplasmic 
location of 53BP2 
(Nakagawa et 
al., 2000) 
APP-BP1 ASPP2 ASPP2 is a negative regulator of the 
neddylation pathway through specific 
interaction with APP-BP1 
(Chen et al., 
2003) 
Bcl-2 53BP2 Hinders cell cycle progression/induces 
apoptosis through the mitochondrial cell death 
pathway   
(Naumovski et 
al., 1996; 
Takahashi et al., 
2005) 
DDA3 ASPP2 ASPP2/DDA3 interaction appears to inhibit 
ASPP2 stimulation of p53  apoptotic 
signalling  
(Sun et al., 
2008b) 
Ddx42p ASPP2 This DEAD box protein inhibits ASPP2 
apoptotic induction 
(Uhlmann-
Schiffler et al., 
2009) 
HCV core 
protein 
53BP2/ASPP2 Hepatitis C virus core protein inhibits p53-
mediated apoptosis by blocking the interaction 
between p53 and ASPP2 
(Cao et al., 
2004) 
IRS1 53BP2 53BP2 interacts with and modulates the 
insulin signals mediated by insulin receptor 
substrate-1 
(Hakuno et al., 
2007) 
p65, a 
subunit of 
NFκB 
53BP2 53BP2 may act as a NFκB inhibitor and 
control NFκBs role in apoptosis 
(Yang et al., 
1999; 
Benyamini et 
al., 2009) 
YAP1 53BP2 Functional association  between 53BP2 and 
Yes-associated protein is undefined 
(Espanel et al., 
2001) 
dCsk Drosophila ASPP 
(dASPP) 
dASPP binds to and positively regulates dCsk 
(C-terminal Src kinase) 
(Langton et al., 
2007) 
SAM68 ASPP1 The ASPP1:SAM68 interaction appears to be 
restricted to human germ cells, may be 
involved in regulation of alternative splicing 
(Thornton et al., 
2006) 
Table 12. Published ASPP1, ASPP2 and/or 53BP2 interacting proteins.  53BP2 is a short form splicing 
variant of ASPP2.  
Our experimental results reported in chapter 5 imply that ASPP1 and ASPP2 are 
regulated at the post-transcriptional level by the E3 ubiquitin ligase SIAH1, and we 
speculate that targeted degradation of ASPP proteins represents an important mechanism 
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in regulating activation of the apoptotic programme.  However, despite the identification 
of a number of ASPP interacting protein partners which are apoptotic regulators the exact 
mechanism by which ASPP1 and ASPP2 stimulate apoptosis remain elusive. 
One conundrum surrounding ASPP protein function is that ASPP1 and ASPP2 appear to 
locate to the cytoplasm in cell lines and mouse tissue (Samuels-Lev et al., 2001; Thornton 
2005; Thornton et al., 2006) whereas p53 and its target genes are located in the nucleus.  
In order to bind to p53 and its family members and stimulate their ability to activate 
expression of pro-apoptotic genes then presumably ASPP1 and ASPP2 need to 
translocate to the nucleus.   
In an attempt to better understand ASPP1 function, and to identify pathways which 
modulate ASPP1 function in the cytoplasm and possible translocation to the nucleus, we 
set out to identify its major protein binding partners.  Firstly positive hits from an ASPP1 
yeast 2-hybrid screen carried out by Dr Jared Thornton (Thornton 2005) were analysed in 
order establish the identity of potential interactors.  Dr Jared Thornton screened a human 
testis cDNA library as ASPP1 was found to be highly expressed in testis tissue and 
surprisingly, in contrast to cell culture and mouse tissues, ASPP1 was nuclear in human 
germ cells  (Thornton et al., 2006).    
As well as elucidating the ASPP1 binding partners from the testes yeast 2-hybrid screen 
we also performed immunoprecipitation experiments in order to get a better 
understanding of ASPP1 function in vivo.   Both endogenous and ectopically expressed 
FLAG-tagged ASPP1 proteins were immunoprecipitated and co-immunoprecipitating 
proteins were analysed by mass spectronomy.  Further co-immunoprecipitation 
experiments were carried out in order to verify the main interactors.  By taking together 
the yeast 2-hybrid results and the proteomics results, we hoped to gain a better 
understanding of protein networks in which ASPP1 is involved.  
6.2 Analysis of ASPP1 yeast 2-hybrid hits 
To determine the identity of the positive hits from Dr Jared Thornton’s yeast 2-hybid 
screen, prey plasmids were isolated from positive yeast colonies by MSc student Febin 
Roy (Human Genetics, Newcastle University), and sequenced from the 5 ́′ end using the 
pACT25 primer.  BLAST searches were carried out with the sequence data to determine 
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which proteins were encoded by the positive hits. Thirty informative sequences were 
obtained.  Results are summarised in Figure 54. 
 
Figure 54. Positive ‘hits’ from the ASPP1 yeast 2-hybrid screen.  Table shows results from BLAST 
database searches with sequences obtained from positive hits. The number of representative hits for each 
protein is shown and summarised in the pie chart.  
By analysing the clone sequences from the multiple hits, two independent cDNA 
constructs were identified out of the four clusterin (CLU) clones and, out of all the other 
multiple hits, only COPB1 and COL1A2 were found to derive from two independent 
cDNAs.  Double-hit results obtained for Clusterin, COPB1 and COL1A2 gave us more 
confidence that these proteins were genuine biological interactors however this may also 
be due to high levels of expression of these proteins in the testes and hence an abundance 
of these clones in the cDNA library.  A brief summary of these principal interactors 
follows: 
Clusterin (CLU) 
Clusterin is a ubiquitously expressed glycoprotein with an apparent involvement in a 
variety of biological processes including DNA repair, cell cycle regulation, and more 
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interesting with regard to the ASPP1 interaction, apoptotic cell death.  There are two 
known isoforms of clusterin; a nuclear isoform (nCLU) which appears to be pro-
apoptotic (Yang et al., 2000; Leskov et al., 2003) and a secretory isoform (sCLU) which 
is, in contrast, pro-survival (Shannan et al., 2007).   sCLU is the major secreted product 
of Sertoli cells (Clark et al., 1997) in the testes and it has been shown to have a protective 
effect against apoptosis in the murine testes after heat exposure (Bailey et al., 2002).  
Despite extensive research on clusterin in the testes and other organs, how exactly the 
secretory and nuclear isoforms exert their protective/pro-apoptotic affects remains 
unknown.  
Coatomer protein complex, subunit beta 1 (COPB1) 
COPB1 is a subunit of the coatomer protein complex which associates with the Golgi 
apparatus and is involved in intracellular protein transport (Lee et al., 2004).  It also 
appears to maintain the physical integrity of Golgi, as it lines the surface of Golgi 
membranes creating a protein ‘scaffold’ (Gaynor et al., 1998).  Interestingly, breakdown 
of the Golgi apparatus is an early event during apoptosis (Mukherjee et al., 2007). 
Collagen alpha-2(I) chain (COL1A2) 
Collagen alpha-2(I) chain is one of the chains which constitutes type I fibrillar collagen.  
Collagens are secreted by connective tissue cells, forming a major part of the 
extracellular matrix, and type I collagen is the commonest form of collagen in the human 
body.  Col1a2 expression in germ cells of immature and adult mouse testis is believed to 
play a potential role in mediating the detachment and migration of germ cells during 
spermatogenesis (He et al., 2005). 
6.2.1 Testing the protein interaction between ASPP1 and Clusterin in mouse testes 
Having established that an interaction between clusterin and ASPP1 occurs in yeast in 
vitro, and due to clusterin having identifiable characteristics which overlap with ASPP1 
function, we chose to further investigate this interaction.  Firstly, we wanted to ascertain 
whether or not this interaction actually takes place in vivo.  To do this we utilised the α-
ASPP1 antibody previously generated (see previous chapter, section 5.7) to 
immunoprecipitate ASPP1 from testes tissue.  Although the ASPP1:CLU interaction was 
identified using a human testes cDNA library, we used mouse testes tissue due to human 
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testes tissue being in short supply and also since ASPP1 has been found to be highly 
expressed in mouse testes (Thornton et al., 2006).   
Cell lysate was prepared from two murine testes and endogenous ASPP1 protein was 
immunoprecipitated using α-ASPP1 antibody and protein A Dynabeads (see methods, 
section 2.3.10).  As the α-ASPP1 antibody was raised in sheep, control 
immunoprecipitations were carried out using total IgG which I prepared from crude sera 
from the pre-immune ASPP1 sheep (see methods, section 2.3.9).  Mouse testes soluble 
lysate (input), ASPP1- and sheep IgG- immunoprecipitates and IP supernatants were 
analysed by SDS-PAGE and Western blot (Figure 55).   
To ensure that the IP was successful, and that the ASPP1 antibody was 
immunoprecipitating a protein of the correct size, the Western blot presented in Figure 55 
was probed with the α-ASPP1 antibody.  The presence of a strong ASPP1 band running 
at the 175kDa marker in the ASPP1 IP lane and its absence from the negative control 
Sheep IgG IP showed that the ASPP1 protein had immunoprecipitated efficiently.  A 
number of distinct smaller bands were seen, particularly in the input and IP supernatant 
lanes (*).  These are often observed when using this particular antibody for Western blot 
(see previous chapter, Figures 51 and 52) and are likely to be either ASPP1 degradation 
products or are representative of proteins made from alternatively spliced ASPP1 
transcripts.  It is possible that the antibody may also cross-react with a non-specific 
protein, however results from the pre-absorption assay described in Chapter 5 (section 
5.7.3), suggest that the bands detected are specific to ASPP1 protein.  The full length 
ASPP1 protein runs at the 175kDa marker.  The strong ~62kDa bands present in the IP 
lanes are likely to be IgG heavy chain.   
Chapter 6                                                                                                       The ASPP1 interacting proteome 
147 
 
 
Figure 55. Testing co-immunoprecipitation of ASPP1 and CLU in mouse testes tissue.  Soluble mouse 
testes tissue lysates were incubated with either α-ASPP1 antibody or sheep IgG and Protein A Dynabeads.  
After washing, samples were eluted by boiling in sample loading buffer. Mouse testes soluble cell lysates 
(Input), immunoprecipitates (IP) and IP supernatants were separated on 7% SDS PAGE and probed with α-
ASPP1 and α-CLU antisera.  Antibody binding was detected using an HRP-conjugated α-sheep and HRP-
conjugated α-goat secondary antibodies, respectively. The migration of molecular weight markers is 
indicated on the left.  The asterisk highlight potential smaller ASPP1 isoforms or ASPP1 degradation 
products. 
To determine whether or not ASPP1 and CLU interact in mouse testes, the same samples 
were ran on a second polyacrylamide gel and analysed by Western blot using a α-CLU 
antibody (gift from Dr Arturo Sala, UCL, London, UK).  Clusterin is synthesised as a 449 
amino acid polypeptide with a molecular weight of 70kDa.  This 70kDa band is clearly 
observable in the input and IP supernatant lanes, and absent from the IP.  The lower 
molecular weight bands are likely to be the Clusterin α/β-subunits as the 449 amino acid 
precursor peptide is post-translationally cleaved to give α and β subunits which associate 
via disulphide bonds.  Therefore, in this IP experiment ASPP1 and clusterin do not 
appear to co-immunoprecipitate.  It is possible that the amount of ASPP1 protein 
immunoprecipitated was insufficient to detect association between the two proteins.  As 
we have no positive control for this experiment it remains feasible that ASPP1 and 
clusterin associate in murine testes.   
6.2.2 Testing protein interaction between ASPP1 and p53 in mouse testes  
Although p53 was not pulled out of the ASPP1 yeast 2-hybrid human testes screen, this 
does not necessarily mean that these proteins do not interact in vivo.  In order to interact, 
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ASPP1 and/or p53 may require modification which may only occur in mammalian cells, 
not yeast.  Also, the yeast 2-hybrid screen was not saturating.  We therefore wanted to 
determine whether or not ASPP1 and p53 interact in mouse testes.  To do this, Sheep-IgG 
and ASPP1 IPs were separated by SDS-PAGE and analysed by Western blot probing 
with an antibody specific to p53 (Figure 56). 
 
Figure 56. Co-immunoprecipitation of ASPP1 and p53 in mouse testes tissue.  Soluble mouse testes 
tissue lysates were incubated with either α-ASPP1 antibody or sheep IgG and Protein A Dynabeads.  After 
washing, samples were eluted by boiling in sample loading buffer, separated by SDS-PAGE and probed 
with α-ASPP1 and α-p53.  Antibody binding was detected using a HRP-conjugated α-sheep and HRP-
conjugated α-mouse secondary antibodies, respectively. The migration of molecular weight markers is 
indicated on the left.   
A clear p53 band, running just above the 47.5kDa marker, is present in the ASPP1 IP 
lane and absent from the control.  This result shows that ASPP1 and p53 associate in 
murine testes tissue however further investigation is required to determine whether or not 
these two proteins directly interact with one another.   
6.3 Identifying endogenous ASPP1 interacting proteins by mass spectrometry  
One limitation of the yeast 2-hybrid screen is that it identifies pairs of protein 
interactions, hence it does not reveal much about the nature of the complexes in which 
these proteins interact.  Thus in order to identify protein complexes in which ASPP1 is 
involved we carried out a large scale immunoprecipitation experiment, whereby 
endogenous ASPP1 protein was pulled down from cells and co-immunoprecipitating 
proteins were determined by mass spectrometry. 
Chapter 6                                                                                                       The ASPP1 interacting proteome 
149 
 
Given the tumour suppressor and oncogenic activities of ASPP1, identification of ASPP1 
interacting proteins and regulators may have therapeutic implications.  Therefore, rather 
than studying ASPP1 interacting proteins in mouse testes, we wanted to focus on ASPP1 
interacting proteins in human cells, as proteins and signalling pathways that govern 
ASPP1 function may vary between humans and mice. 
Due to the inherent problems in using human tissue we chose to use a human cell line, 
allowing us to bulk up cell number and isolate as much ASPP1 protein as possible.  We 
chose to use Saos2 cells, an osteosarcoma cell line, as we had previously found that 
ASPP1 was expressed at reasonable levels in these cells (data not shown). 
6.3.1 Saos2 ASPP1 immunoprecipitation 
Saos2 cell lysate was prepared from forty confluent T75 flasks.  Proteins were 
immunoprecipitated using protein A Dynabeads, the α-ASPP1 antibody and Sheep IgG 
control (see methods, section 2.3.10).  Saos2 soluble lysate (Input) ASPP1- and sheep 
IgG-IPs were first subjected to SDS-PAGE and Western blot analysis (Figure 57A).  By 
probing with the α-ASPP1 antibody it was evident that ASPP1 immunoprecipitated 
successfully from Saos2 cells. 
The remaining ASPP1 and Sheep IgG IP samples were then resolved on a 4-12% gradient 
gel and proteins were visualised with SimplyBlue SafeStain (Figure 57B).  It was clear 
from the stained gel that there were many more proteins present in the ASPP1 IP lane 
compared to the Sheep IgG control IP.  A faint band running at the 175kDa marker was 
predicted to be ASPP1 protein.   
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Figure 57. Immunoprecipitation of ASPP1 in Saos2 cells.  Forty confluent T75 flasks of Saos2 cells 
were harvested, cell lysates prepared and incubated with α-ASPP1/Sheep IgG and dynabeads.  After 
washing, samples were eluted by boiling in sample loading buffer.  (A) Saos2 soluble cell lysate (Input) 
and immunoprecipitates were separated on 7% SDS PAGE and probed with α-ASPP1.  (B)  Remaining IP 
samples were resolved by SDS-PAGE (NuPAGE 4-12% Bis-Tris Gel) and ASPP1 and Sheep IgG 
interacting proteins were visualised by staining with SimplyBlue.  Molecular weight size markers are 
shown on the left and in lane 1.  (C)  To determine protein identities the ASPP1 IP and control lanes were 
cut up in the fashion outlined. 
6.3.2 Mass spectrometry results 
To determine the identities of the ASPP1 interacting proteins, the two lanes (control 
Sheep IgG IP and ASPP1 IP) were divided into 8 slices as indicated in Figure 57C.  The 
8 slices were digested with trypsin, peptides were eluted and samples were analysed by 
liquid chromatography-mass spectronomy (LCMS).  The digest was carried out by Karen 
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Lowden, the MS analysis by David Blinco, and the data analysis by Dr Achim Treuman, 
all members of the North East Proteome Analysis Facility (NEPAF), Newcastle 
University.  
Proteins pulled down with the α-ASPP1 antibody are listed in Table 13.  Proteins that 
were detected only in the ASPP1 IP lane, not in the control lane, are shown. 
Table 13. ASPP1-interacting proteins identified by LCMS in Saos2 cells. Identifications of uncertain 
significance are highlighted*.  The BLAST search with CA198 did not indicate homology with any other 
human protein.   
Interestingly, ASPP1 was identified in slices 3, 4 and 6.  We would expect to pull full 
length ASPP1 protein out of slice 3 as this includes the 175kDa region.  It is possible that 
the ASPP1 protein identified in slices 4 and 6 represent the smaller molecular weight 
bands that are often picked up on Westerns which we suspect are alternate ASPP1 
isoforms or degradation products (see chapter 5, section 5.7.3).  A number of other 
proteins, including Sec16A and NTE (Neuropathy target esterase), were also identified in 
multiple slices in the ASPP1 IP lane.  Again it is possible that these may represent 
alternate isoforms of differing molecular weight, or these proteins may have degraded 
and we may be detecting smaller degradation products.   Indeed multiple splice forms of 
Gel slice Swiss-Prot entry 
name 
Accession number Gene name Protein ID Nominal 
mass Mr 
1 PYR1_HUMAN P27708 CAD CAD  242.8 
1, 2, 3, 8 SC16A_HUMAN O15027 SEC16A Sec16A 233.4 
1, 2, 3, 4 PLPL6_HUMAN Q8IY17 PNPLA6 NTE 149.9 
3 IQEC2_HUMAN Q5JU85 IQSEC1 ARF-GEP100 161.6 
3 CYFP1_HUMAN Q7L576 CYFIP1 CYPFIP1 145.1 
3, 4, 6 ASPP1_HUMAN  Q96KQ4 PPP1R13B ASPP1 119.5 
3 SC24C_HUMAN P53992 SEC24C Sec24C 118..2 
4 SC23A_HUMAN Q15436 SEC23A Sec23A 86.1 
4 GRP75_HUMAN P38646 HSPA9 Hsp70-9 73.6 
4 HS71L_HUMAN P34931 HSPA1L Hsp70-Hom 70.3 
6 RTN4_HUMAN* Q9NQC3 RTN4 RTN4 129.9 
6 TBA1A_HUMAN Q71U36 TUBA1A TUBA1A 50.1 
6 PP1A_HUMAN P62136 PPP1CA PP1cα  37.5 
6 CA198_HUMAN* Uncharacterised protein 36.3 
6 YBOX1_HUMAN P67809 YBX1 YBX1 35.9 
6, 7 SEC13_HUMAN P55735 SEC13 Sec13 35.5 
6 SYPL1_HUMAN* Q16563 SYPL1 SYPL1 28.5 
6, 7 ODO2_HUMAN P36957 DLST DLST 48.6 
7 SCAM3_HUMAN O14828 SCAMP3 SCAMP3 38.3 
7 SCAM1_HUMAN O15126 SCAMP1 SCAMP1 37.9 
7 KCD15_HUMAN Q96SI1 KCTD15 KCTD15 31.9 
7 HAX1_HUMAN O00165 HAX1 HAX-1 31.6 
7 DIPA_HUMAN Q15834 CCDC85B DIPA 22.1 
8 TCP4_HUMAN P53999 SUB1 PC4 14.4 
8, 4 DCD_HUMAN* P81605 DCD Dermcidin 11.3 
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Sec16 have been identified which are expressed together in the same tissues (Watson et 
al., 2006). 
In order to get an overall idea of the cellular processes in which ASPP1 is involved, the 
proteins identified by mass spectrometry were grouped according to their primary 
function and cellular locations upon preliminary assessment of the literature (summarised 
in Figure 58).   
 
Figure 58. Summary of cellular location (A) and function (B) of ASPP1-interacting proteins in Saos2 
cells.  Sec13, Sec23A and Sec24C are components of the COPII coat protein complex, which transports 
proteins within the cell.  They locate to the endoplasmic reticulum (ER) and associated vesicles in the 
cytoplasm.  Sec16A locates to discrete locations on the ER membrane known as ER exit sites and acts as a 
scaffold for assembly of the COPII coat.  It can however cycle on and off the ER membrane (Watson et al., 
2006; Iinuma et al., 2007).  Sec13 has also been observed to shuttle between the nucleus and the cytoplasm 
(Enninga et al., 2003).  Neuropathy target esterase (NTE) is an ER resident phospholipase which is 
important in regulating ER-cargo traffic (Li et al., 2003a).  ARF-GEP100 is a guanine nucleotide-exchange 
factor which locates to the cytosol and is involved in endosomal membrane trafficking (Someya et al., 
2001).  The Secretory carrier-associated membrane proteins, SCAMP1 and SCAMP3 and synaptophysin-
like protein 1 (SYPL1) locate to cytoplasmic transport vesicles.  They often co-localise and participate in 
post-Golgi trafficking (Haass et al., 1996; Windoffer et al., 1999).  TUBA1A, α-tubulin is a major 
constituent of microtubules.  Microtubules are found in both the cytoplasm, where they form part of the 
cytoskeleton, and the nucleus, where they constitute the mitotic spindle.  Cytoplasmic FMR1-interacting 
protein 1 (CYFIP1) is a cytosolic protein which regulates the actin cytoskeleton and appears to play a role 
in endosomal membrane trafficking from the Golgi (Anitei et al., 2010).  PP1cα (protein phosphatase 1 
catalytic subunit alpha) is a catalytic subunit of a major eukaryotic phosphatase enzyme.  It can be found in 
both the cytoplasm and nucleus.  It is highly mobile in cells and can relocalise via interactions with other 
proteins (Cohen 2002).  Heat shock 70 kDa protein 1-like (Hsp70-Hom) is predominantly cytoplasmic 
however, it appears to move to the nucleus in response to the stress of heat shock (Fourie et al., 2001).  
Heat shock 70 kDa protein 9 (Hsp70-9) resides in multiple subcellular sites including mitochondria, ER, 
plasma membrane, cytoplasmic vesicles and cytosol (Wadhwa et al., 2002a).  Dihydrolipoamide 
succinyltransferase (DLST) is a mitochondrial enzyme involved in the Krebs cycle (Nakano et al., 1994).   
The CAD enzyme localises to the cytoplasmic compartment and participates in pyrimidine biosynthesis 
(Chaparian et al., 1988).  HCLS1-associated protein X-1 (HAX-1) is mainly localised in mitochondria and 
to a lesser extent in ER and nuclear envelope (Suzuki et al., 1997). Reticulon-4 (RTN4) is an ER membrane 
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protein with unknown function (van de Velde et al., 1994).  DIPA is a nuclear protein which plays a role in 
regulation of gene expression and cell proliferation (Bezy et al., 2005; Du et al., 2006).  PC4 is a 
transcriptional regulator which locates to the nucleus (Conesa et al., 2010).  YBX1 is a multi-functional 
protein which localises in both the cytoplasm and nucleus. It translocates to the nuclear compartment 
following cytotoxic stress (Koike et al., 1997) where it can act as a transcription factor.   The function and 
subcellular localisation of the potassium channel tetramerisation domain containing 15 protein (KCTD15) 
is unknown.  CA198 is also an uncharacterised protein.    
This dataset clearly suggests that ASPP1 interacts with the protein transport machinery in 
the cell, implying ASPP1 plays a role in protein trafficking.  A number of transcriptional 
regulators, metabolic enzymes and heat shock proteins were also identified.   These 
proteins locate to both the cytosol and nucleus, and some reportedly shuttle between these 
cellular compartments.  
6.3.3 Testing protein interaction between ASPP1 and alpha tubulin in Saos2 cells 
One of the ASPP1-interacting proteins identified by mass spectrometry was α-tubulin 
(Gene name TUBA1A).  Tubulin is the primary building block of microtubules which 
function as structural and mobile elements in intracellular transport, mitosis, flagella 
movement and the cytoskeleton.  Tubulin is a heterodimer consisting of an alpha- and 
beta-tubulin subunit, both of which have a molecular weight of approximately 50kDa.   
In an attempt to confirm the ASPP1:α-tubulin interaction, the IP experiment was 
repeated, this time using 36 T75 flasks of confluent Saos2 cells.  However, upon 
repeating the experiment and probing the samples after Western blotting with an anti-α-
tubulin antibody, α-tubulin protein was not detected as co-immunoprecipitating with 
ASPP1 (Figure 59).   
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Figure 59. Testing co-immunoprecipitation of ASPP1 and α-tubulin in Saos2 cells.  Soluble Saos2 cell 
lysate was incubated with either α-ASPP1 antibody or sheep IgG and Protein A Dynabeads.  After washing, 
samples were eluted by boiling in sample loading buffer. Soluble Saos2 cell lysate (Input), and 
immunoprecipitates (IP) were separated on 7% SDS PAGE and probed with α-ASPP1 and α-tubulin.  
Antibody binding was detected using HRP-conjugated α-sheep and HRP-conjugated α-mouse secondary 
antibodies, respectively. The migration of molecular weight markers is indicated on the right.   
6.3.4 Analysing the ASPP1:Sec16A interaction 
A number of Sec proteins were pulled down specifically in the Saos2 ASPP1-IP.   The 
Sec genes were first identified in a genetic screen in Saccharomyces cerevisiae aimed at 
identifying mutants that are defective in protein secretion (Deshaies et al., 1987; Deshaies 
et al., 1989).  The Sec proteins identified by mass spectrometry in this screen interact 
with one another to form a large protein complex known as the COPII coat which is 
responsible for transporting proteins synthesised in the endoplasmic reticulum (ER) to the 
Golgi.  For further information on COPII assembly and function see the review by 
Hughes and Stephens (2008).  
Four Sec proteins, Sec13, Sec16A, Sec23A and Sec24C were identified in this screen 
suggesting that ASPP1 is somehow involved in this step of intracellular transport.  In 
order to further investigate this we acquired an antibody and GFP-fusion construct 
specific to, and encoding, one of these proteins, Sec16A.  Generation of this antibody and 
construct is described in Watson et al., (2006) and they were kindly given to us by Dr 
David Stephens (University of Bristol, UK).   
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Sec16A is a large (234kDa) protein which is bound to the cytosolic surface of the 
endoplasmic reticulum (ER) (Watson et al., 2006).  It has been shown to be tightly 
associated with ER exit sites (ERES), which are long-lived, ribosome free sub-domains 
of the ER that are specialised for the production of COPII transport vesicles (Watson et 
al., 2006). 
Firstly we wanted to determine whether or not ASPP1 and Sec16A co-localise in the cell.  
Presumably if these proteins directly interact with one another then full or partial co-
localisation should be observed.  Unfortunately, we were unable to detect either 
endogenous or over expressed Sec16A by Western using the α-Sec16A antibody 
suggesting it had deteriorated.  We therefore decided to utilise the Sec16A-GFP construct 
to analyse cellular location. 
6.3.3.1 Sec16A-GFP localisation 
To ensure the Sec16A-GFP construct expressed and localised as expected, Sec16A-GFP 
alone was transfected into HeLa cells and incubated for 24 hours before checking for 
GFP fluorescence. Following confirmation of GFP expression, the cells were fixed in 
methanol and fluorescence images were taken using the DAPI and FITC channels on a 
Zeiss Axiovert fluorescent microscope (Figure 60). 

Figure 60. Fluorescence images of typical distributions of Sec16A-GFP in HeLa cells.  24 hours after 
transfection cells were fixed with methanol. The individual DAPI and FITC channels and a merge of both 
channels are shown.  Nuclei are represented by blue DAPI stain. Scale bars represent 20µm. A) Transfected 
cells showing general cytoplasmic and perinuclear localisation of Sec16A-GFP. B) Transfected cell 
showing accumulation of perinuclear Sec16A-GFP with multiple small cytoplasmic concentrations. 
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In some cases we found Sec16A-GFP looked rather punctate (Figure 60B) while in others 
it seemed quite continuous around the nuclear envelope (Figure 60A).  This is consistent 
with previous reports on Sec16A localisation.  Watson et al., (2006) analysed localisation 
of both endogenous and GFP-tagged Sec16A.  They observed both a membrane bound 
(ERES) pool in the juxtanuclear area, and a cytosolic pool, and they suggested Sec16A 
recycles on and off the ER membrane.  Similarly, Iinuma et al., (2007) analysed Sec16A 
localisation using a Sec16A specific antibody and found in some cases it had a punctate 
pattern, with some concentration at the perinuclear region, and in other cases they found 
Sec16A exhibited diffuse cytosolic staining.   
6.3.3.2 Endogenous ASPP1, ASPP1-V5 and Sec16A-GFP localisation 
As our analysis of Sec16A-GFP localisation corresponded with previously published 
reports we utilised this construct to determine whether or not ASPP1 and Sec16A co-
localise in the cell.  Previous experiments analysing ASPP1 localisation using ectopically 
expressed V5-tagged ASPP1 and a α-V5 antibody worked well (data not shown).  
Therefore Sec16A-GFP was co-transfected into HeLa cells along with equal amounts of 
an ASPP1-V5 expression plasmid (gift from Professor Xin Lu, Ludwig Institute for 
Cancer Research, University of Oxford, UK).  24 hours after transfection cells were 
fixed, permeabilised and stained with the α-V5 antibody (Figure 61). 
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Figure 61. Localisation of ectopically expressed ASPP1-V5 and Sec16A-GFP in HeLa cells.  24 hours 
after transfection cells were fixed, permeabilised and stained with the α-V5 antibody.  ASPP1-V5 was 
visualised with an Alexa Flour 594 (red) conjugated α-mouse secondary antibody.  DNA was visualised 
with DAPI (blue) and Sec16A-GFP via FITC. (A) Transfected cells showing accumulation of perinuclear 
Sec16A-GFP with multiple small cytoplasmic concentrations. (B) Transfected cells showing general 
cytoplasmic localisation of Sec16A-GFP.  Scale bars represent 50µm. 
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ASPP1-V5 had a general cytoplasmic distribution, which is consistent with previous 
reports (Thornton 2005).  Again both punctate, cytoplasmic and perinuclear localisation 
of Sec16A-GFP was observed (Figure 61A and B).  Despite the primary cytoplasmic 
localisation of both proteins, the bulk of ASPP1 and Sec16A-GFP did not co-localise 
(Figure 61A).  In some cells however, partial overlap of proteins was observed (Figure 
61B).   
6.3.3.3 Sec16-GFP Immunoprecipitation 
Visualisation of ASPP1 and Sec16A-GFP by immunofluorescence suggested that in some 
cells there appeared to be partial co-localisation.  In order to test for protein-protein 
interactions we attempted to immunoprecipitate ectopically expressed Sec16A-GFP from 
HEK293 cells using the α-GFP antibody.   
In one experiment Sec16A-GFP was transfected alone in attempt to determine whether or 
not endogenous ASPP1 immunoprecipitates with Sec16A-GFP.  In a second experiment 
Sec16A-GFP was co-transfected with ASPP1-V5, to determine whether or not both 
proteins needed to be over-expressed in order to detect an interaction.  One six well plate 
of HEK293 cells was used for each immunoprecipitation.  24 hours after transfection, and 
upon confirmation of GFP fluorescence, cell lysates were prepared.  Half of the cell 
lysate from each transfection was incubated with the α-GFP antibody and the other half 
without any antibody as a negative control.  After an overnight incubation lysates +/- 
GFP antibody were incubated with Protein A Dynabeads and immunoprecipitated (see 
methods, section 2.3.10).   
To determine whether or not the Sec16A-GFP IP was successful, immunoprecipitates 
were first separated by SDS-PAGE and subject to Western blot analysis, probing with the 
α-GFP antibody (Figure 62).  Unfortunately, after repeated attempts, even though 
Sec16A-GFP was being expressed efficiently (see input lane in Figure 62) I was unable 
to immunoprecipitate any notable amount of Sec16A-GFP.  Blots shown in Figure 62 
were stripped and re-probed with ASPP1 antibody and V5 antibody in the hope that 
enough Sec16A-GFP had immunoprecipitated to detect ASPP1/ASPP1-V5 co-
immunoprecipitation.  However, neither endogenous nor ectopically expressed ASPP1 
were present in the IP lanes.  We did note that expression of Sec16-A GFP was reduced 
when co-expressed with ASPP1-V5. 
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Figure 62. Testing co-immunoprecipitation of Sec16A-GFP, endogenous ASPP1 and ectopically 
expressed ASPP1-V5 in HEK293 cells.  Soluble HEK293 cell lysate was incubated either with or without 
α-GFP antibody and Protein A Dynabeads.  After washing, samples were eluted by boiling in sample 
loading buffer. Total HEK293 cell lysate, soluble cell lysate (input), and immunoprecipitates (IP) were 
separated on 7% SDS PAGE and probed with α-GFP and HRP-conjugated α-mouse secondary antibody to 
visualise Sec16A-GFP.  Blots were then stripped and re-probed with either α-ASPP1 or α-V5, and α-sheep 
and HRP-conjugated α-mouse secondary antibodies, respectively. The migration of molecular weight 
markers is indicated on the left.   
6.4 Generation of an inducible ASPP1 HEK293 cell line 
In order to further follow up on the mass spectrometry results obtained for the 
endogenous ASPP1 Saos2 IP, rather than obtaining antibodies to each of the hits and 
repeating IP experiments, we wanted to analyse ASPP1 interactors in a second human 
cell line with the hope that we would identify common interacting proteins, giving us a 
better indication of the protein complexes in which ASPP1 is involved. 
One of the main problems encountered when trying to identify ASPP1 interacting 
proteins endogenously was the inherently low ASPP1 expression/protein level.  Despite 
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using large quantities of cells (which are time consuming and expensive to grow and 
maintain), the amount of ASPP1 protein immunoprecipitated was small.  As a result, we 
were unable to distinguish any specific ASPP1 interacting protein bands on the 
SimplyBlue stained gel and expensive high sensitivity analysis was necessary.  Also, due 
to low ASPP1 abundance we were less likely to identify low abundance interactors.   In 
order to isolate large amounts of ASPP1 protein and assay interacting proteins, we 
wanted to create a stable ASPP1-inducible cell line, whereby we could ‘switch on’ 
ASPP1 expression in order to produce large amounts of ASPP1 protein.   To do this we 
utilised the Flp-In HEK293 cell line (Invitrogen).    
This system permits the generation of stable, tetracycline-regulated, inducible cell lines 
by taking advantage of a Saccharomyces cerevisiae derived DNA recombination system.  
This DNA recombination system utilises a recombinase enzyme called Flp and a FRT 
site which serves as a binding and cleavage site for the Flp recombinase.  
To generate an inducible cell line, the gene of interest is cloned into a specialised Flp-In 
expression vector (pCDNA5) which is co-transfected with a plasmid encoding Flp 
recombinase (pOG44) into Flp-In HEK293 cells.  These cells are engineered to 
continually express the Tet repressor and they contain a stably integrated FRT site in their 
genome.  Co-expression of the Flp-In expression vector containing the gene of interest, 
and the Flp recombinase, results in targeted integration of the expression vector in the 
same locus in every cell.   
The Flp-In expression vector is designed so that the gene of interest is expressed under 
the control of a tetracycline inducible promoter.  Hence, addition of tetracycline to the 
culture medium ensures homogeneous and high level gene expression.   
Firstly, we needed to clone the ASPP1 cDNA sequence into the specialised inducible 
expression vector.  We utilised a modified version of this vector (pCDNA5-FLAG) 
which was kindly given to us by Dr Andrew Knox (Institute for Cell and Molecular 
Biosciences, Newcastle University, UK).  Dr Andrew Knox cloned a 2x FLAG Tag and a 
His-Tag between the KpnI and BamHI sites of pCDNA5 thus creating an in-frame N-
terminal FLAG-His-fusion protein.  Addition of the epitope tags bypasses the need for an 
efficient antibody specific to the expressed protein for purification and analysis purposes. 
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We know from previous experience that α-FLAG affinity resin (Sigma) 
immunoprecipitates FLAG fusion proteins very efficiently, therefore we wanted to utilise 
this in the hope that it would be a more efficient method to pull down large amounts of 
ASPP1 protein. 
6.4.1 Cloning ASPP1 into the pCDNA5-FLAG vector 
To construct ASPP1-FLAGpCDNA5, full length ASPP1 was amplified by PCR (from the 
ASPP1-V5 construct) using primers ASPP1-F(BglII) and ASPP1-R(XhoI).  Due to the 
size of the amplification product (3.4Kb) a high fidelity DNA polymerase (Phusion Taq) 
was used as well as a longer extension period (3.5 minutes).  The BglII/XhoI digested 
PCR product was then ligated into complementary sites in pCDNA5-FLAG before 
selection on ampicillin-LB plates.  Colonies were then screened by PCR using an ASPP1-
specific forward primer (ASPP1(1839)F) and a pCDNA5 specific reverse primer 
(BGHrev).  Insert positive colonies were further grown overnight before plasmid 
purification. To ensure that the pCDNA5-FLAG clone contained the correct full length 
ASPP1 sequence, it was sequenced from both the 5′ end 3′ ends using the ASPP1-
F(BglII) and BGHrev primers, respectively. 
6.4.2 Stable transfection of Flp-In HEK293 cells with ASPP1-FLAGpCDNA5 
The pCDNA5-FLAG vector containing the ASPP1 coding sequence was then co-
transfected with pOG44 into Flp-In HEK293 cells (see methods, section 2.5.5).  The Flp-
In HEK293 cells were kindly given to us by Dr Nicholas Watkins (ICaMB, Newcastle 
University, UK).  When co-transfected, the Flp recombinase is expressed from pOG44 
and catalyses a homologous recombination event between the FRT sites in the host cell 
line and the pCDNA5-FLAG expression vector, resulting in the integration of ASPP1-
FLAGpCDNA5 into the genome.  As a negative control, cells were co-transfected with 
the empty pCDNA5-FLAG vector and pOG44. 
Approximately forty eight hours after transfection, stably transfected cells were selected 
for by adding the selective antibiotic hygromycin B to the culture medium.  The 
pCDNA5-FLAG vector contains a hygromycin resistance gene, therefore integration of 
the expression construct confers hygromycin resistance to the cells. 
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Over the following weeks, dead cells were removed by washing, the medium was 
changed and hygromycin selection was maintained.  Cells were monitored for the 
development of clonal colonies daily and after approximately two weeks of selection, 
ASPP1-FLAGpCDNA5 and pCDNA5-FLAG colonies were selected and re-plated.   
Once hygromycin clones were selected and sufficiently established we were then ready to 
induce ASPP1-FLAG expression.    
6.4.3 Testing induction of ASPP1-FLAG 
Before commencing with the FLAG-IP we first wanted to ensure that the ASPP1-FLAG 
protein expressed efficiently and determine the time point at which to harvest cells for IP.  
Considering ASPP1 is a reported pro-apoptotic protein, we wanted to check whether 
continually elevated levels resulted in cell death.   
A 6 well plate of ASPP1 Flp-In HEK293 cells and pCDNA5 Flp-In control cells were 
grown to ~60% confluence.   To induce expression, tetracycline was added to each well 
(final concentration 1µg/ml).  Over the next 3 days cells were harvested every 12 hours.  
Harvested cells were lysed and subjected to SDS-PAGE and Western blot.  Blots were 
probed with the α-FLAG antibody and α-tubulin (Figure 63).  
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Figure 63. Induction of ASPP1-FLAG expression in Flp-In HEK293 cells.  (A) Cell lysates were 
prepared every 12 hours after addition of 1µg/ml of tetracycline, and the level of ASPP1-FLAG was 
measured by immunoblotting with α-FLAG antibody and α-tubulin for a loading control.  Both antibodies 
were detected using the HRP-conjugated α-mouse secondary antibody.  Two separate cell harvests (0 hour 
and 60 hours) of the negative control pCDNA5-only stable cells are also presented.  The migration of 
molecular weight markers is indicated on the left.  (B) The graph shows the relative amount of ASPP1-
FLAG protein compared to the α-tubulin loading control.   
The Western shows that the ASPP1-FLAG protein band migrated at a molecular weight 
consistent with the size of the ASPP1 protein (175kDa), and it was clear that ASPP1-
FLAG was efficiently expressed 12 hours after tetracycline addition.  Maximal ASPP1-
FLAG protein levels were observed at the 24 hour and 48 hour time points (see graph in 
Figure 63).  Also, after 60 hours cells looked healthy, implying that elevated ASPP1 
expression was not having a detrimental effect.  
6.4.4 Immunoprecipitation of ASPP1-FLAG 
Cell lysate was prepared from two confluent T75 flasks of both ASPP1-FLAGpCDNA5 
and control cells which had been induced with tetracycline for 48 hours.  FLAG-fusion 
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protein was immunoprecipitated using α-FLAG affinity resin (see methods, section 
2.3.11).   
The resulting samples from the FLAG immunoprecipitations were firstly analysed by 
Western to ensure the ASPP1-FLAG fusion protein was immunoprecipitating efficiently 
(Figure 64A).  A strong ASPP1-FLAG band was detected with α-FLAG antibody in the 
IP lane from the ASPP1-FLAGpCDNA5 cells.  ASPP1-FLAG was also present in the IP 
supernatant showing us that an ample amount of tagged ASPP1 protein was expressed.   
This band was absent from our control IP using the cells containing the empty pCDNA5-
FLAG construct, as expected.  Remaining IP samples were resolved on a 4-12% gradient 
gel and protein was visualised with SimplyBlue SafeStain (Figure 64B). 
 
Figure 64. Immunoprecipitation of ASPP1-FLAG fusion protein.  (A)  After 48 hours, induced cell 
lysates were prepared and incubated with α-FLAG affinity resin.  After washing, samples were boiled, 
electrophoresed on a 7% SDS-polyacrylamide gel and analysed by immunoblotting with α-FLAG antibody.  
(B)  FLAG immunoprecipitation samples resolved on a NuPAGE 4-12% Bis-Tris protein gel and stained 
with SimplyBlue.  Numbered protein bands (1-7) were excised from the gel and subjected to analysis by 
mass spectrometry.  The migration of molecular weight markers is indicated on the right. 
The immunoprecipitating ASPP1-FLAG fusion protein was clearly observable on the 
stained gel (band 2).  In comparison to our endogenous ASPP1 IP in Saos2 cells (see 
Figure 57), this IP was much more efficient.      
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6.4.5 Analysis of ASPP1-FLAG interactors by mass spectrometry  
Protein bands specific to the ASPP1-FLAG IP were predicted to result from proteins that 
specifically co-immunoprecipitated with the ASPP1-FLAG fusion protein. Protein bands 
1-7 were chosen as they were the strongest in intensity compared to the FLAG only 
control IP lane (Figure 64B).   We also included the suspected ASPP1-FLAG band (Band 
2).   To determine the identity of these proteins, the seven bands were excised from the 
gel and digested with trypsin using the Trypsin profile IGD Kit (see methods 2.3.12).  
Samples were then subjected to mass spectrometry analysis by Dr Kaveh Emami at the 
North East Proteome Analysis Facility, Newcastle upon Tyne. 
Of the seven bands sent for peptide mass fingerprinting, six were positively identified 
(Figure 65).  The significance threshold was set at p<0.05. 
 
Figure 65. Proteomic analysis of ASPP1-FLAG interacting proteins.  The identities of ASPP1-FLAG 
interacting proteins are listed in the table. Swiss-Prot names and primary accession numbers for proteins 
are shown.  The distribution of identified peptides (highlighted red) matching the protein sequence for each 
band is shown. 
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There were no proteins identified in band 1.  As expected, band 2 was correctly identified 
as ASPP1, however, ASPP1 was also identified in band 3.  Again, it is possible that this 
may be an alternate ASPP1 isoform or a product of proteolytic degradation.  
Alternatively this may be the result of cross-contamination when cutting bands 2 and 3. 
There were three different heat shock proteins positively identified from bands 3, 4 and 5, 
Hsp74, Hsc70 and Hsp72.  Protein band 6 was identified as Y box binding protein 1 
(YBX1), which was also pulled out in the endogenous ASPP1 IP in Saos2 cells, and band 
7 was identified as Protein phosphatase 1 beta (PP1cβ).  
By SimplyBlue staining, the levels of co-precipitated Hsc70, Hsp72 and PP1cβ were 
approximately half the level of immunoprecipitated ASPP1-FLAG, and there was 
considerably less Hsp74 and YBX1 present. 
A brief description of each of the ASPP1-FLAG interactors identified in this experiment 
follows.  The cellular function of each of these proteins is discussed further in the 
discussion.   
Heat shock 70 kDa protein 4 (HSP74) 
Protein band 3, which ran between the 175 and 83 kDa markers, was positively identified 
as Heat shock 70 kDa protein 4 (HSP74).  This protein, encoded by the HSPA4 gene, was 
originally reported as a member of the heat shock protein 70 family (Fathallah et al., 
1993).  However, it was later found to belong to the Hsp110 family and is equivalent to 
the mouse apg-2 protein (Kaneko et al., 1997).  
Heat shock 70 kDa protein 8 (Hsc70) 
Band 4, running just below the 83 kDa marker, was identified as Hsc70.  Hsc70 is a 
74kDa protein encoded by the HSPA8 (heat shock 70kDa protein 8) gene. Two 
alternatively spliced variants have been characterised to date.  When analysing the 
sequence coverage of the peptides identified in this band, one of the peptides was specific 
to isoform 1, the larger of the two isoforms with an extra 153 amino acids in the N-
terminal half of the protein.   We cannot rule out the possibility that isoform 2 is also 
present in this band, however it is likely that this smaller isoform would migrate faster.   
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Heat shock 70 kDa protein 1A/1B (Hsp72) 
Band 5, another strong band running closely with the Hsc70 band, was identified as heat 
shock 70kDa protein 1, another member of the heat shock protein 70 family, often known 
as Hsp72 or Hsp70.  It is a 70kDa protein which is encoded by the HSPA1A gene.  
Y box binding protein 1 (YBX1) 
Band 6, migrating below the 62kDa marker, was identified as Y-box binding protein 1 
(YBX1).  YBX1, encoded by the NSEP1 gene, is member of the cold shock family of 
proteins that contain a highly conserved nucleic acid binding motif.  It is a 47kDa protein 
which can bind to double-stranded and single-stranded DNA and RNA.  It is involved in 
a variety of cellular functions including regulation of transcription, DNA repair and stress 
responses to extracellular signals.  The multiple functions of YBX1 are reviewed by 
Kohno et al., (2003).  YBX1, like ASPP1, has also been shown to interact with p53 and 
regulate its activity (Okamoto et al., 2000).   
Protein phosphatase (PP1)-beta catalytic subunit (PP1cβ) 
Band 7, a strong band, corresponded to PP1cβ.  This protein, encoded by the PPP1CB 
gene, is one of the three catalytic subunits of the serine/threonine- protein phosphatase 1.  
PP1 is known to be involved in the regulation of a variety of cellular processes (see 
summary and discussion for further information). 
6.4.6 Testing protein interaction between ASPP1 and Hsp72 
To confirm the novel protein-protein interaction detected between ASPP1 and Hsp72, the 
ASPP1-FLAG IP experiment was repeated.  Again, ASPP1 Flp-In HEK293 cells and 
control cells were induced for 48 hours, cell lysates prepared and incubated with FLAG-
affinity resin.  Immunoprecipitates were subjected to immunoblot analysis.  Probing with 
α-FLAG revealed that ASPP1-FLAG immunoprecipitated efficiently as expected. The 
Western was then stripped and re-probed with an α-Hsp72 antibody (Figure 66) which 
was kindly given to us by Professor Anne Dickinson (Haematological Sciences, Institute 
of Cellular Medicine, Newcastle upon Tyne).     
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Figure 66. Co-immunoprecipitation of ASPP1-FLAG and Hsp72 in Flp-In HEK293 cells.  48 hours 
after tetracycline induction, cell lysates were prepared and incubated with α-FLAG affinity resin.  After 
washing, samples were boiled, electrophoresed on a 7% SDS-polyacrylamide gel, and subjected to Western 
blotting. The blot was first probed with α-FLAG antibody to ensure the IP was successful.  The blot was 
then stripped and re-probed with α-Hsp72.  In both cases, antibody binding was detected using a HRP-
conjugated α-mouse secondary antibody. The migration of molecular weight markers is indicated on the 
left. 
A Hsp72 band was clearly present in the ASPP1-FLAG IP and absent from the control 
thus confirming that ASPP1-FLAG and Hsp72 co-immunoprecipitate.  Comparing the 
Hsp72 band in the IP and IP supernatant lanes (IP SUP) shows that only a small 
proportion of the Hsp72 protein present in the cell was pulled down in the ASPP1-FLAG 
complex.   
6.4.7 Testing protein interaction between ASPP1 and YBX1 
Considering YBX1 was identified in both the Saos2 and Flp-In HEK293 screens, and 
given it is a p53 interacting protein with a role in apoptosis, we were keen to follow up on 
this interaction.  We therefore acquired a YBX1-specific antibody, a kind gift from 
Professor Anthony Braithwaite (Children's Medical Research Unit, University of Sydney, 
Australia).  Generation of this antibody is described in Cohen et al., (2009).  In order to 
confirm the interaction detected between ASPP1 and YBX1, the ASPP1-FLAG IP 
samples and the endogenous ASPP1 IP from Saos2 cells, presented in Figures 66 and 59 
respectively, were electrophoresed on a 10% polyacrylamide gel and analysed by 
Western blot using the α-YBX1 antibody (Figure 67).   
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Figure 67. Testing co-immunoprecipitation between ASPP1 and YBX1.  (A) FLAG-IP samples from 
the Flp-In293s and (B) endogenous ASPP1 IP from Saos2 cells were ran on a 10% SDS-polyacrylamide 
gel and probed with α-YBX1 and HRP-conjugated α-rabbit secondary.   
A band of the expected size (~47kDa) was clearly visible in the input and IP supernatant 
lanes in both the ASPP1-FLAG, and control immunoprecipitations (Figure 67A).  A faint 
band of approximately equal size is observable in both the ASPP1-FLAG IP and 
pCDNA5-FLAG IP lanes.  A similar result was observed with the Saos2 IP (Figure 67B).  
This suggests that YBX1 is interacting non-specifically with the FLAG epitope and the 
Sheep IgG antiserum.  However, only proteins which were present in the Saos2 ASPP1-
IP and absent from the Sheep IgG control were included in our dataset (Table 13) thus it 
is unlikely that this is YBX1.  It is possible that these bands are IgG heavy chain as this 
has a molecular weight of approximately 50kDa.  Thus, although we cannot conclude 
from these Westerns that ASPP1 and YBX1 interact nor can we exclude the possibility.    
6.5 Summary and discussion  
In attempt to identify the major binding partners of ASPP1 and better understand how 
ASPP1 functions in vivo we analysed positive hits from an ASPP1 yeast 2-hybrid screen 
and took a proteomic approach to elucidate proteins co-immunoprecipitating with both 
endogenous and ectopically expressed ASPP1.   
Twenty ASPP1 interacting proteins were identified from the human testes cDNA library 
yeast 2-hybrid screen.  Two of these proteins, the E3 ubiquitin ligase SIAH1 and the 
protein phosphatase PP1cγ were previously identified ASPP1 interactors.  The 
ASPP1:SIAH1 interaction was detected in both the SIAH1 and ASPP1 testes yeast 2-
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hybrid screens (carried out by Dr Julian Venables and Dr Jared Thornton, respectively), 
however SIAH1 was not found to co-immunoprecipitate with ASPP1 from Saos2 cells or 
Flp-In HEK93 cells.  It is tempting to speculate that the ASPP1:SIAH1 interaction may 
be specific to human testes, however the SIAH1:ASPP1 interaction in vivo is likely to be 
transient hence it is unlikely that we would pull SIAH1 down in complex with ASPP1. 
The remaining 18 proteins identified in the yeast 2-hybrid screen represented novel 
interactors.   A number of these proteins are highly expressed in the testes and appear to 
play an important role in spermatogenesis.  For example, clusterin is produced 
abundantly by the Sertoli cells which line the walls of the seminiferous tubules.   It is 
associated with both apoptosis and cell survival and is often proposed as a regulator of 
germ cell fate. 
We were unable to detect an interaction between clusterin and ASPP1 when ASPP1 
protein was immunoprecipitated from mouse testes tissue (Figure 55).  However, 
although ASPP1 is expressed in the same germ cell types in human and murine testes, in 
humans ASPP1 locates to the nucleus and in mice it is cytoplasmic (Thornton et al., 
2006).   Therefore it is possible that the ASPP1-CLU interaction occurs only in the 
human testes.  
Other proteins identified with a role in spermatogenesis included SPATS1 
(spermatogenesis associated serine rich-1 protein), a highly conserved testis-specific 
protein which appears to play an important role in meiosis (Capoano et al., 2010), and 
Protamine 2, which is one of the most abundant nuclear sperm proteins found in humans 
and mice.  Protamines replace histones during spermatogenesis and are essential for DNA 
condensation and stabilisation in the sperm head (Carrell et al., 2007).   
Thus, results from the yeast 2-hybrid screen imply that ASPP1 may play an important 
role in germ cell development in the testes.  This is consistent with ASPP1 being a 
SIAH1 regulated protein as the murine homolog, Siah1a, is essential for germ cell 
development. 
In order to further characterise ASPP1 function in vivo, and identify protein complexes in 
which ASPP1 was involved, proteins co-immunoprecipitating with endogenous ASPP1 
from Saos2 cells, and with ectopically expressed FLAG-tagged ASPP1 from the 
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inducible Flp-In HEK293 cells, were elucidated by mass spectrometry and as a result of 
these experiments a diverse set of interacting proteins were identified.   
One common hit from all 3 of the ASPP1 screens were the catalytic subunits of protein 
phosphatase 1 (PPI), a major eukaryotic serine/threonine specific phosphatase.  The 
ASPP-PP1 interaction was previously identified by Helps and colleagues (1995) who 
showed that 53BP2, the C-terminal 528 amino acids of ASPP2, can inhibit PP1 activity.  
ASPP1 and ASPP2 are approximately 49% homologous, with the highest regions of 
homology at their N- and C-terminal ends, thus it was not unexpected that ASPP1 would 
also interact with PP1. 
Four mammalian PP1 catalytic (PP1c) gene products have been identified, designated 
PP1cα, PP1cβ, PP1cγ1 and PP1Cγ2, the latter two arising from alternative splicing.   The 
catalytic subunits have ~90% amino acid sequence identity.  Through their interaction 
with various proteins, the PP1 subunits are believed to control an array of cellular 
functions, including gene transcription, translation, RNA splicing, metabolism, cell cycle 
progression, and apoptosis.  The multifunctional roles of PP1 are reviewed by Cohen 
(2002), Garcia et al., (2003) and Ceulemans and Bollen (2004).   
Intriguingly, three different PP1 catalytic subunits were pulled out of each of our ASPP1 
screens (Table 14).  PP1cγ was identified in the testes yeast 2-hybrid screen, PP1cα in the 
Saos2 screen, and PP1cβ in the Flp-In 293 screen.  The original ASPP-PP1 interaction 
published by Helps et al., (1995) was identified via yeast 2-hybrid using the catalytic 
subunit, PP1γ1, and they confirmed this interaction in vitro.  Owing to the high level of 
amino acid sequence conservation of the catalytic subunits, it is perhaps not surprising 
that we found ASPP1 interacts with each of them.  Also, PP1c isoforms possess distinct 
tissue distribution and subcellular locations (Shima et al., 1993; Andreassen et al., 1998) 
which may explain why we pulled out different isoforms in each of our screens.   
Gene 
Symbol 
Description Protein ID Identified ASPP1:PP1c 
interaction 
Table 14.  The PP1c genes and protein products.  The catalytic subunits identified in the ASPP1-protein 
PPP1CA Protein phosphatase 1, catalytic 
subunit, alpha isoform  
PP1cα  ASPP1 IP in Saos2 cells 
PPP1CB Protein phosphatase 1, catalytic 
subunit, beta isoform  
PP1cβ ASPP1-FLAG IP in Flp-In 
HEK293 cells 
PPP1CC Protein phosphatase 1, catalytic 
subunit, gamma isoform 
PP1cγ1/PP1cγ2 Human testes Y2H screen and  
Helps et al., 1995 
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interactor screens are shown.   
Interestingly, the PP1cγ2 isoform is predominantly expressed in the testes and we 
identified the gamma isoform in our testes yeast 2-hybrid screen (Vijayaraghavan et al., 
1996).  PP1cγ2 is a key enzyme in mammalian spermatozoa and a number of regulatory 
proteins that regulate PP1cγ2 in spermatozoa have been identified (Chakrabarti et al., 
2007).  Targeted disruption of the Ppp1cc gene, which encodes both the PP1cγ1 and 
PP1cγ2 isoforms results in male infertility in mice (Varmuza et al., 1999).  Chakrabarti et 
al., (2007) studied the localisation of the PP1 isoforms in murine testes and observed that 
PP1cγ2 was prominently expressed in the cytoplasm of secondary spermatocytes, round 
spermatids, and elongating spermatids, whereas expression was weak or absent in 
spermatogonia, and interstitial cells.  Similarly, analysis of ASPP1 localisation in mouse 
testes by Thornton et al., (2006) revealed that ASPP1 is present in the cytoplasm of round 
spermatids and is absent in the elongating spermatids and spermatogonia.   
Given that ASPP1 and PP1cγ2 are present at elevated levels in mouse testes, are 
expressed at similar stages of spermatogenesis and Helps et al., (1995) demonstrate that 
ASPP2 can affect PP1 activity, it is possible that ASPP1 may add to the list of  PP1cγ2 
regulatory proteins in the mouse testes.  As noted earlier, ASPP1 is found in the nuclei 
rather than the cytoplasm in human testes therefore it would be interesting to analyse 
PP1cγ expression in human testes too.  We can also propose that ASPP1 is a regulator of 
PP1cα in Saos2 cells and PP1cβ in HEK293 cells. 
It is also worth noting that Helps et al., (1995) found that ASPP2 appears to bind to PP1 
more strongly than to p53 and they also showed that PP1 and p53 cannot bind 
simultaneously, thus suggesting that ASPP2 is more likely to exist in a complex with PP1 
in the cell than with p53.  As a PP1 catalytic subunit was pulled out in the FLAG-ASPP1 
IP from Flp-In HEK293 cells and HEK293 screens, this may indicate why p53 was 
absent from this set of ASPP1 interactors.  Saos2 cells are a p53 null cell line therefore it 
was no surprise that p53 was not detected in the endogenous ASPP1-IP from Saos2 cells. 
As well as PP1c, a number of Sec proteins were pulled down in the endogenous ASPP1 
IP from Saos2 cells.  Sec proteins and a small GTPase (Sar1) collaborate to form the 
COPII complex which is the primary vesicle coat complex used to transport newly 
synthesised proteins from the ER to the Golgi apparatus.  Also, one of the double hits 
from the ASPP1 yeast 2-hybrid screen was COPB1 (coatomer protein complex, subunit 
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beta 1) which a subunit of the COPI complex which mediates Golgi-to-ER protein 
trafficking.  The protein components of the COP complexes are listed in Table 15 and the 
mechanism of COPII coat formation is summarised in Figure 68.  For in depth reviews on 
COPII coat formation and function see Lee and Miller (2007), Hughes and Stephens 
(2008), and Budnik and Stephens (2009). 
Vesicle Coat and Adaptor Proteins Small GTP-
Binding protein 
Transport step 
Table 15. Protein components of COPI and COPII vesicles.  The coats of COPI and COPII vesicles 
consist of large protein complexes composed of varying individual protein subunits.  Budding is initiated 
by recruitment of a small GTP-binding protein to a patch of membrane. Proteins identified as ASPP1 
interactors in our studies are highlighted. 
 
Figure 68. Schematic depiction of the COPII coat machinery mediating ER cargo export. COPII 
assembly on ER membranes initiates with the transmembrane protein Sec12.  Inactive GDP-bound Sar1 is 
attracted to the cytosolic side of the endoplasmic reticulum (ER) by Sec12.  Sec12 functions as a guanine 
nucleotide exchange factor (GEF) and mediates nucleotide exchange of GTP on Sar1.  The GTP-bound 
form of Sar1 then recruits the Sec23/Sec24 heterodimer, an adaptor complex that recognises sorting-
peptide motifs on membrane bound cargo proteins.  This in turn binds the Sec13/Sec31 complex which 
constitutes the coat framework of COPII coated vesicles.   The Sec23/24-Sec13/31-Sar1 complexes then 
coalesce to form a much larger complex which deforms the membrane enough to bud a vesicle off.  Sec16 
appears to plays a central role organising COPII formation functioning as a scaffold for assembly of the 
vesicle coat. Figure re-drawn with modification from Roy et al., (2006). 
Although four Sec proteins were identified by mass spectronomy it is unlikely that 
ASPP1 interacts specifically with all four of these proteins.  A relatively stable 
interaction with either one of these proteins may be sufficient to pull down all of these 
COPII components. 
COPI COP α, β, β1, γ, δ, ε, ζ ARF Golgi to ER 
COPII Sec23/Sec24 complex, Sec13/Sec31 complex, Sec16 Sar1 ER to Golgi 
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We were unable to detect an association between ASPP1 and Sec16A by IP and 
immunofluorescence studies showed they may partially co-localise.  This suggests that 
ASPP1 may be specifically interacting with other Sec proteins which are not bound to the 
ER membrane.  It is also possible that the ASPP1-Sec16A interaction is cell cycle 
specific or dependent on activation of a particular intracellular signalling pathway. 
As well as the Sec proteins, α–tubulin was also detected in the complex pulled down with 
the ASPP1 antibody. COPII coated packages which bud from the ER translocate via 
microtubules to the Golgi.  Thus microtubules function as ‘railroad tracks’.  The ASPP1-
COPII complexes pulled down in this IP are indeed likely to be in association with 
microtubules hence α-tubulin, a major constituent of microtubules, was also pulled down.  
Although we were unable to detect co-immunoprecipitation between ASPP1 and α-
tubulin upon repeat of the IP, judging by the Western blot less ASPP1 protein was pulled 
down in the repeated experiment (compare Figure 57A and Figure 59).  Therefore, in this 
instance there may be so little α-tubulin being pulled down in this complex that we are 
unable to detect it by Western.   
A number of other proteins were also identified which are likely to play an important role 
in protein trafficking.  For example, neuropathy target esterase (NTE), a phospholipaseB 
enzyme tethered to the cytoplasmic face of the ER, plays an important role in regulating 
vesicular transport (Li et al., 2003b; Zaccheo et al., 2004).   On a similar theme, a protein 
called Synaptojanin-2 was pulled out of the ASPP1 yeast 2-hybrid screen.  Synaptojanin 
2 is a regulatory lipid phosphatase enzyme which also appears to be involved in distinct 
vesicle trafficking and signal transduction pathways in mammalian cells (Malecz et al., 
2000).  Other identified proteins with a role in endosomal trafficking include ARF-
GEP100 (encoded by the IQSEC1 gene) (Someya et al., 2001; D'Souza-Schorey et al., 
2006), SCAMP1, SCAMP3 (Castle et al., 2005), CYFIP1 (Cytoplasmic FMRP-
Interacting Protein 1) and SYLP1 (Synaptophysin-like protein 1, often called 
Pantophysin) (Haass et al., 1996; Egea et al., 2006).   
Co-immunoprecipitation of ASPP1 and various proteins involved in ER-Golgi trafficking 
and post-Golgi trafficking suggests that ASPP1 plays a functional role in protein 
transport.  Alternatively, ASPP1 may simply be exported from the ER and transported to 
the Golgi for processing in COPII vesicles and then directed to another destination in the 
cell via the post-Golgi network.   
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A number of Heat shock proteins (HSPs) were pulled down in the Saos2 and Flp-In 
HEK293 immunoprecipitations (summarised in Table 16).  Heat shock proteins are a 
class of highly conserved, functionally related proteins many of which are expressed 
when cells are exposed to elevated temperatures or other stress so that they can protect 
protein substrates against conformational damage, aggregation and denaturation.   Many 
HSPs, however, are synthesised in the absence of stress and are involved in a variety of 
cellular functions such as folding of newly synthesised proteins, transport of proteins 
between cellular compartments, activity control of regulatory proteins, assembly and 
disassembly of protein complexes, and assistance of proteolytic degradation (Becker et 
al., 1994; Hartl 1996; Daugaard et al., 2007).  Also, HSPs often play key regulatory roles 
in apoptosis as the events of cell stress and cell death are not surprisingly linked and a 
number of HSPs have been reported to act as, or interact with, both anti-apoptotic and 
pro-apoptotic proteins.  For a review on HSPs and apoptosis see Garrido et al., (2001). 
Gene 
Symbol 
Description Protein ID Identified ASPP1:HSP 
interaction 
Table 16. Heat shock proteins identified in the ASPP1-protein interaction screens.   
Hsp72 was pulled down in the ASPP1-FLAG immunoprecipitation and we confirmed 
this interaction by Western (Figure 66).  Hsp72 is a ubiquitously expressed heat shock 
protein, but it is also known to be up regulated after exposure to a variety of cellular 
stresses (Wu et al., 1985; Hartl 1996).  Park et al., (2002) reported that Hsp72 can 
negatively regulate apoptosis by binding to and inhibiting the function of ASK1 
(apoptosis signal-regulating kinase 1), a widely expressed serine-threonine kinase that 
induces apoptosis.  Potentially Hsp72 may have a similar inhibitory effect on ASPP1’s 
pro-apoptotic function.  Also Hsp70-9, which was pulled down with ASPP1 from Saos2 
cells, has been reported to interact with wild type p53 and this interaction is believed to 
promote sequestration of p53 in the cytoplasm, inhibiting its nuclear activity (Wadhwa et 
al., 1998; Wadhwa et al., 2002b).  Thus, HSPs may bind to ASPP1 and sequester it in the 
cytoplasm, preventing its pro-apoptotic activities in the nucleus, much like Hsp70-9 does 
with p53.  In response to cell stress, Hsp70-Hom and Hsp74 may assist in transporting 
HSPA9 Heat shock 70 kDa protein 9 Hsp70-9 
ASPP1 IP in Saos2 cells 
HSPA1L Heat shock 70 kDa protein 1-like Hsp70-Hom  
HSPA4 Heat shock 70 kDa protein 4 Hsp74 
ASPP1-FLAG IP in Flp-In 
HEK293 cells HSPA8 Heat shock 70 kDa protein 8 Hsc70 
HSPA1A Heat shock 70 kDa protein 1A Hsp72 
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ASPP1 into the nucleus, as these proteins have been shown to re-localise from the cytosol 
to the nucleus after heat shock (Milner et al., 1990; Kaneko et al., 1997; Fourie et al., 
2001).  The regulatory mechanisms that control the translocation of these HSPs into the 
nucleus, however, are unknown.  Alternatively, HSPs may bind to partially translated or 
newly synthesised ASPP1 and contribute to its efficient folding.  They may assist in 
ASPP1 stabilisation or prevent ASPP1 aggregation during both normal cellular 
conditions and adverse conditions.  ASPP1 is a relatively large protein implying it is 
likely to need assistance in assembly.   They may also transport old or excess ASPP1 
protein, which may have been tagged for degradation by SIAH1, to the proteasome. 
Despite the high sequence homology of the individual HSPs pulled down in our IPs, they 
appear to reside in varying subcellular compartments and display functional diversity.  It 
is likely that the functional consequence of the interaction between ASPP1 and HSPs is 
dependent on the individual HSP, and a number the scenarios suggested above may take 
place simultaneously.   
A number of transcriptional regulators were also identified in our screens, including 
DIPA (delta-interacting protein A), PC4 (positive co-activator-4) and YBX1 (Y-box 
binding protein 1).  DIPA regulates gene expression and cell proliferation by interacting 
with various transcription factors (Bezy et al., 2005; Du et al., 2006; Iwai et al., 2007).  
PC4, like ASPP1, has been reported to interact with p53 and enhance p53 dependent 
apoptosis (Banerjee et al., 2004).  EMSA experiments carried out by Banerjee et al., 
(2004) show that PC4 stimulates the sequence-specific DNA binding of p53 and they 
demonstrate that PC4 induces expression of the p53-targeted pro-apoptotic gene, Bax.  
Similarly, chromatin immunoprecipitation (ChIP) assays carried out by Samuels-Lev et 
al., (2001) show that ASPP1 and ASPP2 can selectively stimulate the binding of p53 to 
the promoters of pro-apoptotic genes, such as Bax and PIG3.  Thus, ASPP1 and PC4 
appear to function in a similar manner and potentially cooperate with one another.      
YBX1, commonly referred to as YB-1, was positively identified in both the endogenous 
ASPP1 IP and the ASPP1-FLAG IP.  YBX1 has also been shown to directly associate 
with p53 and again this association activates the binding activity of p53 to its consensus 
sequence (Okamoto et al., 2000).  However, in contrast to PC4 and ASPP proteins, 
YBX1 prevents p53 from inducing apoptosis by selectively preventing p53 from 
transactivating pro-apoptotic genes, including Bax (Homer et al., 2005).  We were unable 
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to confirm the ASPP1:YBX1 interaction by Western using a YBX1 antibody as we 
suspect that IgG heavy chain and the YBX1 protein are migrating similarly.  Thus, 
further analysis is required to resolve this issue.    
In addition to transcriptional regulators, HSPs and several protein transport machinery 
proteins, there were several other proteins pulled down in the Saos2 IP, some of which 
are metabolic enzymes (e.g. DLST and CAD) and some of whcih whose functions are 
unknown (e.g. RTN4, HAX-1 and KCTD15).   
Overall, the ASPP1-protein interaction screens revealed that ASPP1 interacts with 
diverse set nuclear and cytoplasmic proteins.  In comparison to the ASPP1 interacting 
proteins identified in Saos2 and Flp-In HEK293 cells, a rather different set of interactors 
was identified in the testes yeast 2-hybrid screen.  Contrasting cellular location is likely 
to affect potential binding partners as ASPP1 is nuclear in human testes and cytoplasmic 
in mouse tissues and cell lines.  ASPP1 therefore, is likely to have a different function in 
human testes compared to other tissues   It is also important to bear in mind that one of 
the limitations of the yeast 2-hybrid system is that spurious interactions are sometimes 
detected that are not displayed by proteins in their native environment.  Synthetically 
made fusion proteins may not be able to fold properly and/or proteins may not be 
correctly modified in yeast in comparison to mammalian tissue, consequently altering 
their properties.  Also, interactions detected in yeast may not occur in mammalian tissues 
due to the possibility of cell-specific or subcellular compartment specific expression of 
detected prey proteins.  Therefore all yeast 2-hybrid results must be dealt with caution, 
and interactions must be validated in the appropriate biological system.  The ASPP1 
interacting proteins we have most confidence in are PP1c, which was previously 
identified by Helps and colleagues (1995), and Hsp72, as we were able to verify this 
interaction by Western (Figure 66).  Further investigation is required in order to confirm 
that the remaining interactors identified in these screens are genuine molecular interactors 
in vivo.  Never the less, the diverse set of interacting proteins identified in these studies 
implicate ASPP1 involvement in a range of cellular processes, as well as apoptosis. 
 Chapter 7. Concluding remarks and future work 
Since the initial characterisation of the mammalian Siah family in the mid 90’s, and the 
realisation that Siah proteins are key regulators of protein turnover, a multitude of Siah 
interacting proteins have been identified (see Tables 1 and 2 in the introduction to this 
thesis).   Siah proteins regulate a diverse set of substrates and as a result they have been 
implicated in a number of cellular processes (Figure 69). 
 
Figure 69. Pathways involving Siah family proteins.   The Drosophila Sina protein controls R7 
photoreceptor development by targeting the transcription repressor tramtrack (Ttk) for degradation.  
Mammalian Siah family proteins have been implicated in the degradation of many proteins including PHD 
and FIH, negative regulators of hypoxia signalling; HIPK2, the protein kinase with a key role in the 
hypoxic response and apoptosis; DCC, the netrin receptor which controls axonal patterning and cell 
migration; β-catenin, c-myb and TEIG1, transcriptional regulators involved in apoptosis and cell 
proliferation; repp86,  a component of the mitotic spindle which plays a role in cell cycle progression; Kid, 
a microtubule binding protein involved in mitosis; RINGO, a cell cycle regulator; CtIP, a transcriptional 
regulator involved in cellular proliferation;  TRAF2, the signal transducer which in turn leads to diminished 
NFκB activation; Spry2, a negative regulator of RAS signalling involved in cell growth and differentiation; 
NUMB, a membrane protein which plays a role in the determination of cell fate during development.  
Mammalian Siah proteins also bind to Vav, a guanine nucleotide exchange factor which regulates 
cytoskeletal reorganisation and suppress its function.  An interaction with GAPDH leads to Siah 
stabilisation and promotion of apoptosis.  Interactions with the inhibitors of apoptosis PEG10 and BAG-1 
have also been observed, however the outcomes of these interactions are not clear.  Figure redrawn with 
modification from House et al., (2009).  
Generation of Siah1a and Siah2 knockout mice were valuable in establishing the 
significance of the role Siah proteins play in these cellular processes and, although Siah2-
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/-
 mice were phenotypically normal, it was revealed that Siah1a had a novel role in the 
testes as Siah1a null male mice were sterile (Dickins et al., 2002).  Thus, to better 
understand SIAH1 function in the testes, the primary aim of this thesis was to 
characterise a number of SIAH1 interacting proteins identified in a yeast 2-hybrid screen 
of a human testes cDNA library and determine whether or not any of these proteins were 
targets for SIAH1-mediated degradation.  If so, we could then speculate on the 
consequences of the SIAH1 interaction on cellular processes.  The experimental 
approaches taken to characterise each interaction and our findings have been discussed at 
the close of each chapter.  Here, the major discoveries from this study are summarised 
and the future direction this research may take is considered.   
Initial analysis of the eight SIAH1 yeast 2-hybrid hits revealed that the most likely targets 
for SIAH1 mediated degradation were PHC2, a polycomb protein which is part of a large 
chromatin associated complex involved in the stable repression of genes during early 
development; NELF-A, a component of the NELF complex which regulates transcription 
of developmental control genes by stalling RNA polymerase II; ASPP1, an apoptosis 
promoting protein, which is dependent on its interaction with p53; and ZC3H11A, a zinc 
finger protein with unknown function.   
Whist writing this thesis, the SIAH1:PHC2 interaction was published by Wu and 
colleagues (2010).  They identified this interaction in a SIAH1 yeast 2-hybrid screen of a 
human foetal brain cDNA library.  Therefore the SIAH1:PHC2 interaction is unlikely to 
be exclusive to the testes.  Similar to our findings they report that PHC2 interacts with the 
C-terminal domain of SIAH1.  They recognise the same SIAH-binding motif that we 
identified (Chapter 3, section 3.4) and show that deletion of the motif abrogates the 
interaction.  They also provide evidence to show that SIAH1 mediates PHC2 
ubiquitination and targets it for proteasomal degradation.  Confirmation of the 
SIAH1:PHC2 interaction implies that SIAH1 has a role during early development.  By 
regulating the stability of PHC2, SIAH1 may in turn regulate the expression of Hox genes 
which are repressed by the Polycomb complex.  Regulation of PHC2 by SIAH1 may be 
important in the testes as large numbers of genes involved in spermatogenesis are 
differentially expressed during germ cell development and so their expression must be 
tightly controlled.  Potentially a subset of genes essential for successful germ cell 
production might be repressed by the polycomb complex and so Siah1a may be required 
to degrade PHC2 to permit their expression.   
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Further analysis of the SIAH1:NELF-A interaction (Chapter 4) via transient transfection 
assays and monitoring of endogenous protein levels in Siah1a-/-Siah2-/- fibroblasts 
revealed that SIAH1 predominantly targets over-expressed NELF-A-GFP fusion protein 
for degradation, and endogenous NELF-A protein was largely unaffected.  These results 
suggest that SIAH proteins preferentially target excess proteins which might not be 
present within intracellular complexes.  In the study by Wu and colleagues (2010) 
mentioned above, they solely analyse ectopically expressed FLAG-tagged PHC2 protein 
when co-expressed with SIAH1 and endogenous PHC2 is not studied.   Thus, it is 
possible that SIAH proteins also preferentially degrade excess PHC2 which is not part of 
the polycomb chromatin associated complex.  So why should proteasome mediated 
destruction of certain excess protein components be important?  We speculate that this 
homeostatic control of protein levels might be a particularly important component of 
gene expression in the testis which has high levels of general transcription. Due to the 
many cellular differentiation events that occur during spermatogenesis, many gene 
products are required, more than at any other time during development.  High levels of 
general transcription are also thought to be associated with efficient DNA repair 
processing during recombination (Hackstein et al., 2000).  Potentially many of the 
mRNAs which are translated into protein are surplus to requirements and are hence 
targets for proteasomal degradation.  Any defect in this homeostatic control mechanism 
may therefore manifest in the infertility shown by Siah1a-/- mice.   However, more 
generally this data also strongly suggests that an important trigger for SIAH1-mediated 
protein degradation of endogenous proteins sequestered in complexes will be the 
dissolution of these intracellular protein complexes to make target proteins accessible to 
SIAH1-mediated ubiquitination.  
An investigation into the effect of the murine family of Siah proteins on the stability of 
NELF-A-GFP revealed that Siah1a and Siah2 proteins target NELF-A for degradation 
but Siah1b does not.  Nor was Siah1b able to autoregulate its own stability like Siah1a 
and Siah2.  This was a surprising result as Siah1a and Siah1b are much more similar to 
each other than to Siah2 in terms of protein sequence.  We also analysed the effect of the 
murine family of Siah proteins on the stability of PHC2- and ASPP1-GFP fusion proteins 
and similar results were obtained (data not shown in this thesis).  Thus, Siah1a and Siah2 
target an overlapping, heterologous set of target proteins for proteasome-mediated 
destruction, but Siah1b does not.   
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The finding that one Siah1 protein rather than two is sufficient in humans and rats (see 
section 1.3 in the introduction to this thesis) suggests that the Siah1b protein has little or 
no role in the mouse.  However, Siah1b is being maintained under purifying selection (Dr 
Michael Jackson, IHG, Newcastle University, unpublished observations), Siah1b is 
activated during p53-mediated apoptosis (Amson et al., 1996; Fiucci et al., 2004), and 
Siah1b-/- mutant mice exhibit an embryonic lethal phenotype (Frew et al., 2002).  
Therefore, Siah1b clearly has an important role in the mouse as it is essential for viability 
during embryonic development, but this seems to be outside targeting proteins for 
proteasomal degradation.   
In the literature, most Siah protein studies have focused on either human SIAH1 or 
SIAH2 and mouse Siah1a or Siah2 and, as far as we are aware, no Siah1b interacting 
proteins or target proteins have been identified.  To our knowledge, we are the first to 
report that Siah1b has functionally diverged.  
Further analysis of the interaction between SIAH1 and the pro-apoptotic protein ASPP1 
(Chapter 5) revealed that SIAH1 is a likely E3 ligase candidate responsible for 
controlling the stability of both ASPP1 and its homologue ASPP2, which was previously 
found to be regulated by a proteasome dependent mechanism.  Detection of elevated 
levels of ASPP1 in meiotic and post meiotic male germ cells by Thornton et al., (2006) 
suggests that this protein may play an important role in germ cell development.  Indeed, 
apoptosis of spermatogenic cells is an essential homeostatic process in the testes, 
maintaining the correct proportion of germ cells and somatic cells and eliminating any 
defective or damaged gametes (Print et al., 2000).  If ASPP1 is involved in this 
homeostatic process then the finding that SIAH1 regulates ASPP1 stability suggests that 
SIAH1 might inhibit ASPP1-dependent apoptosis in the testis.  Contrarily, SIAH1 has 
been shown to activate apoptosis (discussed in sections 1.3.3 and 1.3.4 in the introduction 
to this thesis).  It is possible that activation of apoptosis by SIAH1 is via an ASPP1-
independent pathway and that SIAH1-mediated degradation of ASPP1 is a method by 
which various pro-apoptotic signals are regulated.  However, protein interaction screens 
carried out to identify major ASPP1 protein binding partners revealed that ASPP1 
bound/co-immunoprecipitated with a diverse array of proteins implying ASPP1 is a 
multifunctional protein with a role in many cellular pathways (Chapter 6).  Thus, SIAH1 
mediated degradation of ASPP1 is likely to have downstream effects on multiple 
pathways and cellular processes, as well as apoptosis. 
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Much of the literature on the ASPP proteins focuses predominately on ASPP2, and the 
majority of ASPP interacting proteins identified are ASPP2 interactors (Table 12, 
Chapter 6).  Due to the identification of various ASPP2 interacting partners, it is 
becoming increasingly recognised that ASPP2 may have many other functions in the cell 
beyond enhancing apoptosis (Kampa et al., 2009b).  To our knowledge this is the first 
comprehensive study aimed at identifying ASPP1 interacting partners and, as a result, we 
also found that ASPP1, like ASPP2, appears to be involved in a perplexing range of 
biological pathways.  The ASPP1 protein interaction network elucidated in this study is 
surmised in Figure 70.  Aside from PP1c, we did not identify any of the published ASPP2 
interacting partners in our ASPP1 protein interaction screens (Table 12, Chapter 6).  This 
suggests that, aside from promoting apoptosis via their interaction with p53 and family 
members, ASPP1 and ASPP2 also have distinct roles in the cell.   
 
Figure 70. ASPP1 interacting proteome.  Previously identified interactions are depicted by red lines.  
Blue lines represent interactions identified in this study.  It is likely that some of the proteins identified in 
our ASPP1 protein interaction screens also interact with one another, however only the interactions 
identified upon my assessment of the literature are shown.   
Despite identification of SIAH1 targets, PHC2, NELF-A and ASPP1, all of which 
potentially play an important role in germ cell development in the testes and also in other 
tissues, the signals which trigger SIAH-mediated degradation of these proteins in vivo are 
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yet to be determined.  It is becoming increasingly recognised that Siah proteins do not 
function constitutively in the cell, but rather are recruited into action by certain signals.  
For example, Siah2 has been shown to primarily target TRAF2 for degradation, but only 
in response to stress (Habelhah et al., 2002).  Habelhah and colleagues (2002) compared 
TRAF2 abundance in wild-type and Siah2-/- MEFs and found that there was a limited 
difference in TRAF2 protein levels between wild-type and Siah2 null cells under normal 
growth conditions.  In response to stress however, in the form of actinomycin D treatment 
(a DNA intercalator which inhibits transcription), there was a marked decrease in the 
half-life of TRAF2 in wild type MEFs compared with Siah2-/- cells.  It would therefore be 
interesting to analyse NELF-A and ASPP1 stability in MEFs subjected to particular stress 
stimuli.   
As well as cell stress, there are many other potential pathways and signals that may 
trigger SIAH-mediated degradation.  Due to SIAH proteins interacting with such a 
diverse set of substrates it is likely that signals and triggers for degradation vary 
depending on the substrate.   In order to better understand when and where SIAH proteins 
initiate degradation, and what the downstream consequences are, further knowledge of 
ASPP1 function and the triggers for dissolution of the NELF complex is required.  
The function of the murine specific Siah1b protein also remains to be determined.  Due to 
the only amino acid differences between Siah1a and Siah1b proteins residing in the  
RING finger and zinc finger regions it will be of interest to determine which E2 enzymes 
these proteins interact with, as recent evidence indicates that it is the E2 enzyme which 
dictates the type of ubiquitin modification that will occur on the substrate (Ikeda et al., 
2008).  Potentially, Siah1b may assist in either protein monoubiquitination, 
polyubiquitination of atypical ubiquitin chains or conjugation of UBL proteins which 
instead of targeting proteins for degradation may alter protein function or localisation 
(discussed in sections 1.2.1 and 1.2.2 in the introduction to this thesis).  Also, due to the 
Siah1b knock out having an embryonic lethal phenotype (Frew et al., 2002), creation of a 
conditional Siah1b knock out would help clarify Siah1b function in different tissues and 
in varying stages of development. 
Moreover, now that we have identified a large number of candidate ASPP1 interacting 
proteins, many of which are highly intriguing, interactions need to be verified in vivo and 
the functional implications of these interactions remain to be determined.  The PP1c 
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interaction was verified previously and we were able to confirm the ASPP1:Hsp72 
interaction by co-immunoprecipitation.  However, it is unlikely that all of the ASPP1 
interactors identified are genuine physiological binding partners.  Never the less, in order 
to better understand ASPP1 function in the nucleus, and the mechanisms by which 
ASPP1 itself stimulates apoptosis, it may be interesting to follow up on the interaction 
with the p53 interacting transcriptional regulators PC4 and YBX1 (discussed in the 
summary and discussion in Chapter 6).  ASPP1 and PC4 specifically promote p53-
dependent apoptosis and YBX1 acts in an opposite manner, specifically preventing p53-
dependent apoptosis.  Interestingly, prior to this study it was hypothesised in a review by 
Braithwaite et al., (2006) that the outcome of the p53 response may be determined by the 
relative concentrations of YBX1 and ASPP proteins in the nucleus.  Presumably the more 
YBX1 present in the nucleus, the more likely apoptosis is to be inhibited and the more 
ASPP1/2 present, the more apoptosis is promoted.  If this is indeed the case, there must 
be some sort of control mechanism regulating the amount of ASPP1 and YBX1 
translocating to the nucleus.  Like ASPP1, YBX1 is predominantly cytoplasmic, however 
it translocates to the nucleus in response to cytotoxic stress and DNA damage (Koike et 
al., 1997).   Therefore, it would also be interesting to monitor ASPP1 localisation after 
cytotoxic stress.  We did perform some preliminary studies whereby ASPP1-V5 
localisation was analysed by cell staining before and after UV treatment and results 
suggest that ASPP1 translocates to the nucleus similarly to YBX1 (data not shown).  
Further analysis of the ASPP1, PC4 and YBX1 protein interaction network identified in 
this study may provide further insight into how these proteins dictate how p53 behaves.   
As a number of proteins involved in protein trafficking were identified in the ASPP1 
protein interaction screens then ASPP1’s role in COPII coat formation, ER-Golgi and 
post-Golgi protein trafficking also requires further investigation.  One way to better 
understand ASPP1 roles in protein transport may be to construct recombinant genes 
encoding ASPP1 and COPII chimeric fluorescent proteins and monitor their migration in 
the cell in real time.  The interaction between ASPP1 and the various heat shock proteins 
also requires further investigation in order to determine the functional consequences of 
these interactions.  As we confirmed the interaction between ASPP1 and Hsp72 by co-
immunoprecipitation (Chapter 6, section 6.4.6) it would be interesting to do some co-
staining in order to determine whether these proteins co-localise and if this interaction is 
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affected by cytotoxic damage such as UV.    A model of ASPP1 function based on the 
interacting proteome identified in this study is presented in Figure 71. 
 
Figure 71. A model of ASPP1 function in the cell.  This figure summarises our protein interaction data 
discussed in the text.  One might envisage that ASPP1 carries out activities in the cytoplasm that are part of 
the normal cell physiology, possibly regulating PP1 activity or assisting in protein transport in COPII 
vesicles which bud from the ER.  Alternatively, ASPP1 may be transported in the cell within COPII 
vesicles to the Golgi for processing, and sorting.  ASPP1 may be sequestered in the cytoplasm by heat 
shock proteins or support HSP cellular function, for example assisting in control of regulatory proteins or 
assembly and disassembly of protein complexes.  Any ASPP1 in excess of cellular requirements may be 
targeted for proteasomal degradation by SIAH1.  Upon genotoxic stress/or other exogenous signals, ASPP1 
may translocate into nucleus potentially with the aid of HSPs.  In the nucleus ASPP1 may associate with 
PC4 and p53 to promote transcription of pro-apoptotic genes.  It may also bind to YBX1 in order to 
sequester it away from anti-apoptotic promoters. The cellular decision to promote cell growth or undergo 
programmed cell death may be dependent on the relative levels or activity of ASPP1 and YBX1 in the 
nucleus.  
Clearly, identifying the proteins that interact with the E3 ubiquitin ligase SIAH1, and the 
tumour suppressor protein ASPP1, has provided an important first step towards our 
understanding of the functional responsibilities of these proteins in the cell.  However, as 
is often the case with scientific research, many unanswered questions remain.  No doubt 
further understanding of the triggers of SIAH-mediated degradation will lead to 
fascinating discoveries on how SIAH proteins contribute to development by regulating 
NELF-A, ASPP1 and PHC2 stability.  In addition, further analysis of the ASPP1 
interacting partners identified will lead to new and interesting discoveries on how ASPP1 
functions in the cell and a better understanding of ASPP1 function is also likely to lead to 
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an expansion in our understanding of the downstream effects of SIAH-mediated 
degradation.      
 Appendix A. Primers used for PCR 
Primer name Target Sequence (5′-3′) Site Purchased 
from 
ASPP1(252)F ASPP1 AAAAAAAAAGAATTCTCCCCAACTGAGAACAGTGAA EcoRI Sigma 
ASPP1(624)F ASPP1 AAAAAAAAAGAATTCAATCTGTCTGCTGAAATAGAAAGG EcoRI Sigma 
ASPP1(624)R ASPP1 AAAAAAAAACTCGAGCCTTTCTATTTCAGCAGACAGATT XhoI Sigma 
ASPP1(1050)R ASPP1 AAAAAAAAACTCGAGTCCGGCACTGGGAACCTG XhoI Sigma 
ASPP1(1575)F ASPP1 AAAAAAAAACATATGCCAAGTCCCACGTACCCG NdeI Sigma 
ASPP1(1839)F ASPP1 AAAAAAAAACATATGTTACCTTCGGGTTCAACCTCT NdeI Sigma 
ASPP1(1839)R ASPP1 AAAAAAAAACTCGAGAGAGGTTGAACCCGAAGGTAA XhoI Sigma 
ASPP1(2259)R ASPP1 AAAAAAAAACTCGAGATTGTCCACATCGGCCAAGGT XhoI Sigma 
ASPP1-F(BglII) ASPP1 AAAAAAAAAGATCTATGATGCCGATGATATTAACTGTTT BglII IDT 
ASPP1-R-(XhoI) ASPP1 AAAAAAAACTCGAGTCAGGCGAGTGTTCGCTGT XhoI IDT 
ASPP2-F ASPP2 AAAAAAAAACATATGATGGATCTGACTCTTGCTGAAC NdeI Sigma 
ASPP2-R ASPP2 AAAAAAAAACTCGAGTCAGGCCAAGCTCCTTTGTCT XhoI Sigma 
ASPP2(1668)F ASPP2 AAAAAAAAACATATGCCTGTTTCTTCAGTTCAGGAG NdeI Sigma 
ASPP2(1668)R ASPP2 AAAAAAAAACTCGAGCTCCTGAACTGAAGAAACAGG XhoI Sigma 
BGHrev BGH seq TAGAAGGCACAGTCGAGG - MWG 
CMV-F CMV prom CGCAAATGGGCGGTAGGCGTG - Eurogentec 
HPH2F PHC2 AAAAAAAAACAATTGGACATGACCTCAGGGAACG MfeI Eurogentec 
HPH2B PHC2 AAAAAAAAACTCGAGCTAGGAGTCCTTGAGCATGC XhoI Eurogentec 
KIAA0663F ZC3H11A AAAAAAAAAGAATTCACAGGAGTTGACATCACTAAAATTC EcoRI Eurogentec 
KIAA0663B ZC3H11A AAAAAAAAACTCGAGTTCAGCTATCAATCATTTCTGTAG XhoI Eurogentec 
KIAA0663(1638)F ZC3H11A AAAAAAAAAGAATTCACAGGAGTTGACATCACTAAAATTC EcoRI VHBio 
KIAA0663(2034)F ZC3H11A AAAAAAAAAGAATTCGTCATTGCCGCTGTGAAGC EcoRI VHBio 
KIAA0663(2100)R ZC3H11A AAAAAAAAACTCGAGCGGGACAACAGCCACAGC XhoI VHBio 
KIAA0663(1875)F ZC3H11A AAAAAAAAAGAATTCGGGATTGGAGACTCATTATTGAAT EcoRI Sigma 
KIAA0663(1875)R ZC3H11A AAAAAAAAACTCGAGATTCAATAATGAGTCTCCAATCCC XhoI Sigma 
Limkain-β2F CCDC92 AAAAAAAAAGAATTCCTGGAGGAGCTGAAGGCC EcoRI Eurogentec 
Limkain-β2B CCDC92 AAAAAAAAAGCGGCCGCCTTCACACAGTTCTGTCCGTC NotI Eurogentec 
pACT25-F pACTII CGCGTTTGGAATCACTACAGGGAT - MWG 
pCDNArev pGFP3 CTAGAAGGCACAGTCGAGGCT - MWG 
pGEX5 pGEX5X1 GGCAGATCGTCAGTCAGTCACGA - MWG 
PUF60F SIAH1BP1 AAAAAAAAAGAATTCACGGCGACCATAGCTCTCC EcoRI Eurogentec 
PUF60B SIAH1BP1 AAAAAAAAACTCGAGTCACGCAGAGAGGTCACTGT XhoI Eurogentec 
SIAH95-F SIAH1 AAAAAAAAGAATTCCTTTTCCCCTGTAAATATGCGT EcoRI MWG 
SIAH155-B SIAH1 AAAAAAAACTCGAGAATGGACTTATGCTGATGCATC XhoI MWG 
SIAH153-F SIAH1 AAAAAAAAGAATTCAAGTCCATTACCACCCTACAGG EcoRI MWG 
SIAH1 protein-B SIAH1 AAAAAAACTCGAGTCAACACATGGAAATAGTTACAT XhoI MWG 
Siah1a-F(FLAG) Siah1a AAAAAAAAAGAATTCAATGAGCCGCCAGACTGCTA EcoRI IDT 
Siah1b/a-R(FLAG) Siah1b/a AAAAAAAAATCTAGAACACATGGAAATAGTTACATTGATG XbaI IDT 
Siah1b(F) Siah1b AAAAAAAAAGAATTCATGAGCCGTCAGGCTGCT A EcoRI VHBio 
Siah1b(R) Siah1b AAAAAAAAACTCGAGTCAACACATGGAAATAGTTACATTGA XhoI VHBio 
Siah1b-F(FLAG) Siah1b AAAAAAAAAGAATTCAATGAGCCGTCAGGCTGCTA EcoRI IDT 
Siah1b-R(FLAG) Siah1b AAAAAAAAATCTAGATCAACACATGGAAATAGTTACATTGA XbaI IDT 
Siah2-F(FLAG) Siah2 AAAAAAAAAGAATTCAATGAGCCGCCCGTCCTC EcoRI IDT 
Siah2-R(FLAG)+STOP Siah2 AAAAAAAAATCTAGATCACTGACAGCATGTAGATATCG XbaI IDT 
Siah2-R(FLAG)-STOP Siah2  AAAAAAAAATCTAGACTGACAGCATGTAGATATCGTG XbaI IDT 
T7-F T7 prom TAATACGACTCACTATAGGG - Eurogentec 
Uk-p68F ZC3H14 AAAAAAAAAGATATCAAGTTCCACAGAAACAGACACTTC EcoRV Eurogentec 
Uk-p68B ZC3H14 AAAAAAAAACTCGAGCTATTCGCTGGTTTGAGGTCG XhoI Eurogentec 
UKp68(1449)F ZC3H14 AAAAAAAAAGAATTCCAAGAGTCGGGGATGAAGACT EcoRI Sigma 
UKp68(1449)R ZC3H14 AAAAAAAAACTCGAGAGTCTTCATCCCCGACTCTTG XhoI Sigma 
UKp68(1122)F ZC3H14 AAAAAAAAACATATGGTTCCACAGAAACAGACACTTC NdeI VHBio 
UKp68(1662)F ZC3H14 AAAAAAAAACATATGAAGGGACTCAGAGGTCTCC NdeI VHBio 
UKp68(1782)R ZC3H14 AAAAAAAAACTCGAGACAAGCAGGCCAGTACTTGCA XhoI VHBio 
VAPAF VAPA AAAAAAAAAGAATTCATGGCGTCCGCCTCAGG EcoRI Eurogentec 
VAPAB VAPA AAAAAAAAACTCGAGCTACAAGATGAATTTCCCTAGAAAG XhoI Eurogentec 
WHSC2F WHSC2 AAAAAAAAAGAATTCGAGAGCGACACGGGCCT EcoRI Eurogentec 
WHSC2B WHSC2 AAAAAAAAACTCGAGCTAGGACACATTGGTCATGGG XhoI Eurogentec 
WHSC2(744)F WHSC2 AAAAAAAAAGAATTCCTGCGGAAGGAACGAGGTG EcoRI Eurogentec 
WHSC2(744)B WHSC2 AAAAAAAAACTCGAGCAGCAGCGTCCTGGAAGG XhoI Eurogentec 
WHSC2(951)F WHSC2 AAAAAAAAAGAATTCGCGCTGCCCTCCACGAG EcoRI Eurogentec 
WHSC2(951)B WHSC2 AAAAAAAAACTCGAGAGGCTCATTGTTCAGGGACC XhoI Eurogentec 
WHSC2(1281)B WHSC2 AAAAAAAAACTCGAGAGGCTGCTGCTGAGCAGG XhoI Eurogentec 
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Appendix B. Plasmids used in this thesis 
Gene Vector Selective 
Antibiotic 
Source/Cloning method 
ASPP1 pACTII Ampicillin Julian Venables, unpublished data 
ASPP1 pCDNA5-FLAG Ampicillin PCR amplification from ASPP1-V5 clone using ASPP1-
F(BglII) and ASPP1-R-(XhoI) incorporating BglII and XhoI 
restriction sites.  Ligated into complementary sites in the 
pCDNA5-FLAG vector. 
ASPP1 pGFP3 Ampicillin Thornton 2005 
ASPP1 pV5 Ampicillin Gift from Professor Xin Lu, University of Oxford, UK 
ASPP1(357-532)Epi pET32a Ampicillin Thornton, 2005 
ASPP1(1-1090) pGADT7 Ampicillin Thornton, 2005 
ASPP1(1-86) pGADT7 Ampicillin Thornton, 2005 
ASPP1(87-352) pGADT7 Ampicillin Thornton, 2005 
ASPP1(353-531) pGADT7 Ampicillin Thornton, 2005 
ASPP1(532-760) pGADT7 Ampicillin Thornton, 2005 
ASPP1(761-871) pGADT7 Ampicillin Thornton, 2005 
ASPP1(872-1090) pGADT7 Ampicillin Thornton, 2005 
ASPP1(86-216) pGADT7 Ampicillin PCR amplification from ASPP1-V5 clone using 
ASPP1(252)F and ASPP1(624)R incorporating EcoRI and 
XhoI restriction sites.  Ligated into complementary sites in the 
pGADT7 vector. 
ASPP1(208-355) pGADT7 Ampicillin PCR amplification from ASPP1-V5 clone using 
ASPP1(624)F and ASPP1(1050)R incorporating EcoRI and 
XhoI restriction sites.  Ligated into complementary sites in the 
pGADT7 vector. 
ASPP1(525-620) pGADT7 Ampicillin PCR amplification from ASPP1-V5 clone using 
ASPP1(1575)F and ASPP1(1839)R incorporating NdeI and 
XhoI restriction sites.  Ligated into complementary sites in the 
pGADT7 vector. 
ASPP1(613-760) pGADT7 Ampicillin PCR amplification from ASPP1-V5 clone using 
ASPP1(1839)F and ASPP1(2259)R incorporating NdeI and 
XhoI restriction sites.  Ligated into complementary sites in the 
pGADT7 vector. 
ASPP2 pGFP3 Ampicillin Jared Thornton, unpublished data 
ASPP2 (1-563)  pGADT7 Ampicillin PCR amplification from ASPP2-V5 clone using ASPP2-F and 
ASPP2(1668)R incorporating NdeI and XhoI restriction sites.  
Ligated into complementary sites in the pGADT7 vector. 
ASPP2 (556-1005)  pGADT7 Ampicillin PCR amplification from ASPP2-V5 clone using 
ASPP2(1668)F and ASPP2-R incorporating NdeI and XhoI 
restriction sites.  Ligated into complementary sites in the 
pGADT7 vector. 
HA-Ubiquitin pCDNA3 Ampicillin Purchased from Professor Yue Xiong, University of North 
Carolina, USA 
KIAA0663 (ZC3H11A) pACTII Ampicillin Venables, unpublished data 
KIAA0663 (ZC3H11A) pGFP3 Ampicillin PCR amplification from pACTII using KIAA0663-F and 
KIAA0663-B primers incorporating EcoRI and XhoI 
restriction sites.  Ligated into complementary site in pGFP3 
vector. 
Limkain-β2 (CCDC92) pACTII Ampicillin Venables, unpublished data 
Limkain-β2 (CCDC92) pGFP3 Ampicillin PCR amplification from pACTII using Limkainβ2-F and 
Limkainβ2-B primers incorporating EcoRI and NotI 
restriction sites.  Ligated into complementary site in pGFP3 
vector. 
PHC2 pACTII Ampicillin Venables, unpublished data 
PHC2 pGFP3 Ampicillin PCR amplification from pACTII using HPH2-F and HPH2-B 
primers incorporating MfeI and XhoI restriction sites.  Ligated 
into complementary site in pGFP3 vector. 
Sec16A pEGFP Kanamycin Dr David Stephens (University of Bristol, UK).  Watson et 
al., 2006 
SIAH1 pGBKT7 Kanamycin Venables et al., 2004 
SIAH1(153+) pGADT7 Ampicillin Venables, unpublished data 
SIAH1(153+) pGBKT7 Kanamycin PCR amplification from SIAH1pGADT7 using SIAH153-F 
and SIAH1 protein-B primers incorporating EcoRI and XhoI 
restriction sites.  Ligated into complementary sites in the 
pGBKT7 vector. 
SIAH1 pCDNA3.1 Ampicillin Venables et al., 2004 
SIAH1(-98) pGBKT7 Kanamycin Venables et al., 2004 
SIAH1(99-155) pGADT7 Ampicillin Venables, unpublished data 
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SIAH1(99-155) pGBKT7 Kanamycin PCR amplification from pGADT7 using SIAH195-F and 
SIAH155-B primers incorporating EcoRI and XhoI restriction 
sites.  Ligated into complementary sites in the pGBKT7 
vector. 
Siah1a pKH3 Ampicillin Gift from Professor David Bowtell, Peter MacCallum Cancer 
Centre, Melbourne, Australia  
Siah1a(N-FLAG) p3XFLAG(N) Ampicillin PCR amplification from Siah1a-pKH3 using Siah1a-
F(FLAG) and Siah1b-R(FLAG) primers incorporating EcoRI 
and XbaI restriction sites.  Ligated into complementary sites 
in the p3XFLAG(N) vector. 
Siah1a(C-FLAG) p3XFLAG(C) Ampicillin PCR amplification from Siah1a-pKH3 using Siah1a-
F(FLAG) and Siah1b/a-R(FLAG) primers incorporating 
EcoRI and XbaI restriction sites.  Ligated into complementary 
sites in the p3XFLAG(C) vector. 
Siah1b pCDNA3.1 Ampicillin PCR amplification from a full length Siah1b clone (Siah1b 
image ID; 30053109) using Siah1b(F) and Siah1b(R) primers 
incorporating EcoRI and XhoI restriction sites.  Ligated into 
complementary sites in the pCDNA3.1 vector. 
Siah1b  pGBKT7 Kanamycin PCR amplification from a full length Siah1b clone (Siah1b 
image ID; 30053109) using Siah1b(F) and Siah1b(R) primers 
incorporating EcoRI and XhoI restriction sites.  Ligated into 
complementary sites in the pGBKT7 vector. 
Siah1b(N-FLAG) p3XFLAG(N) Ampicillin PCR amplification from a full length Siah1b clone (Siah1b 
image ID; 30053109) using Siah1b-F(FLAG) and Siah1b-
R(FLAG) primers incorporating EcoRI and XbaI restriction 
sites.  Ligated into complementary sites in the p3XFLAG(N) 
vector. 
Siah1b(C-FLAG) p3XFLAG(C) Ampicillin PCR amplification from a full length Siah1b clone (Siah1b 
image ID; 30053109) using Siah1b-F(FLAG) and Siah1b/a-
R(FLAG)primers incorporating EcoRI and XbaI restriction 
sites.  Ligated into complementary sites in the p3XFLAG(C) 
vector. 
Siah2 pKH3 Ampicillin Gift from Professor David Bowtell, Peter MacCallum Cancer 
Centre, Melbourne, Australia 
Siah2(N-FLAG) p3XFLAG(N) Ampicillin PCR amplification from a full length Siah2-pKH3 using 
Siah2-F(FLAG)and Siah2-R(FLAG)+STOP primers 
incorporating EcoRI and XbaI restriction sites.  Ligated into 
complementary sites in the p3XFLAG(N) vector 
Siah2(C-FLAG) p3XFLAG(C) Ampicillin PCR amplification from a full length Siah2-pKH3 using 
Siah2-F(FLAG)and Siah2-R(FLAG)-STOP primers 
incorporating EcoRI and XbaI restriction sites.  Ligated into 
complementary sites in the p3XFLAG(C) vector 
SIAH2 pACTII Ampicillin Venables et al., 2004 
SIAH1BP1 pACTII Ampicillin Venables, unpublished data 
SIAH1BP1 pGFP3 Ampicillin PCR amplification from pACTII using PUF60-F and PUF60-
B primers incorporating EcoRI and XhoI restriction sites.  
Ligated into complementary sites in the pGFP3 vector. 
T-STAR pGFP3 Ampicillin  Venables et al., 2004 
T-STAR(RG) pGEX5X1 Ampicillin Venables et al., 2004 
Uk-p68 (ZC3H14) pACTII Ampicillin Venables, unpublished data 
Uk-p68 (ZC3H14) pGFP3 Ampicillin PCR amplification from pACTII using UKp68-F and Ukp68-
B primers incorporating EcoRV and XhoI restriction sites.  
Ligated into complementary site in pGFP3 vector. 
VAPA pACTII Ampicillin Venables, unpublished data 
VAPA pGFP3 Ampicillin PCR amplification from pACTII using VAPA-F and VAPA-
B primers incorporating EcoRI and XhoI restriction sites.  
Ligated into complementary site in pGFP3 vector. 
WHSC2 pACTII Ampicillin Venables, unpublished data 
WHSC2 pGFP3 Ampicillin PCR amplification from pACTII using WHSC2-F and 
WHSC2-B primers incorporating EcoRI and XhoI restriction 
sites.  Ligated into complementary site in pGFP3 vector. 
WHSC2(1-248) pGADT7 Ampicillin PCR amplification from pACTII using WHSC2-F and 
WHSC2(744)B primers incorporating EcoRI and XhoI 
restriction sites.  Ligated into complementary sites in the 
pGADT7 vector. 
WHSC2(248-317) pGADT7 Ampicillin PCR amplification from pACTII using WHSC2(744)F and 
WHSC2(951)B primers incorporating EcoRI and XhoI 
restriction sites.  Ligated into complementary sites in the 
pGADT7 vector. 
WHSC2(317-427) pGADT7 Ampicillin PCR amplification from pACTII using WHSC2(951)F and 
WHSC2(1281)B primers incorporating EcoRI and XhoI 
restriction sites.  Ligated into complementary sites in the 
pGADT7 vector. 
WHSC2(317-528) pGADT7 Ampicillin PCR amplification from pACTII using WHSC2(951)F and 
WHSC2-B primers incorporating EcoRI and XhoI restriction 
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sites.  Ligated into complementary sites in the pGADT7 
vector. 
WHSC2(1-248) pGBKT7 Kanamycin PCR amplification from pACTII using WHSC2-F and 
WHSC2(744)B primers incorporating EcoRI and XhoI 
restriction sites.  Ligated into complementary sites in the 
pGBKT7 vector. 
WHSC2(248-317) pGBKT7 Kanamycin PCR amplification from pACTII using WHSC2(744)F and 
WHSC2(951)B primers incorporating EcoRI and XhoI 
restriction sites.  Ligated into complementary sites in the 
pGBKT7 vector. 
WHSC2(317-427) pGBKT7 Kanamycin PCR amplification from pACTII using WHSC2(951)F and 
WHSC2(1281)B primers incorporating EcoRI and XhoI 
restriction sites.  Ligated into complementary sites in the 
pGBKT7 vector. 
WHSC2(317-528) pGBKT7 Kanamycin PCR amplification from pACTII using WHSC2(951)F and 
WHSC2-B primers incorporating EcoRI and XhoI restriction 
sites.  Ligated into complementary sites in the pGBKT7 
vector. 
WHSC2(317-427) pGEX5X1 Ampicillin PCR amplification from pACTII using WHSC2(951)F and 
WHSC2(1281)B primers incorporating EcoRI and XhoI 
restriction sites.  Ligated into complementary sites in the 
pGEX5X1 vector. 
ZC3H14(374-594) pGADT7 Ampicillin PCR amplification from Uk-p68 pACTII clone using 
UKp68(1122)F and UKp68(1782)R primers incorporating 
NdeI and XhoI restriction sites.  Ligated into complementary 
sites in the pGADT7 vector. 
ZC3H14(554-736) pGADT7 Ampicillin PCR amplification from Uk-p68 pACTII clone using 
UKp68(1662)F and UKp68B primers incorporating NdeI and 
XhoI restriction sites.  Ligated into complementary sites in the 
pGADT7 vector. 
ZC3H14(374-490) pGADT7 Ampicillin PCR amplification from Uk-p68 pACTII clone using 
UKp68(1122)F and UKp68(1449)R primers incorporating 
EcoRI and XhoI restriction sites.  Ligated into complementary 
sites in the pGADT7 vector. 
ZC3H14(483-607) pGADT7 Ampicillin PCR amplification from Uk-p68 pACTII clone using 
UKp68(1449)F and UKp68(1782)R primers incorporating 
EcoRI and XhoI restriction sites.  Ligated into complementary 
sites in the pGADT7 vector. 
ZC3H11A(546-700) pGADT7 Ampicillin PCR amplification from KIAA0663 pACTII clone using 
KIAA0663(1638)F and KIAA0663(2100)R primers 
incorporating EcoRI and XhoI restriction sites.  Ligated into 
complementary sites in the pGADT7 vector. 
ZC3H11A(678-810) pGADT7 Ampicillin PCR amplification from KIAA0663 pACTII clone using 
KIAA0663(2034)F and KIAA0663B incorporating EcoRI 
and XhoI restriction sites.  Ligated into complementary sites 
in the pGADT7 vector. 
ZC3H11A(546-633) pGADT7 Ampicillin PCR amplification from KIAA0663 pACTII clone using 
KIAA0663(1638)F and KIAA0663(1875)R primers 
incorporating EcoRI and XhoI restriction sites.  Ligated into 
complementary sites in the pGADT7 vector. 
ZC3H11A(625-706) pGADT7 Ampicillin PCR amplification from KIAA0663 pACTII clone using 
KIAA0663(1875)F and KIAA0663(2100)R primers 
incorporating EcoRI and XhoI restriction sites.  Ligated into 
complementary sites in the pGADT7 vector 
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